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ABSTRACT 
Saquinavir (SQV) is the first antiretroviral protease inhibitor approved by Food and 
Drug Administration in the United States for the treatment of HIV infection due to its 
potent anti-HIV activity. However, some unfavorable properties including low aqueous 
solubility, low intestinal absorption and fast biotransformation lead to its poor oral 
bioavailability and limited therapeutic efficacy. The objective of this dissertation project 
is to investigate whether stereoisomerized peptide prodrugs targeting influx transporter 
system could improve intestinal absorption and oral bioavailability of SQV. 
Four stereoisomeric dipeptide prodrugs of SQV including L-valine-L-valine-SQV 
(LLS), L-valine-D-valine-SQV (LDS), D-valine-L-valine-SQV (DLS) and D-valine-D-
valine-SQV (DDS) and two amino acid prodrugs including L-valine-SQV (LS) and D-
valine-SQV (DS) were synthesized and investigated using in vitro cell culture models. 
All dipeptide prodrugs exhibit improved aqueous solubility, lowered cytotoxicity, and 
reduced P-gp/MRP2-mediated efflux activities regardless of stereochemistry in 
promoieties. SQV attached with L-isomers shows higher affinity for peptide transporters 
but lower stability and higher toxicity, whereas conjugation with D-isomers can enhance 
stability and reduce toxicity, but not be recognized by peptide transporters. Subsequently, 
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results of metabolism studies performed in rat liver microsomes indicate that elimination 
half life of SQV was prolonged dramatically by 7- to 40-fold due to prodrug modification 
with the rank order of DDS > DLS > LDS > LLS > DS > LS > SQV. In comparison with 
D-configuration, L-configuration favors the interaction between prodrugs and rat hepatic 
CYP3A enzymes, resulting in a relatively rapid clearance by CYP3A. Stereoselectivity is 
also observed in protein binding of prodrugs in rat plasma. Lower protein binding was 
obtained by LS, LLS and LDS but higher by DS, DDS and DLS as compared with SQV.  
Pharmacokinetics studies performed in rats provide further evidences that oral 
bioavailability of SQV is drastically enhanced by conjugation with dipeptide L-valine-D-
valine. In conclusion, stereoisomeric dipeptide prodrug modification targeting specific 
influx transporters could be a successful strategy to improve bioavailability of poorly 
absorbed drug SQV.  
Additionally, influence of exogenous human efflux transporters (P-gp, MRP2 and 
BCRP) on functional activities of endogenous peptide transporters (PepT) was also 
delineated in MDR-transfected MDCK cell lines in this project. Results demonstrate that 
overexpression of MDR genes reduces PepT function probably due to the phenomenon of 
transporter-compensation resulting in down-regulation of endogenous genes. It may 
provide some mechanistic insight into possible reasons for underestimation in drug 
screening using these cell models.  
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CHAPTER 1 
INTRODUCTION 
Overview 
HIV protease inhibitors (PIs) are currently considered to be the most important 
therapeutic agents for the treatment of human immunodeficiency virus (HIV) infection. 
Their anti-HIV activities result from the blockage of the active site of HIV aspartyl 
protease, which cleaves the viral gag and gag-pol precursor polyproteins, and the 
consequent inhibition of production of infectious virions. Saquinavir (SQV) is the first 
antiretroviral PI drug approved by Food and Drug Administration (FDA) in the United 
States with significant activity against HIV. Hard gelatin capsule formulation of SQV 
mesylate (Invirase
®
) and SQV soft gelatin capsule (Fortovase
®
) developed by Roche 
Pharmaceuticals were marketed in the US for the treatment of HIV/AIDS in 1995 and 
1997, respectively. However, some unfavorable properties, such as low aqueous 
solubility, low intestinal absorption and fast biotransformation into inactive metabolites, 
contribute to its poor oral bioavailability and limit its clinical outcomes. Oral 
bioavailability of SQV was reported to be only 4% for 600-mg hard gelatin capsules 
(Invirase
®
) and around 12% for 1200-mg soft gelatin capsules (Fortovase
®
) in healthy 
adults after a single dose administration. 
    Transporter-targeted prodrug modification could be a viable option for improving 
cellular permeation of SQV. Recently the influx transporter has attracted a lot of attention 
since it could be used as target ligand for drug delivery. Oligopeptide transporters such as 
PepT1 and PepT2 expressed in intestinal and renal epithelial cells transport not only 
small peptides but also peptide-mimetic drugs like lactam antibiotics and antiviral drug. 
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We hypothesize that, by conjugating of SQV molecule with proper dipeptides such as 
stereoisomeric valine-valine, prodrugs could be converted to the substrates for influx 
transport system and undergo facilitated transport to permeate endothelial cells efficiently. 
In addition, this drug-peptide conjugate will bypass the recognition by membrane efflux 
pumps and metabolizing enzymes. Following transport across cellular membrane, active 
parent drug SQV can be regenerated through the cleavage of covalent bond between drug 
and pro-moieties catalyzed by hydrolytic enzymes, specifically the intracellular 
cholinesterases, dipeptidases and aminopeptidases.  
All amino acids (except for glycine) have a chiral center. Therefore dipeptide 
prodrugs derived from SQV containing two chiral centers are found to be stereoisomeric. 
Generally stereoisomers of drug molecules possess differing potencies for 
pharmacokinetic processes and pharmacological effects. This “stereoselectivity” have 
been observed in many aspects in pharmaceutical research, such as affinity for certain 
receptors or enzymes, drug distribution, metabolism, excretion, and toxicity. Therefore, 
we hypothesize that derivatives of SQV conjugating with different stereoisomeric 
dipeptide promoieties are featured with varied physicochemical properties, as well as 
different pharmacokinetic and pharmacological effects. Based on previous results 
demonstrating that valine-based dipeptide prodrugs exhibited a 4.6-fold enhanced 
absorption relative to parent drug in rat jejunum, we developed a series of SQV prodrugs 
conjugated with various stereoisomeric amino acids and dipeptides (L-Val-, D-Val-, L-
Val-L-Val-, L-Val-D-Val-, D-Val-L-Val-, and D-Val-D-Val-), and the in vitro/in vivo 
evaluations regarding to targeting to peptide transporters, evasion of P-gp- or MRP-
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mediated efflux and CYP-mediated biotransformation, and subsequent oral 
bioavailability are illustrated in this dissertation project. 
 
Statement of the Problem 
Although SQV possesses high anti-HIV potency, its therapeutic efficacy is very 
limited. One major obstacle is that SQV shows high affinity for ATP dependent efflux 
pumps like P-glycoprotein (P-gp) and multidrug resistance associated proteins (MRP). 
Efflux pumps are membrane transporters which bind and translocate molecules against a 
concentration gradient at the expense of ATP hydrolysis. Drug accumulation in cells is 
result of dynamic balance between influx, efflux and sequestration. Therefore, both P-gp 
and MRP play an important role in drug disposition through limiting the absorption and 
accumulation of xenobiotics and conferring resistance to a diverse range of compounds. 
Another main obstacle is rapid cytochrome P450 (CYP)-mediated metabolism. CYP is 
the most abundant drug metabolizing enzyme family and is present predominantly in 
intestine and liver. A significant amount of CYP3A, one of major subtype of CYP, is 
expressed in the enterocytes metabolizing xenobiotics including SQV during their transit 
across intestinal epithelium. In addition, poor solubility (2.47 µg/ml in water) and high 
plasma protein binding (98% in human) also partly result in poor oral bioavailability of 
SQV.  
In order to reach its efficient inhibitory levels against virus in human, high doses of 
SQV have to be administered with food and fluid restrictions. However, drug-resistance 
can be developed due to this high-dose treatment, which also leads to the development of 
serious long-term metabolic complications, such as atherosclerosis, hyperlipidemia, 
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lipodystrophy, insulin resistance, and diabetes. Another efficient way to enhance drug 
exposure is the application of a “boosting agent”, typically small dose (50–200 mg) of 
ritonavir (RTV), to boost therapeutic concentration of the co-administered PI like SQV in 
PI-based regimens for the treatment of HIV/AIDS. Subtherapeutic RTV appears to 
potently inhibit both P-gp-mediated efflux and CYP-mediated metabolism, consequently 
increases the bioavailability and cellular penetration of the “boosted” SQV. However, 
coadministration of RTV and SQV leads to some side effects like increased serum lipids 
levels and higher risk of coronary disease and stroke, and long-term inhibition of 
metabolizing enzymes. 
Therefore, new approaches to increase SQV bioavailability are necessary. The 
primary objective of this dissertation project is to develop a novel drug delivery strategy 
to circumvent the unfavorable physicochemical and biological barriers of SQV, 
consequently enhance its intestinal obsorption and oral bioavailability.  
 
Objective 
The objectives of this dissertation are: 
1. To synthesize, purify and identify SQV prodrugs, including stereoisomeric amino acid 
conjugated SQV (L-Val, D-Val), and stereoisomeric peptide conjugated SQV (L-Val-
L-Val, L-Val-D-Val, D-Val-L-Val, and D-Val-D-Val). Quantitative analytical methods 
such HPLC and LC-MS/MS will be developed.  
2. To conduct in vitro uptake and transport studies using P-gp and MRP overexpressiong 
cell lines to investigate the affinity of synthesized prodrugs for efflux pumps and 
peptide transporters. Physicochemical and biological properties including aqueous 
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solubility, chemical/enzymatic stability, cytotoxicity and protein binding will be 
evaluated. 
3. To investigate CYP-mediated metabolism of the synthesized SQV prodrugs in rat liver 
microsomes, and to compare the kinetics of biotransformation of SQV with its 
prodrugs. Hydrolysis of dipeptide prodrugs will also be evaluated in rat plasma and 
intestinal homogenates to predict drug degradation in vtro. 
4. To study oral bioavailability of SQV and prodrugs following oral administration in 
Sprague-Dawley rats. Pharmacokinetic parameters such Cmax, AUC, clearance and 
MRT will be calculated with noncompartmental analysis (NCA) of plasma drug 
concentration-time profiles. 
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CHAPTER 2 
LITERATURE REVIEW 
Overview of HIV Infection 
Human immunodeficiency virus (HIV) is a member of the retrovirus family. It 
gradually infects immune cells such as lymphocytes and monocytes, produces massive 
numbers of new viral particles, causes the death of the infected cells, and ultimately 
destroys immune system. People infected with HIV usually develop slowly progressive 
(10-15 years) but life-threatening diseases such as acquired immunodeficiency syndrome 
(AIDS). About 33.3 millions of people worldwide have been infected with HIV in 2009, 
and at least 25 million people have died due to HIV associated diseases (Adamson et al., 
2009). In the United States, approximately more than 56,000 people are infected each 
year, and more than one million people are now living with HIV (Figure 1). Since the 
epidemic began, 641,976 Americans living with HIV/AIDS have died by the year of 
2009 (Hall et al., 2008; Hall HI, 2008).   
Three stages of HIV infection have been identified currently. The initial stage 
(primary infection), that generally occurs within weeks of acquiring virus, is 
characterized by a flu- or mono-like illness. During this period, large amount of virus are 
producing in human body. The second stage is chronic asymptomatic infection. HIV 
reproduces at very low levels but it is still alive during this period. The patients may not 
have any symptoms for 8 to 10 years. The third stage is symptomatic infection. The 
human's immune system has been severely damaged by HIV and complications of AIDS 
have developed. Symptoms in this stage include severe loss of weight, and one or more 
unusual opportunistic infections or cancers in skin, respiratory system, gastro-intestinal 
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(GI) system and central/peripheral nervous system. Without treatment, the patients 
typically can survive about 3 years (Bartlett, 1990; Belman, 2002; O'Brien et al., 2004). 
 
 
Figure 1. Estimation of population of HIV infections and living with HIV/AIDS in US 
(1977–2006). Adapted from United States Centers for Disease Control and Prevention 
website.  
 
HIV-1 Structure and Replication Cycle 
HIV is divided into two strains, HIV type 1 (HIV-1) and HIV type 2 (HIV-2), and 
both can cause HIV infection in humans. HIV-1 originated from chimpanzees and 
gorillas living in central Africa, and HIV-2 has been identified as the virus that infect 
sooty mangabeys (Cercocebus atys) in western coast of Africa (Robertson et al., 1995; 
Gao et al., 1999). Genetically, HIV-1 and HIV-2 are superficially similar, but HIV-1 is 
considered to be principle cause of AIDS globally. Structure of HIV-1 shows the 
characteristics of a typical lentivirus retroviridae (Figure 2).  It is a 120-200 nm roughly 
spherical virion enveloped with 2 single RNA strands. It uses the host cell membrane to 
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form the viral envelope covered by gp41 and gp120 surface proteins which inserting into 
the lipid envelope. Inside the envelope, the matrix formed by Gag protein p17 holds a 
cylindrical core, which not only stores the viral RNA and various proteins, but also 
contains complementary RNA synthesized by the viral reverse transcriptase (Zhu et al., 
2003; Karlsson Hedestam et al., 2008; White et al., 2008).   
 
 
 
Figure 2. Structure of HIV-1 virion. Adapted from NIAID. 
 
HIV can only replicate inside human cells, therefore HIV life cycle can be divided 
into 4 steps: entry to the cell, reverse transcription and integration, transcription and 
translation, and assembly and maturation (Figure 3). First, HIV enters host cell by the 
binding of glycoproteins (gp120) present on its surface to CD4-receptor on cell 
membrane which allows the viral envelope to fuse with cell membrane and subsequently 
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release HIV capsid into the cell (Chan and Kim, 1998; Wyatt and Sodroski, 1998). Once 
inside the cell, the HIV enzyme reverse transcriptase converts viral single-strand RNA 
genome into double-strand DNA. Then the DNA is transported to the cell's nucleus 
where it is integrated into the human DNA by integrase (Zheng et al., 2005). This 
integrated viral DNA provirus may lie dormant within a cell for a long time in the latent 
stage of HIV infection. When the cell becomes activated, a certain cellular transcription 
factors like NF-κB is up-regulated (Hiscott et al., 2001). Then HIV DNA provirus is 
converted into mRNA and spliced into smaller pieces. These small mRNA pieces are 
transported from the nucleus into the cytoplasm, where they are translated into the 
regulatory proteins Tat and Rev (Pollard and Malim, 1998). The final stage of HIV 
replication cycle is assembly of new HIV virions. Enzyme protease plays a vital role at 
this stage by cleaving the polyproteins into individual functional HIV proteins. This 
cleavage step can be inhibited by protease inhibitors (Hallenberger et al., 1992). The 
newly matured HIV virions are ready to infect another cell and begin the replication 
process all over again. In this way the virus quickly spreads through the human body. 
 
Current Treatment for HIV Infection 
To date, totally 31 antiretroviral (ARV) drugs belonging to six mechanistic classes 
have been approved by FDA for the treatment of HIV infection in the United States 
(Table 1). These medicines have greatly increased patient survival. 
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Figure 3. Steps in the HIV Replication Cycle. Adapted from NIAID. 
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Table 1. Antiretroviral drugs approved by FDA for the treatment of HIV infection by 
2012. 
Drug Class Brand Name Generic Name 
Non-nucleoside 
Reverse 
Transcriptase 
Inhibitors 
(NNRTIs) 
Viramune Nevirapine (NVP) 
Rescriptor Delavirdine (DLV) 
Sustiva Efavirenz (EFV) 
Intelence Etravirine (ETV) 
Edurant Rilpivirine (RPV) 
Nucleoside Reverse 
Transcriptase 
Inhibitors (NRTIs) 
Retrovir Zidovudine (ZDV, AZT) 
Ziagen Abacavir (ABC) 
Videx  
Videx EC (enteric-coated) 
Didanosine (ddl) 
Zerit Stavudine (d4T) 
Epivir Lamivudine (3TC) 
Viread Tenofovir DF (TDF) 
Emtriva Emtricitabine (FTC) 
Protease Inhibitors 
(PIs) 
Invirase Saquinavir (SQV) 
Ritonavir  Ritonavir (RTV) 
Crixivan Indinavir (IDV) 
Viracept Nelfinavir (NFV) 
Reyataz Atazanavir (ATV) 
Lexiva Fosamprenavir (FPV) 
Aptivus Tipranavir (TPV) 
Prezista Darunavir (DRV) 
Fusion Inhibitors Fuzeon Enfuvirtide (T-20) 
CCR5 Antagonists Selzentry Maraviroc (MVC) 
Integrase Inhibitors Isentress Raltegravir (RAL) 
Fixed-Dose 
Combination 
(contain two or 
more anti-HIV 
medications from 
one or more drug 
classes) 
Combivir Lamivudine, Zidovudine 
Kaletra Lopinavir, Ritonavir 
Trizivir Abacavir, Lamivudine, Zidovudine 
Epzicom Abacavir, Lamivudine 
Truvada Emtricitabine, Tenofovir DF 
Atripla Efavirenz, Emtricitabine, Tenofovir DF 
Complera Emtricitabine, Rilpivirine, Tenofovir DF 
Stribild Elvitegravir, Cobicistat, Emtricitabine, 
Tenofovir DF 
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Highly active antiretroviral therapy (HAART), the recommended treatment for HIV 
infection, involves taking a combination of three or more anti-HIV drugs (a regimen) 
from at least two different drug classes daily. These treatments prevent HIV from 
multiplying and thereby suppress viral levels in the body. Multi-drug HAART regimens 
do not cure the people infected with HIV but help them live longer, healthier lives (Clotet, 
2004; Peters and Conway, 2010; Spaulding et al., 2011; Stock, 2011). However, HAART 
was observed to be associated with some problems, including drug-resistance, side 
effects of the medication, drug interactions with one another as well as non-HAART 
drugs, and the high cost of treatment (Belman, 2002; Lambotte et al., 2003; Sunner et al., 
2008; Peters and Conway, 2011). The emergence of drug-resistance occurs very rapidly 
and leads to treatment failure, therefore it must be suppressed. Usually drug-resistance 
emerges during drug mono-therapy, but it can still be developed even in the face of multi-
drug HAART therapy (Richman, 2001; Simon et al., 2006; Temesgen et al., 2006; Chen 
et al., 2007).   
Development of drug-resistance by HIV is similar to the way in which bacteria 
develop resistance to antibiotics. The virus population in the patient with HIV exists as a 
diverse but related viral swarm, known as a quasi-species (Thomson et al., 2002). A rapid 
viral replication combined with the error-prone nature of viral reverse transcriptase leads 
to the high degree of genetic diversity, which results in nucleotide substitutions, 
insertions and deletions (Svarovskaia et al., 2003). When the viral population is placed 
under ARV drugs, these mutant strains of HIV replace wild-type virus due to their 
selective replication advantage in the face of drug pressure, thereby drug-resistance 
develop to the medications administered to the patient (Thomson et al., 2002). Generally 
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ARV drug resistance within drug classes is common. It has been reported that HIV-1, 
which is resistant to nevirapine (NVP), is very likely to be highly resistant to etravirine 
(ETV), both belonging to NNRTI agents (van Zyl et al., 2011). Therefore considerations 
of potential drug-resistance must be incorporated into the design of treatment regimens 
for HIV infections. 
 
Saquinavir 
HIV protease is an enzyme required to cleave viral gag and gap-pol polyprotein 
precursors into individual functional proteins found in infectious virions. Inhibition of 
HIV protease is considered to be the most important therapeutic approach to date in the 
treatment of HIV infection since protease inhibitors (PI) prevent the early stage assembly 
and maturation of infectious virions and effectively block virus replication (Markowitz et 
al., 1995; 1998; Garcia-Lerma and Heneine, 2001). Therefore discovery of PIs, including 
saquinavir, lopinavir, ritonavir, nelfinavir and amprenavir, has introduced a new class of 
first-line drug therapies for mid-stage and advanced-stage HIV-infected patients.  
Saquinavir (SQV) is the first PI drug marketed in the United States in 1995 (Figure 
4). Hard gelatin capsule formulation of SQV mesylate (Invirase
®
) and SQV soft gelatin 
capsule (Fortovase
®
) discovered by Roche Pharmaceuticals were approved by FDA for 
the treatment of HIV/AIDS in 1995 and 1997, respectively. Results of in vitro studies 
indicated that SQV is highly active against HIV in human cells, results in the formation 
of immature, noninfectious virus particles (Kohl et al., 1988; Plosker and Scott, 2003). 
Clinical trials have shown that 600 mg SQV (mesylate salt) administered orally three 
times per day is effective in both raising CD4 cell counts and reducing HIV viral load 
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(Vella, 1995; Noble and Faulds, 1996). Currently Invirase in 200 mg capsules and 500 
mg tablets are still widely used in combination with other ARV drugs for the prevention 
and treatment of HIV infection in adults and children.  
 
 
 
Figure 4. Chemical structure of saquinavir 
 
Although SQV has been reported for its potent activity against HIV, its therapeutic 
efficacy is limited in clinical application due to its unfavorable properties such as low 
oral bioavailability, low plasma levels, and poor penetration into central nervous system 
(CNS) (Kim et al., 1998a; Kim et al., 1998b; Williams and Sinko, 1999). Oral 
bioavailability of SQV is very limited, only 4% for 600-mg hard gelatin capsules 
(Invirase) and about 12% for 1200-mg soft gelatin capsules (Fortovase) in healthy adults 
after single-dose administration (Kaul et al., 1999; Figgitt and Plosker, 2000). In order to 
increase its efficient inhibitory levels against virus in human cells, high daily doses must 
be administered, and with food and fluid restrictions. Consequently it contributes to the 
development of drug-resistance and leads to the appearance of serious long-term 
metabolic complications, such as atherosclerosis, hyperlipidemia, lipodystrophy, insulin 
resistance, and diabetes (Gyalrong-Steur et al., 1999; Kaul et al., 1999; Penzak and 
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Chuck, 2002; McComsey et al., 2003; Duong et al., 2006; Chandra et al., 2009), thereby 
lowers its clinical outcomes.  
Another efficient way to enhance adequate drug exposure is the application of 
“boosting agent”, typically small dose of ritonavir (RTV), to boost therapeutic 
concentration of the second PI such as SQV in PI-based regimens for the treatment of 
HIV/AIDS (Llibre, 2009; Holmstock et al., 2012; Tomaru et al., 2013). Since all PIs are 
substrates of both cytochrome P450 isoenzyme 3A4 (CYP3A4), one of key enzymes 
associated with drug metabolism, and P-glycoprotein (P-gp), an efflux transporter that 
can effectively pump drugs out of the gut wall and back into the intestinal lumen (Kaul et 
al., 1999; Eagling et al., 2002; Plosker and Scott, 2003; Pal et al., 2011). Subtherapeutic 
RTV (50–200 mg) appears to inhibit potently both of these proteins and, consequently, 
can increase the bioavailability and cellular penetration of the “boosted” PI as well as 
reduced doses and less frequent administration, the antiretroviral activity of the second PI 
is, consequently, enhanced (Rathbun and Rossi, 2002; Gallant, 2004; Youle, 2007; 
Ananworanich et al., 2008). It has been reported that the area under plasma 
concentration-time profile curves (AUC) of SQV delivered orally remarkably increased 
325-fold by coadministration with 50 mg RTV, from 165.6±128.7 ng·h/ml to 
53850.1±12758.9 ng·h/ml, in mice. Moreover, oral bioavailability of SQV was observed 
to be enhanced from 0.0093 to 0.675 under the boosting effect of RTV (Tomaru et al., 
2013). 
However, SQV concentration in cerebrospinal fluid was not observed to be enhanced 
to any significant extent in the presence of boosting agent RTV (Gisolf et al., 2000). 
Hence RTV/SQV cannot inhibit the infection of HIV-1 in brains efficiently. Additionally, 
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coadministration of low dose of RTV with “boosted” lopinavir and SQV leads to an 
increase in serum lipids to a more extent in comparison with application of these PI alone 
(Buss et al., 2001; Arnaiz et al., 2003). These side effects may lead to higher risk for 
coronary disease and stroke. Other drawbacks to RTV boosting include high cost and the 
long-term inhibition to metabolic enzymes CYP3A4 (Gallant, 2004).  
 
Various Factors Contributing to Poor Oral Bioavailability of Saquinavir 
Bioavailability (F) of a drug is defined as the fraction of the dose that appears intact 
in the systemic circulation. Various factors may influence intestinal drug absorption and 
oral bioavailability after oral administration. 
F = fa(1-EG)(1-EH)                                                            
where fa is the fraction of the drug absorbed across intestinal mucosa, (1-EG) is the 
fraction that bypasses the degradation in gut wall, and (1-EH) is the fraction that escapes 
the metabolism and biliary excretion occurring in liver (Wu et al., 1995).  
Absorption of drugs delivered orally is very complicated and influenced by many 
possibilities. These causative factors include physiological factors (absorption sites, 
length of absorbing surface, blood circulation at the absorption site, pH in GI tract, 
gastric emptying rate, permeability of absorbing membrane, transit time in intestinal 
lumen, active influx and efflux transporters as well as metabolic enzymes in gut lumen), 
physicochemical properties of drugs (solubility, pKa, chemical stability, and salt forms), 
and formulation factors (drug particle size and dosage forms, etc.) (Agoram et al., 2001; 
Lipinski et al., 2001; Pang, 2003; Severijnen et al., 2004; Pang et al., 2007). Diminished 
access for absorption site due to physical inactivation and chemical degradation in gut 
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lumen, poor permeability across GI tract mucosa, and fast elimination by first-pass 
effects occurs in intestine and liver may also contribute to poor oral bioavailability of the 
delivered therapeutic agents and thereby limit their clinical outcomes.  
 
Key Physiological Factors Influencing Drug Oral Bioavailability 
Structure of Small Intestine 
Small intestine is the major site for drug oral absorption. Its length (around 7 meters 
for adult human) and wall structure formed by mucosal folds, villi and microvilli provide 
a large surface area (about 250 square meters) for absorption and digestion. Small 
intestine is made up of three segments: duodenum, jejunum and ileum. In which 
duodenum and jejunum, the upper section of small intestine, is the main drug absorption 
site due to its large surface area, generous blood supply and permeable mucosa 
(Severijnen et al., 2004). Epithelium of the intestinal mucosa consists of simple columnar 
epithelium which contains three types of cells with distinct functions: endocrine, exocrine 
and absorptive cells. Endocrine cells secrete digestive hormone peptides, while exocrine 
cells (goblet cells) secrete mucus or antimicrobial peptides. Absorptive cells (also called 
enterocytes), the most abundant epithelial cells, contribute to the translocation of 
compounds and nutrients across intestinal epithelium (Wu et al., 1995). 
Compounds passing from the bulk phase of the intestine to epithelial cell apex 
encounter two distinct regions, the unstirred water layer (USWL) and the acidic 
microclimate (Collet et al., 1992; Sanderson, 1999). The USWL, with the thickness of 
about 530 μm in small intestine, is known to be a significant barrier to the highly 
lipiphilic molecules which exhibit much greater membrane permeation than hydrophilic 
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agents, hence absorption is rate-limited by the inability of traversing the USWL for these 
lipiphilic drugs (Ungell et al., 1998; Pang, 2003). However, hydrophilic or polar 
molecules are not significantly impeded by the lipid layer. Therefore only drugs possess 
both hydrophilic and lipiphilic properties can permeate the USWL and cellular membrane 
well. The mucus coat and outer glycocalyx of the intestinal epithelium are composed of 
negatively charged carbohydrate side chains, thus it forms an acidic microclimate region 
on the surface layer of epithelial cells. It has been reported that the pH of microclimate in 
proximal small intestine is significantly more acidic than in bulk phase (Sanderson, 1999), 
and a pH-dependent transport process through intestinal epithelial cells can be observed 
especially for weak electrolytes. 
 
Transporters and Metabolic Enzymes in Intestine 
Being a major absorption site for orally administered drugs, expression of various 
influx and efflux transporters as well as drug metabolizing enzymes in small intestine 
influences its absorptive function (Pang, 2003; Pang et al., 2007). A variety of influx 
transport systems, illustrated in Figure 5, facilitate the translocation of amino acids, 
peptides, hexose, organic anions, organic cations, nucleosides and other nutrients across 
intestinal epithelium. Among these influx transport systems, peptide transporter 1 (PepT1) 
has attracted a special attention recently. PepT1 is one of identified members of proton-
dependent oligopeptide transporter (POT) family, and shows broad substrate specificity. 
Generally proteins are digested in GI tract and produce a huge number of short-chain 
peptides, like di- and tri-peptides, which can be translocated across intestinal epithelium 
by PepT1 localized on the brush-border membrane (Thamotharan et al., 1997; Terada and 
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Inui, 2004). It has been reported that, in comparison with L-alpha-methyldopa, a 4- to 20-
fold increase in intestinal permeabilities was achieved for five dipeptidyl derivatives 
targeting the peptide transport system (Hu et al., 1989).  
In contrast with influx transporters, the role of efflux transporters is to limit influx 
and facilitate efflux to prevent the intracellular accumulation of their substrates, 
consequently effectively reduce drug translocation within the enterocyte. Drug exsorption 
occurs at apical cell membrane of enterocytes at the villous tips via ATP-binding cassette 
(ABC) efflux transporters including P-glycoprotein (P-gp), multidrug resistance-
associated protein 2 (MRP2) and breast cancer resistance protein (BCRP) (Saitoh and 
Aungst, 1995; Takano et al., 2006; Constantinides and Wasan, 2007). These efflux 
transporters delimit intestinal absorption of a variety of drugs due to their broad substrate 
specificity. P-gp recognizes neutral and positively charged hydrophobic compounds, 
MRP2 effluxes relatively hydrophilic compounds such as glucuronide, glutathione and 
sulfate conjugates, and BCRP recognizes relatively hydrophilic anticancer compounds. 
The detailed characteristics of these efflux transporters will be described in the following 
section. 
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Figure 5. Distribution of metabolic enzymes and transporters present in intestinal 
epithelial cells.  
Influx transporters: PepT1: Oligopeptide transporter 1; ASBT: Apical sodium-dependent 
bile acid transporter; RFC: Reduced folate transporter; NPT1: Sodium-dependent 
phosphate cotransporter type 1; CNT: Concentrative nucleoside transporters; MCT1: 
Monocarboxylic acid transporter 1; OATP: Organic anion transporting polypeptide; 
ENT1/ENT2: Equilibrative nucleoside transporter 1/2. Efflux transporters: MDR1 (P-gp): 
Multidrug resistance-associated protein; MRP2: Multidrug resistance-associated protein 
2; BCRP: Breast cancer resistance protein. Enzymes: CYP: Cytochrome P450; SULT: 
Sulfotransferase; UGT: UDP-Glucuronosyltransferase; GST: Glutathione S-transferase. 
 
Intestinal metabolism plays an important role in limiting the systemic uptake of 
orally ingested therapeutic compounds. Both phase I and phase II enzymes are expressed 
in intestinal tissue, although at lower levels than those in liver. These enzymes include 
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cytochromes P450 (CYP) (Watkins et al., 1987; Paine et al., 2006), uridine diphosphate 
glucuronosyltransferases, sulfotransferases (UGT) (Czernik et al., 2000; Strassburg et al., 
2000), sulfotransferase (SULT) (Chen et al., 2003), glutathione S-transferases (GST) 
(Gibbs et al., 1998), hydrolase (Peters, 1970) and alcohol dehydrogenase (Engeland and 
Maret, 1993). CYP3A, including CYP3A4, CYP3A5, CYP3A7, and CYP3A43 etc, is 
considered as the predominant subfamily (about 70-80%) of P450 enzymes in the 
enterocytes (Peters and Kremers, 1989; Kaminsky and Zhang, 2003; Thelen and 
Dressman, 2009; Honda et al., 2011). CYP3A content in human intestinal microsomes 
has been reported to be 30.6 pmol/mg protein in duodenum, 22.6 pmol/mg protein in 
jejunum, and 16.6 pmol/mg protein in ileum, respectively (Paine et al., 1997). 
Additionally, the median microsomal CYP3A content in these intestinal sections is 
observed to be 44%, 32% and 24% of the median hepatic CYP3A content, respectively 
(Paine et al., 1997). Pharmacokinetic studies of CYP3A4 substrate midazolam after oral 
administration to healthy human subjects indicate that the intestinal extraction ratio of 
midazolam (0.43 ± 0.24) is similar to that of liver (0.44 ±0.14), suggesting that intestinal 
elimination contributes significantly to the first-pass metabolism of orally delivered 
CYP3A substrates (Thummel et al., 1996). Apart from CYP3A, only limited types of 
CYP enzymes are expressed in human small intestine. These enzymes include CYP2C, 
CYP2J, CYP2D6, CYP1A and CYP4F12, etc (Hashizume et al., 2002; Thelen and 
Dressman, 2009). Generally, the range of different CYP enzymes expressed in human 
intestine is markedly less than the range in liver. In comparison with other organs of GI 
tract, small intestine exhibits higher expression levels of phase II enzymes including GST, 
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UGT, and SULT. Interaction between xenobiotic compounds and these enzymes 
facilitates their elimination from the lumen of intestine.   
 
Unfavorable Properties of Saquinavir 
Although SQV exhibits potent activity against HIV-1, its therapeutic efficacy is 
limited in clinical application due to some undesirable properties like poor aqueous 
solubility as well as high affinity for efflux transporters and metabolic enzymes (Kim et 
al., 1998a; Plosker and Scott, 2003).  
 
Low Solubility: 
In vivo efficiency of SQV not only depends on its intrinsic anti-HIV activity, but also 
on its biopharmaceutical availability, i.e. the ability to reach HIV-infected cells after oral 
administration. Therefore a high concentration in intestinal fluid in GI tract is required to 
provide sufficient driving force to penetrate the underlying tissue. SQV is a lipophilic 
(logP = 4.2) and weakly basic (pKa ~ 2 and 7) compound with a very poor aqueous 
solubility (2.47 µg/ml) (Cheng et al., 2007; Buchanan et al., 2008). The mesylate salt of 
SQV shows an improved but still limited solubility in water (2.22 mg/ml at 25C). It 
significantly limits its therapeutic efficacy during its clinical application. 
 
High Affinity for Efflux Pumps: 
ATP binding cassette (ABC) efflux pumps, including multidrug resistance proteins – 
P-glycoprotein (P-gp, MDR1, ABCB1), multidrug resistance-associated protein 2 – 
MRP2 (ABCC2), and breast cancer resistance protein –BCRP (ABCG2), have been 
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widely accepted as important defense against exogenous compounds encountered in daily 
life (Ito et al., 2005). Efflux pumps are responsible for imparting drug resistance by 
actively effluxing out drug molecules out of cytoplasm, thus protect the cells from 
endogenous or exogenous toxins. Due to their broad substrate specificity and high 
expression at apical membranes of epithelial barriers like intestine, blood-brain barrier 
(BBB), liver and kidney, these efflux proteins regulate the pharmacokinetic and 
pharmacodynamic processes of numerous therapeutic compounds. Efflux activity of these 
transporters is the major factor responsible for the poor absorption, low bioavailability, 
and high metabolism of a variety of PIs, consequently exhibits a dramatic impact on their 
therapeutic outcomes and clinical application (Kim et al., 1998a; Pal and Mitra, 2006; 
Thuerauf and Fromm, 2006; Pal et al., 2011).  
 
P-glycoprotein (P-gp):  
P-gp, a transmembrane glycosylated protein and gene product of MDR1, is one of the 
major efflux transporters located on the luminal (apical) surface of epithelial and 
endoethelial cells in a variety of tissues including intestine, liver and blood-brain-barrier. 
P-gp consists of a duplicated structure (tandem structure) composed of around 1,280 
amino acids with a molecular weight of 170 kDa. Each half of the molecule contains a 
nucleotide-binding domain (NBD) including six highly hydrophobic transmembrane 
domains (TMDs) followed by a large cytoplasmic domain with an ATP-binding site 
(Figure 6). The second half of P-gp shows over 65% of amino acid similarity with the 
first half of the polypeptide (Sharom, 1997; Wacher et al., 1998).  
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Figure 6. Topological structure of P-glycoprotein 
 
Compounds with large, amphipathic and aromatic structures tend to be interacted 
with P-gp. This ATP-driven protein binds and translocates these hydrophobic compounds 
from plasma membrane back into extracellular fluid and thereby restricts their entry into 
epithelial cells, subsequently diminishes drug efficacy. Previous research on MDR1 
knockout mice showed remarkable impact of P-gp on oral bioavailability, disposition and 
tissue distribution of many drugs (van Asperen et al., 1997; Marchetti et al., 2008). In the 
case of cytotoxic drugs, this efflux activity leads to the enhanced cell survival. 
Expression of P-gp in epithelial cells of various organs provides a protective barrier 
against the entry of xenobiotics and prevents the accumulation of toxic substances.  
SQV is demonstrated as a high-affinity substrate for P-gp. In comparison with other 
major secretary transporters like MRP2 located in rat jejunum, P-gp displays a 
dominating role on intestinal SQV absorption (Usansky et al., 2008). Transepithelial 
permeation of SQV across gut wall into systemic circulation is mainly restricted by P-gp, 
and consequently a larger fraction of SQV is available for pre-systemic biotransformation 
in GI tract.  
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Multidrug resistance-associated protein 2 (MRP2):  
Human ABC sub-family C (ABCC) includes 12 members, in which MRP1-6 efflux 
proteins are known to be involved in the efflux of many therapeutic agents across lipid 
cellular membranes (Krishnamachary and Center, 1993; Zaman et al., 1994; Hulot et al., 
2005; Letourneau et al., 2005; Gradhand and Kim, 2008; Paumi et al., 2009). MRP1-6 is 
divided into two sub-categories. MRP1, 2, 3, and 6 belong to the category of MRPs 
having an extra N-terminal domain and MRP4 and 5 belong to a category without one. 
MRP2 (190 kDa) is the second member of ABCC efflux pumps cloned from rat and 
human tissues (Buchler et al., 1996). In comparison to P-gp, MRP2 consists of 1545 
amino acids and has an additional amino-proximal membrane-spanning domain 
represented by an extension of approximately 200 amino acids (Figure 7) (Tusnady et al., 
1997; Leslie et al., 2005).  
MRP2 is located on the apical membrane of various polarized cells and involved in 
the secretion of endogenous and xenobiotic substances from cells in the terminal phase of 
detoxification (Konig et al., 1999). Hence in comparison with other efflux pumps P-gp 
and BCRP, MRP2 is the optimal transporter to eliminate toxins and carcinogens that 
conjugated with various GSH, glucuronate, or sulfate from intestinal epithelial cells into 
the intestinal lumen (Nies and Keppler, 2007).  
Results of cytotoxicity and transport studies by Williams et al indicated that SQV is 
transported by both hMRP1 and hMRP2 as well as hP-gp (Williams et al., 2002). 
Moreover, the rank order of apparent permeabilities of SQV on various MDR-transfected 
MDCKII cell models is P-gp > MRP2 ˃˃ MRP1. Apical expression of efflux pump 
proteins P-gp and MRP2 on intestine may lead to the poor oral bioavailability of SQV. 
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Studies on administration of PIs across the blood-cerebrospinal fluid and the BBB also 
demonstrated that MRP2 as well as P-gp contributes to drug-permeability barriers into 
and out of the central nervous system (Rao et al., 1999). 
 
 
Figure 7. Topological structure of MRP2 
 
Breast cancer resistance protein (BCRP):  
Unlike P-gp and MRPs, BCRP is a 72 kDa half-transporter and needs to form multimers 
to be functional (Gradhand and Kim, 2008; Sharom, 2008; Pal et al., 2011). It consists of 
a single hydrophobic membrane spanning domain predicted to contain 6 TMD helices 
preceded by a single NBD (Figure 8) (Leslie et al., 2005). 
BCRP is highly expressed in the epithelial cells of the intestine, liver bile canaliculi, 
human placenta syncytiotrophoblast, lobules of the mammary gland and renal tubules, as 
well as the endothelial cells of capillaries at the BBB and placenta (Doyle et al., 1998; 
Maliepaard et al., 2001; Cooray et al., 2002). Functions of BCRP include regulation of 
intestinal absorption, biliary and renal secretion of substrates as well as protection of 
brain from various xenobiotics and toxins. It influences the disposition of structurally 
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unrelated compounds, typically both hydrophobic and hydrophilic conjugated with 
organic anions (particularly the sulfates) (Doyle and Ross, 2003; Mao and Unadkat, 
2005), from different therapeutic classes throughout the body due to its broad substrate 
specificity. The substrates of BCRP include anti-hypertensive, anti-diabetics and 
chemotherapeutic agents, antibiotics, and numerous diverse drugs like glyburide, 
nitrofurantoin, dipyridamole, cimetidine and leflunomide (Jani et al., 2009; Beery et al., 
2012). The overlap in substrate specificity between BCRP and P-gp increases the barrier 
function of the efflux transporters (Kodaira et al., 2010). BCRP also shares substrates 
with MRP2 but with different affinity. Unlike MRP2 that transports most of glutathione, 
sulfate and glucuronate conjugates, BCRP can efflux out more sulfate than glucuronide 
conjugates (Mao and Unadkat, 2005; Nies and Keppler, 2007). 
 
 
Figure 8. Topological structure of BCRP 
 
Low Resistance to Metabolic Enzymes 
As we mentioned above, drug-metabolizing enzymes are highly expressed in both 
liver and intestine mucosa. Poor pharmacokinetics of orally administered SQV is often 
attributed to rapid and extensive first-pass metabolism in both small intestine and liver 
(Fitzsimmons and Collins, 1997). CYP3A has been identified as the predominant 
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subfamily of hepatic and intestinal CYP enzymes that is responsible for oxidative 
biotransformation of more than 50% of drugs in humans and rats (Gomez et al., 1995; 
Backman et al., 1996). SQV is metabolized primarily by CYP3A4 with Km values of 0.3-
0.5 µM to mono- and di- hydroxylated metabolites with negligible antiviral activity 
(Faesch, 1991; Fitzsimmons and Collins, 1997; Ernest et al., 2005). It inhibits CYP3A4-
dependent biotransformation of terfenadine to its inactive metabolites with a Ki of 0.7 µM 
in human small-intestinal microsomes, suggesting that SQV can be metabolized by 
human intestinal CYP3A4 (Fitzsimmons and Collins, 1997). Another isoform CYP3A5 
also contributes metabolism of SQV in humans. After oral administration of single-dose 
SQV soft gel capsules (1200 mg) to healthy volunteers, median value of AUC0–24h for 
SQV has been reported to be 34% lower in the individuals with functional CYP3A5 
alleles than that among those without functional alleles (Josephson et al., 2007). SQV 
also shows moderate affinity to CYP2C9 and CYP2D6.  It inhibited CYP2C9 activities in 
human liver microsomes with an IC50 of 53.9 ± 9.9 µM (Eagling et al., 1997). While the 
results of inhibitory studies of desipramine hydroxylation, an index reaction used to 
assess human CYP2D6 activity, indicate that SQV can competitively inhibit this 
metabolizing enzyme (Ki =24.0 ± 1.5 µM) (von Moltke et al., 1998). 
 
High Plasma Protein Binding 
 Drug in plasma is in a state of equilibrium between unbound drug and protein bound 
drug. The ratio of unbound to bound drug is generally determined by drug and protein 
concentrations and binding constants. Therefore protein binding in plasma is one of the 
most important characteristics for the evaluation of drug disposition in human bodies, 
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because only the free drug fraction is useful in establishing the actual concentration to 
elicit its pharmacological action and achieve the maximum therapeutic effects. HIV PIs 
exhibit moderate to high affinity to plasma proteins, especially to α1-acid glycoprotein 
(AAG), an acute phase plasma α-globulin glycoprotein (Acosta et al., 2000). SQV is 
highly bound to plasma proteins, and shows more than 98% plasma protein bound in 
humans (Flexner, 1998). It suggests that only 2% of total amount of SQV in plasma is 
free and able to show the potent antiretroviral effects in vivo. Moreover, protein binding 
in plasma must be taken into consideration when using in vitro data to estimate the in 
vivo pharmacokinetic or pharmacodynamic parameters like IC90. The in vivo IC90 of SQV 
would be 50 times higher than that observed in vitro (determined in the absence of any 
plasma proteins) due to its 98% protein bound.  
 
Targeted Prodrug Modification – Way to Improve Saquinavir Oral Bioavailability 
Optimizing the oral administration of drugs with narrow therapeutic index is 
critically important, especially for chronically ill patients requiring long-term treatment. 
SQV is one of such agents. We have discussed that SQV exhibits high affinity for both 
CYP enzymes and efflux transport pumps, as well as poor solubility and high plasma 
protein binding. Absorption, distribution, and disposition of SQV in human body are 
significantly influenced by the combined effects of these unfavorable factors.  
In order to overcome these physicochemical and biological barriers, various 
strategies have been employed to enhance SQV absorption in intestine and brain.  Nano-
sized formulations like nanoparticles (Shah and Amiji, 2006; Kuo and Yu, 2011), 
nanoemulsions (Vyas et al., 2008) and nanosuspensions (Dodiya et al., 2011) constitute 
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one of such strategies. Even through these nanoparticulated carriers exhibit some 
enhancement in SQV oral absorption or BBB penetration, the poor stability and short 
circulating life span within the body dramatically limit the application of these 
formulations. Other strategies to increase oral bioavailability of SQV include co-
administration of absorption enhancers like DeltaG, the biologically active fragment of 
Zonula occludens toxin (Zot) (Salama et al., 2005). It reversibly opens the tight junctions 
present in small intestine and enhances SQV oral absorption in rats. However, cellular 
toxicities have, for the most part, limited their use. 
 
 
 
Figure 9. Transporter-targeted prodrug strategy 
 
Transporter-targeted prodrug strategy, prodrugs targeting towards transporters 
expressed on epithelial cell membranes, seems to provide a good resolution to improve 
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oral bioavailability of SQV (Figure 9). Various nutrient transporters and receptors are 
present on the membrane surface of epithelial cells. The drug conjugating with a specific 
pro-moiety which is a substrate for these membrane transporters/receptors can be 
recognized and facilitated across epithelial cell membrane, subsequently these derivatives 
may permeate the intracellular environment and reach the systemic circulation. Moreover, 
modification of drug molecular structure may evade the recognition by efflux pumps or 
metabolizing enzymes. In addition, solubility of drug molecules may also be enhanced 
due to the conjugation of polar pro-moiety to drug. After translocation across cellular 
epithelial membrane, the pro-moiety of intact compounds can be cleaved by hydrolytic 
enzymes present in systemic circulation or targeting sites to release the active drug. 
Therefore absorption of poorly permeating therapeutic agents can be enhanced by 
targeted prodrug modifications. 
 
Peptide Transport System  
Small intestine has been considered as the major site for nutrients uptake into the 
body. Generally the proteins are hydrolyzed into di- or tri- peptides (80%) and free amino 
acids (20%) by proteases located in the gut lumen, and then transported into enterocytes 
under the facilitation of certain transporters expressed on the apical membrane of 
intestinal epithelial cells (Adibi and Mercer, 1973). Proton-coupled oligopeptide 
transporter (POT) is one of such influx transport systems. POT transporters are integral 
plasma membrane proteins. They are driven by inwardly-directed proton concentration 
gradient and negative membrane potential across the biological membrane. Wide 
spectrum of di- and tri-peptides as well as a number of peptidomimetics can be 
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recognized and transported across epithelial membrane by POTs. Up to date, four 
members of POT family, peptide transporter 1 (PepT1, SLC15A1), peptide transporter 2 
(PepT2, SLC15A2), peptide/histidine transporter 1 (PHT1, SLCA4) and peptide/histidine 
transporter 2 (PHT2, SLCA3), have been identified in mammals. PepT1 and PepT2 have 
attracted more attention due to their high expression in various epithelia, broad substrate 
specificity, as well as high affinity and transporter capacity (Rubio-Aliaga and Daniel, 
2008).  
PepT1, first isolated and cloned from rabbit intestine (Fei et al., 1994), is a low-
affinity (Km  0.5 mM)  and high-capacity transporter with the molecular mass predicted 
to be about 75 KDa (Saito et al., 1995; Brandsch et al., 2008). It is highly expressed in 
the apical membrane of epithelial cells of intestine, kidney, pancreas, extrahepatic bile 
duct and liver (Knutter et al., 2002; Daniel and Kottra, 2004; Biegel et al., 2006; 
Brandsch et al., 2008). PepT1 has been considered to be the primary influx transporter 
that attributes to intestinal absorption of most small peptides and peptidomimetic 
compounds with different conformation, size, polarity and charges. PepT2, a high-affinity 
(Km < 0.1 mM) and low-capacity nutrient transporter (Luckner and Brandsch, 2005), is 
the next identified peptide transporter isolated from human kidney in 1995 (Liu et al., 
1995). PepT2 (~107 KDa) is expressed in a variety of tissues including kidney, lung, 
brain, mammary gland and testis (Boll et al., 1996; Lu and Klaassen, 2006; Brandsch et 
al., 2008). The general function of PepT2 is to remove small peptides from extracellular 
fluids. Typically PepT2 located in kidney reabsorbs amino acids in peptide-bound form 
from glomerular filtrate to avoid the loss of amino acid nitrogen from urine. 
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Both PepT1 and PepT2 exhibit wide substrate specificity. Besides di- and tri- 
peptides, numerous peptidomimetics including β-lactam antibiotics, angiotensin-
converting-enzyme (ACE) inhibitors, renin inhibitors, thrombin inhibitors, anticancer 
drugs like bestatin, and antiviral prodrugs like valacyclovir can be delivered by the 
facilitation of peptide transporters (Yang et al., 1999). Therapeutic efficacy of these drugs 
after oral administration is determined not only by their efficient intestinal absorption, but 
also by their half lives in systemic circulation. Intestinal PepT1 acts as vehicle for their 
effective oral absorption, and rental PepT2 reabsorbs these compounds to maintain their 
half lives in body. Therefore peptide transport system plays an important role in drug 
absorption, distribution and disposition. It is believed to be an ideal targeting transporter 
for prodrug design to achieve improved systemic bioavailability and optimized 
pharmacokinetic profiles. 
 
Peptide Prodrug Modification 
Recently peptide prodrug modification has been considered as a promising strategy 
to improve the therapeutic outcomes of drugs with poor bioavailability, such as SQV. 
Peptide prodrugs are designed by conjugating parent drug to small peptides like di- or tri- 
peptides. The newly formed “peptidomimetic prodrug” may be easily recognized as 
substrates by peptide transporters, which present on both apical and basolateral 
membranes of intestinal epithelial cells, and ferried across the epithelium into the 
systemic circulation (Figure 10) (Irie et al., 2004; Pieri et al., 2010). Structural 
modification may further reduce the interaction of the parent drug with efflux transporters 
and metabolizing enzymes. Therefore enhanced permeation could be achieved by the 
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cumulative effects of reducing secretion and increasing absorption. Moreover, 
physicochemical properties such as water solubility may be also improved based on the 
amino acid chosen for derivatizing the drug. It is reported that valine ester prodrugs of 
acyclovir and ganciclovir showed an increased solubility (Yang et al., 2001). Extensive 
research has been performed towards prodrug design by targeting peptide transporter to 
increase the bioavailability of various therapeutic reagents. In vitro permeability studies 
on L-valyl, L-leucyl, and L-phenylalanyl ester conjugates of SQV and indinavir 
demonstrated an increased translocation across Caco-2 cell monolayers (Rouquayrol et 
al., 2002). Valine-valine and glycine-valine prodrugs derived from SQV have also 
exhibited 4.6- and 1.8- fold enhanced absorption relative to parent drug in rat jejunum, 
respectively (Zappella et al., 2003).  
After evasion these most dominating barriers which may lead to poor oral 
bioavailability, the hydrolysis of intact peptide prodrugs would be catalyzed by a large 
variety of hydrolases i.e. esterases and peptidases, then amino acid prodrugs and free 
parent drugs would be regenerated and further translocated into biological fluids or target 
tissues by amino acid transporters (Figure 10). 
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Figure 10. Cellular processes of peptide prodrug transport across intestinal epithelial cells 
 
Stereoselectivity 
Chiral technology was discovered in 1848, with the identification of two isomers of 
sodium ammonium tartrate by the mold Penicillium glaucum. However, the phenomenon 
of chirality was widely believed to play a major role in pharmaceutical industries until the 
1950’s (Nguyen et al., 2006). Currently chiral drugs have become a majority of newly 
introduced products in global market and is expected to reach 95% by 2020 (Nguyen et 
al., 2006). For many years, the racemic mixture drug products were justified by their 
lower production costs and lack of availability of chirally specific drug synthesis 
techniques. But recently single enantiomer drugs are showing a continuous growth 
worldwide and many of the top-selling drugs are marketed as single enantiomers. 
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The living body is a highly chiral environment because all proteins, enzymes, amino 
acids, carbohydrates, nucleosides as well as a number of alkaloids and hormones are 
chiral compounds. Although they have the same chemical structure, stereoisomeric drugs 
always exhibit different biological activities due to their differential 3-point fit at the 
target sites like transporters, receptors and enzymes (Lees et al., 2012). Therefore 
stereoisomers of drug molecules containing one or more chiral centers exhibit differing 
potencies for pharmacokinetic processes and pharmacological effects, also called 
“stereoselectivity”, with respect to affinity for certain subtypes of receptor or enzymes, 
distribution, metabolism and excretion, as well as in antagonistic actions and their 
toxicological properties (Siccardi et al., 2003; Wang et al., 2010). Thalidomide is an anti-
nausea and sedative drug that was believed to be safe and effective in the 1960’s. 
However, many newborns suffered from severe birth defects were reported to be born to 
the women who had taken thalidomide during pregnancy. The later research found that 
one enantiomer of thalidomide, (R)-, was therapeutically effective whereas another 
isomer (S)- showed severe adverse effects (Eriksson et al., 2001; Smith, 2009).  
Derivatives of a compound conjugating with different stereoisomeric pro-moieties 
may be also featured with various physicochemical and biological properties. Most amino 
acids currently applied in prodrug strategy are L-isomers (levorotatory). Major 
advantages to L-configurations include their natural occurrence in the body, and their 
optimal three-dimensional spatial arrangement of atoms which exhibit high affinity to 
transporters or receptors (Hutt and O'Grady, 1996; Sawada et al., 1999). However, most 
L-isomeric derivatives have limited chemical or enzymatic stability, while D-amino acid 
(dextrorotatory) conjugated prodrugs exhibit much better resistance to enzymatic 
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hydrolysis (Pochopin et al., 1994; Tamura et al., 1996b; Song et al., 2002). L-valine-L-
valine has been reported to be degraded completely in 15 min in Caco-2 cell homogenate 
(1 mg/ml) at 37C which is much faster than the other diastereomers (Tamura et al., 
1996a). In contrast, D-amino acid prodrugs of dapsone exhibited much better resistance 
to enzymatic hydrolysis and showed a longer residence time in vivo (Pochopin et al., 
1994). Half life of L-valine-L-valine-acyclovir in rat intestinal homogenates has been 
reported to be less than 0.08 h, whereas L-D- and D-L- conjugates showed much higher 
stability with the t1/2 values of 0.49 h and 2.82 h, respectively (Talluri et al., 2008). 
Therefore, prodrug modification with different stereoisomeric amino acid or small 
peptide pro-moieties may serve as a promising strategy to provide an optimal medicinal 
treatment and a right therapeutic control for the patient. 
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CHAPTER 3 
INFLUENCE OF EFFLUX PUMPS ON FUNCTIONAL ACTIVITIES OF PEPTIDE 
TRANSPORTERS IN MDR-TRANSFECTED MDCK CELL LINES 
Rationale 
Madin-Darby canine kidney (MDCK) cell line has been widely employed for cell-
based permeability screening model. There are two strains of MDCK cells, both of which 
are derived from the distal tubule or collecting duct of the nephron (Ojakian and 
Herzlinger, 1984). In comparison with MDCK strain I cells which are non-ciliated, the 
strain II cells are ciliated, columnar in shape, and have microvilli on their apical surface 
when grown on permeable supports (von Bonsdorff et al., 1985). MDCK cells express 
various endogenous influx transporters, including amino acid transporters (Boerner et al., 
1986), organic cation transporters (Hantz et al., 2001) and peptide transporters (Putnam et 
al., 2002; Landowski et al., 2005) and efflux transporters like P-gp (Horio et al., 1989) 
and the multidrug resistance protein (MRP, ABCC) family (Flanagan et al., 2002). At 
present, wild-type MDCK strain II cells transfected with the human MDR1, MRP2, or 
BCRP genes are employed as quick assessment models to estimate in vivo permeability 
of new drug candidates, which are substrates, inducers, or inhibitors of these efflux 
pumps, across intestinal mucosa (Tang et al., 2002b; Tang et al., 2002a; Xiao et al., 2006; 
Agarwal et al., 2007a)
 
or the blood-brain barriers (Gumbleton and Audus, 2001; Wang et 
al., 2005). However, a large number of these drug candidates are also substrates for influx 
transporters, and prodrug modification with peptide is a common practice to circumvent 
efflux. The assumption for drug screening using transfected cell models is that the 
function and expression of endogenous transporters in transfected cells are comparable 
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with parental cells. Accordingly a proper prediction for the in vivo drug absorption can be 
obtained from results of permeability assay conducted across these transfected cell 
models. But recently, gene expression of endogenous canine P-gp in MDCK cells has 
been reported to be significantly down-regulated after transfection with human MDR1. 
Transepithelial transport of vinblastine, a substrate for P-gp, was consequently 
underestimated when comparing the result obtained across human MDR1- transfected 
versus wild-type MDCK cells (Kuteykin-Teplyakov et al., 2010). Therefore we asked 
question, does transfection of efflux transporters affect the function of endogenous influx 
transporters too? If so, it might lead to significant bias in screening dual substrates for 
influx/efflux transporters, like “peptidomimetics” using these transfected cell lines.  
In recent years, considerable research in targeted drug delivery indicate that peptide 
transporters are attractive targets for new drug discovery because they have broad 
substrate specificity and high capacity, especially for smaller peptides i.e. di and 
tripeptides (Ganapathy and Leibach, 1996; Steffansen et al., 2004). Also “peptidomimic” 
drugs can be recognized as substrates by the peptide transporter-mediated influx system 
and ferried across epithelial membrane into systemic circulation (Ganapathy et al., 1995; 
Wang et al., 2012). Apical peptide transporters in MDCK cells are H
+
/peptide co-
transporters, mainly peptide transporter-2 (PepT2, SLC15A2) (Sawada et al., 2001; 
Balimane et al., 2007), whereas basolateral peptide transporters are still unknown (Terada 
et al., 2000).  PepT2, a high-affinity and low-capacity nutrient transporter, is expressed in 
a variety of tissues including kidney, lung, brain, mammary gland, and testis (Lu and 
Klaassen, 2006). The driving force for PepT2-mediated peptide transport is provided by 
an inwardly directed H
+
 gradient and an inside-negative membrane potential. It plays a 
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key role in the uptake and transport of mammalian protein nutrients across biological 
membranes as well as another important H
+
/peptide cotransporter PepT1 (SLC15A1). 
Thus several publications have demonstrated the application of intact or transfected 
MDCK cell models to characterize permeability and absorption of substrates for peptide 
transporters (Agarwal et al., 2007b; Jain et al., 2008; Ouyang et al., 2009). However, no 
previous work has been reported about the alteration of endogenous peptide transporter 
system expressed in the MDCK cells, especially on apical membrane, after transfection 
with different human efflux protein genes. 
Functional characterization of peptide transporters was evaluated in various MDCKII 
cell lines in this chapter. Uptake and transport of [
3
H]Gly-Sar were conducted on 
MDCKII-MDR1, MDCKII-MRP2, and MDCKII-BCRP cells as well as MDCKII wild-
type cells. Real-time PCR and Western blot analyses were also performed to investigate 
mRNA and protein levels of both exogenous efflux pumps and endogenous peptide 
transporters respectively. The aim of this work is to determine whether the function of 
peptide transporters is compromised by the overexpressed efflux transporter in 
transfected MDCKII cell lines or not. This study may provide a more accurate assessment 
for these in vitro models to screen the compounds mediated by peptide transporter/efflux 
pumps in drug discovery. 
 
Materials and Methods 
Materials  
Transfected MDCKII cells overexpressing human MDR1 (MDCKII-MDR1, passage 
3-30), human MRP2 (MDCKII-MRP2, passage 3-30), human BCRP (MDCKII-BCRP, 
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passage 3-30), and wild-type MDCK cells (MDCKII-wt) were generously provided by Dr. 
P. Borst and Dr. A. Schinkel (The Netherlands Cancer Institute, Amsterdam, Netherland), 
respectively. [
3
H]Glycylsarcosine ([
3
H]Gly-Sar, 4 Ci/mmol), and [
14
C]Mannitol (58.8 
Ci/mmol) were purchased from Moravek Biochemicals (Brea, CA). Dulbecco’s modified 
Eagle’s Medium (DMEM), TrypLETM Express Stable Trypsin Replacement, and Trizol-
LS
®
 reagent were obtained from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) 
was purchased from Atlanta Biologicals (Lawenceville, GA). M-MLV Reverse 
Transcriptase, Random Hexamers, and M-MLV RT 5 Reaction Buffer were purchased 
from Promega (Madison, WI). Light Cycler 480 SYBR Green 1 master kit was 
obtained from Roche Applied Science (Foster City, CA). ). NuPAGE Novex 4-12% 
Bis-Tris Gels and MagicMark™ XP Western Protein Standard (20-220 kDa) were 
obtained from Invitrogen (Carlsband, CA). Polyclonal canine PepT1 and canine PepT2 
primary antibodies were purchased from Biorbyt Ltd. (Cambridge, Cambridgeshire, UK). 
BioRad protein estimation kit was purchased from BioRad (Hercules, CA). BCA protein 
assay kit was obtained from Thermo Scientific (Rockford, IL). Fosinopril and 
scintillation cocktail reagent was obtained from Fisher Scientific Inc (Fair Lawn, NJ). 
Glycyl-L-proline (Gly-Pro) was purchased from TCI America (Portland, OR). 
Glycylsarcosine (Gly-Sar), cefadroxil, Triton X-100, hydroxyl ethyl piperazine ethane 
sulfonic acid (HEPES), d-glucose and all other chemicals were obtained from Sigma 
Chemical Co (St. Louis, MO). All chemicals were products of special reagent grade and 
used as such. Transwell
®
 inserts and 12-well tissue culture plates were purchased from 
Corning Costar Corp (Cambridge, MA). 
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Cell Culture 
Wild-type and transfected MDCKII cells were seeded at a density of 40,000 
cells/cm
2
 in 75 cm
2
 cell culture flasks and maintained in DMEM containing 10% heat-
inactivated FBS, 20 mM HEPES, 29 mM sodium bicarbonate, 100 units/ml penicillin, 
and 100 μg/ml streptomycin. Medium was replaced every other day. Cells were harvested 
and passaged at 70% – 80% confluency using TrypLETM Express Stable Trypsin 
Replacement at 5-7 days postseeding, and plated at 7 × 10
4
 cells /cm
2
 on 12-well tissue 
culture plates for apical uptake studies, and 2 × 10
5
 cells /cm
2
 on 12-well Transwell
®
 
inserts (diameter 12 mm, pore size 0.4 µm) for basolateral uptake and transport studies. 
Medium was changed every alternate day.  
 
Uptake Studies 
Cells were washed twice with 2 ml Dulbecco’s phosphate-buffered saline (DPBS, 
pH 7.4) before the experiments. Uptake was initiated by adding 1 ml DPBS with 0.5 
μCi/ml of [3H]Gly-Sar into the wells. Incubation was conducted at 37 C or 4 C for 15 
min. The tracer solution was aspirated and cells were rinsed three times with ice-cold 
stop solution (200 mM KCl and 2 mM HEPES) to determine drug uptake. Then the cells 
were lysed by adding 1 ml of 0.3 N NaOH containing 0.1% Triton-X 100 solution to each 
well and left overnight at room temperature. Aliquots from each well were transferred to 
scintillation vials containing 3 ml of scintillation cocktail. Cellular radioactivity was 
quantified using a scintillation counter (Model LS-6500; Beckman Counter, Fullerton, 
CA) and then was normalized by amount of protein measured using BioRad protein 
estimation kit in each well.  
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Growth, Temperature and pH Dependent Uptake 
Uptake of [
3
H]Gly-Sar (0.5 µCi/ml) was conducted at 37 C for different time in 
culture (3 to 8 days) to determine the optimum culture period for uptake studies. 
Temperature and pH dependent uptake of [
3
H]Gly-Sar in various MDCK cell lines at low 
cell-passage was evaluated at 4°C and 37°C, respectively. During final calculation of 
[
3
H]Gly-Sar uptake at 37C, the passive diffusion component (i.e. at 4C) was subtracted. 
To study pH dependency of Gly-Sar uptake, incubation media DPBS with different pHs 
from 4.0 to 7.4 were prepared, and permeant solutions (0.5 µCi/ml [
3
H]Gly-Sar) were  
made accordingly. Cells were pre-incubated with DPBS (pH7.4) for 20 min before 
adding permeant solutions with various pHs.  
 
Concentration Dependent Uptake 
[
3
H]Gly-Sar solutions with various concentrations (5-250 μM) of unlabeled Gly-Sar 
were used in this study to determine concentration dependent Gly-Sar cellular 
accumulation in both wild-type and transfected MDCK cell lines. Uptake was carried out 
at 4°C and 37°C, respectively. Then the data was fitted to a Michaelis-Menten equation 
as shown in “Data Analysis” section to determine the kinetic parameters of peptide 
transporter-mediated specific Gly-Sar uptake.  
 
Passage Dependent Uptake 
In order to illustrate whether various transfected MDCK cell lines exhibit passage 
dependency for Gly-Sar uptake, concentration dependent studies at both 4°C and 37°C 
were conducted on MDCKII-MDR1, MDCKII-MRP2, and MDCKII-BCRP cells with 
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different passage number (3-25). Then the uptake kinetic parameter transport efficiency 
for peptide transporters-mediated Gly-Sar uptake was estimated using Michaelis-Menten 
equation. 
 
Inhibitory Gly-Sar Uptake 
To determine the substrate specificity, apical [
3
H]Gly-Sar (0.5 µCi/ml) in the 
absence or presence of peptide transporter inhibitors, fosinopril (100 µM), cefadroxil (20 
mM) and Gly-Pro (20 mM), was evaluated in various MDCKII cell lines with low (<6) or 
high (>25) cell-passages.  
 
Transport Studies 
Transepithelial transport of Gly-Sar was evaluated across MDCKII cell monolayers 
(cell-passage number < 6) grown on Transwell
®
 inserts. Medium was aspirated before 
experiments and cell monolayers were washed twice with DPBS (pH 7.4).Working 
volumes of the apical (AP) and basolateral (BL) compartments were 0.5 and 1.5 ml, 
respectively. The monolayer integrity was evaluated by measuring transepithelial 
electrical resistance (TEER) values using volt–ohm meter (EVOM-G, World Precision 
Instruments, Sarasota, FL). Only the monolayers with TEER values of about 600 ±60 
ohm·cm
2
 was used in this study. Transport was initiated when 0.5 µCi/ml [
3
H]Gly-Sar or 
0.25 μCi/ml of [14C]Mannitol in DPBS was added in donor chambers and only fresh 
DPBS in receiving chambers. The pH of incubation media varied from 4.0 to 7.4 in AP 
chambers only, but remained consistent in BL chambers to pH 7.4. Aliquots (200 µl) 
were withdrawn from receiving chambers at predetermined time intervals over a period 
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of 60 min and replaced with same volume of fresh DPBS to maintain sink conditions. 
Samples were analyzed using a liquid scintillation counter described in uptake studies. At 
the end of experiments, the integrity of monolayers was checked by measuring TEER 
values. Cell monolayers with less than 10% of initial TEER values dropped was 
considered as integrity unchanged. Specific Gly-Sar transport across both parental and 
transfected MDCKII cell lines was calculated by subtracting nonspecific transport 
(passive diffusion) estimated from [
14
C]Mannitol from [
3
H]Gly-Sar transport. 
 
Tight Junction Determination 
To evaluate the intercellular tight junctions of different MDCKII cell lines, transport 
of [
14
C]Mannitol (0.125 µCi/ml) in DPBS (pH 7.4) was performed across MDCK cell 
monolayers for up to 60 min, as outlined above. 
 
Real-time PCR Assay 
Total RNA from different MDCK cells was isolated using Trizol reagent according 
to the manufacturer’s protocol. Concentration and purity of RNA were estimated using 
spectrophotometer at 260 and 280 nm. Total RNA (1.5 µg) was reverse transcribed to 
cDNA using random hexamers and M-MLV Reverse Transcriptase Reagent. After the 
first strand cDNA synthesis, 100 ng of cDNA was amplified by real-time PCR using 
LightCycler 480 SYBR Green-1 Master mix on an ABI Prism 5700 Sequence 
Detection System (PE Applied Biosystems, Foster City, CA) to evaluate the gene 
expression of hMDR1 (human), hMRP2 (human), hBCRP (human), cPepT1 (canine), and 
cPepT2 (canine). Sequences of primers used in this study are summarized in Table 2. 
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GAPDH gene was used as endogenous reference to normalize target gene mRNAs in 
samples. Comparative threshold method was used to calculate the relative amount of 
mRNA in comparison with control (cells with lowest passage number). 
 
Table 2. PCR primers used in real-time RT-PCR assay of transporter expression. 
General 
names 
Species 
Primer 
directions 
Primer sequences 
PepT1 Canine 
Forward 5’-GCTTGTTACCCACTGGCATT-3’ 
Reverse 5’-GCAAAACCAATGCACTTGAC-3’ 
PepT2 
Human & 
canine 
Forward 5’-CAGCTTTTGGTGGAGACCAG-3’ 
Reverse 5’-AAATCAAGCTCCCTGCATTG-3’ 
MDR1 Human 
Forward 5’-GAAGCCAGAACATTCCTCCTGGAA-3’ 
Reverse 5’-AGCCGCTACTCGAATGAGCTC-3’ 
MRP2 Human 
Forward 5’-GGTCATCCTTTACGGAGAACATCA-3’ 
Reverse 5’-GGACTGCGTCTGGAACGAAG-3’ 
BCRP Human 
Forward 5’-CCGCCACTCCCACTGAGATT-3’ 
Reverse 5’-CTCGGAGGCAGCGCTTTAAC-3’ 
 
Western Blot Assay 
Confluent cells grown on 75 cm
2
 cell culture flask were washed twice with ice-cold 
PBS and lysed on ice in RIPA buffer containing freshly added protease inhibitor cocktail. 
Protein lysate was collected by centrifugation at 15,000 g, 4C for 10 minutes and the 
total protein content was determined using BCA protein assay kit. Subsequently an equal 
amount of total protein (20 μg) was loaded and separated on ready-made Novex 4-12% 
Bis-Tris Gels. Proteins then were transferred to a polyvinylidene fluoride (PVDF) 
membrane, blocked with 5% non-fat dry milk and 1% BSA for non-specific binding and 
probed with primary antibodies specific to canine PepT1 and PepT2, respectively. 
Following three 5-minute washes in TBST (Tris buffered saline + 0.1% Tween 20), blots 
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were probed with secondary antibody in TBST (1:20,000 anti-rabbit IgG-HRP) and 
visualized by Fujifilm LAS 4000 imaging system (FUJIFILM Medical Systems USA, Inc. 
Stamford, CT). The images of immunoreactive staining were measured and analyzed by 
ImageJ 1.46r software. 
 
Data and Statistical Analysis 
Affinity and capacity of Gly-Sar to peptide transporters were fit to Michaelis-Menten 
equation by nonlinear regression to determine the kinetic parameters Km and Vmax. Data 
modeling was performed using KaleidaGraph (Synergy Software). Transport efficiency 
of peptide transporters was subsequently represented by dividing Vmax by Km. 
 
Where V is the total rate of Gly-Sar uptake, Vmax is the maximum uptake rate for 
transporter-mediated process, Km (Michaelis-Menten constant) is the concentration at 
half-saturation, and [S] is the Gly-Sar concentration.  
 Apparent permeability coefficients Papp (cm/s) were calculated by linear regression 
analysis on the time course plot of amount of drugs transported across cell monolayers.  
      Where TRcum/dt  is the flux rate of [
3
H]Gly-Sar or [
14
C]Mannitol obtained from the 
slope of transport profile. A is the surface area of cell monolayers. C0 is initial 
concentration of Gly-Sar/mannitol in the donor chambers. 
All experiments were conducted at least in triplicate and repeated independently 
three or four times. The results were expressed as mean ± SD. One-way analysis of 
𝑉 =
𝑉𝑚𝑎𝑥 × [𝑆]
𝐾𝑚 + [𝑆]
 
𝑃app =
TRcum 𝑑𝑡 
𝐶0 × 𝐴
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variance (ANOVA) followed by Tukey post hoc test was performed to test for 
statistically significant differences. Statistical analysis and data fitting were performed 
using PASW Statistics 17.0 (SPSS Inc., Chicago, IL). Difference between mean values 
was considered statistically significant at p < 0.05 and very statistically significant at p < 
0.01.   
 
Results 
Tight Junction Determination of MDCKII Cell Lines 
The change of tight junction of MDCK cells after transfection with various human 
efflux genes was evaluated by determining AP-BL mannitol permeability across different 
cell lines. Results in Figure 11 indicate that [
14
C]Mannitol permeability across wild-type 
MDCK cells significantly reduced from (4.21 ± 0.05)  10-5 cm/s to (1.84 ± 0.09)  10-5 
cm/s, (2.18 ± 0.22)  10-5 cm/s, and (1.07 ± 0.12)  10-5 cm/s after  transfection with 
human MDR1, MRP2 and BCRP genes, respectively. 
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Figure 11. AP-BL permeability of [
14
C]Mannitol (0.125 µCi/ml) across various MDCKII 
cell lines at pH 7.4.   
Each point represents mean ± SD (n=4). ** P < 0.01 compared with MDCKII-wt cells. 
 
Growth Dependence of Gly-Sar Uptake in MDCKII Cell Lines  
Results in Figure 12 demonstrate growth dependent Gly-Sar uptake by apical peptide 
transporters in different MDCKII cell lines through 3-8 days of culture period. The most 
[
3
H]Gly-Sar uptake was observed after 4-5 days post seeding in MDCKII-wt, MDCKII-
MRP2 and MDCKII-BCRP  cell lines. The transfected MDCKII-MDR1 cell line did not 
show statistically significant different in growth dependent Gly-Sar uptake study. 
Therefore all subsequent experiments were conducted on the 5th day of seeding to 
normalize and compare results. Apical uptake of [
3
H]Gly-Sar was diminished 
significantly in all transfected MDCKII cell lines compared to wild-type cells. 
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Figure 12. Growth dependent [
3
H]Gly-Sar (0.5 µCi/ml)  uptake at pH 7.4 for 15 min in 
various MDCKII cell lines.  
Each point represents mean ± SD (n=4). * P < 0.05 and ** P < 0.01 compared with 
uptake of same cell line at day 4. 
 
Temperature Dependence of Gly-Sar Uptake in MDCKII Cell Lines  
Results of temperature dependent Gly-Sar uptake by apical peptide transporters in 
different MDCKII cell lines are described in Figure 13. Around 3- to 5- fold higher 
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3
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0.45 ± 0.06, and 0.64 ± 0.12 fmol/mg protein/min in MDCKII-wt, MDCKII-MDR1, 
MDCKII-MRP2, and MDCKII-BCRP cells, respectively.  
 
 
Figure 13. Temperature dependent [
3
H]Gly-Sar (0.5 µCi/ml) uptake at pH 7.4 for 15 min 
in various MDCKII cell lines.  
Each bar represents mean ± SD (n=4). ** P < 0.01 compared with MDCKII-wt cells at 
37C.   
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pH and summarized in Figure 14. Uptake in wild-type cells were 3- to 5- fold higher than 
that in transfected MDCKII cells at all pHs determined.  The specific Gly-Sar uptake by 
apical peptide transporters in MDCKII-wt cells showed gradient enhancement when 
extracellular pH increased from 4.0 to 6.0, then decreased when environmental pH keeps 
increasing to 7.4. Similar trends were observed for MDCKII-MDR1, MDCKII-MRP2, 
and MDCKII-BCRP cells. The maximal apical Gly-Sar uptake was obtained at pH 6.0 in 
all MDCKII cell lines. 
 
 
Figure 14. The pH dependent specific [
3
H]Gly-Sar (0.5 µCi/ml) uptake by apical peptide 
transporters for 15 min in various MDCKII cell lines.  
Each point represents mean ± SD (n=4). * P < 0.05 and ** P < 0.01 compared with same 
cell line at pH 4.0. 
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Concentration Dependence of Gly-Sar Uptake in MDCKII Cell Lines 
Concentration dependent uptake of [
3
H]Gly-Sar was carried out at both 37C and 
4C to evaluate the uptake kinetics of Gly-Sar by apical peptide transporters in different 
MDCKII cell lines. Concentration dependence of apical peptide transporter-mediated 
specific Gly-Sar uptake was calculated by subtracting nonspecific uptake estimated at 
4C from total uptake determined at 37C (Figure 15). Uptake kinetic parameters 
including apparent Km, Vmax, and transport efficiency (Vmax / Km) are summarized in Table 
3. The value of Vmax for apical peptide transporters in MDCKII-wt cells was 10.76 ± 1.68 
fmol/mg protein/min. After transfection with human MDR1, MRP2, and BCRP genes, it 
decreased to 1.30 ± 0.36, 4.62 ± 0.76, and 4.50 ± 0.83 fmol/mg protein/min respectively. 
Transport efficiency values, which represent the amount of Gly-Sar translocated by unit 
peptide transporters in unit time, were estimated to 0.180 ± 0.009, 0.045 ± 0.010, 0.055 ± 
0.011, and 0.074 ± 0.016 nl/mg protein/min for apical Gly-Sar uptake in MDCKII-wt, 
MDCKII-MDR1, MDCKII-MRP2, and MDCKII-BCRP cell lines, respectively. It 
indicates that transport efficiency for apical peptide uptake was also diminished in all 
transfected MDCKII cell lines. 
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Figure 15. Concentration dependence of [
3
H]Gly-Sar uptake by apical peptide 
transporters for 15 min in MDCKII-wt cells at 37C and 4C respectively.  
Insert: Concentration dependence of apical peptide transporter-mediated specific Gly-Sar 
uptake in MDCKII-wt cells. Data (□) were calculated by subtracting nonspecific uptake 
estimated at 4C (∆) from total uptake at 37C (). Solid line represents the calculated fit 
of the data to Michaelis-Menten equation. Each point represents mean ± SD (n=3). 
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Table 3. Kinetic parameters for Gly-Sar uptake mediated by apical or basolateral peptide transporters in various MDCKII cell lines.  
 
Apical uptake 
 
Basolateral uptake 
 
MDCKII-wt 
MDCKII-
MDR1 
MDCKII-
MRP2 
MDCKII-
BCRP  
MDCKII-wt 
MDCKII-
MDR1 
MDCKII-
MRP2 
MDCKII-
BCRP 
Km (µM) 59.69±1.10 29.13±3.29 84.75±18.59 60.67±8.56  
13.71±2.22 50.87±7.86 64.56±4.09 46.15±2.26 
Vmax (fmol/mg 
protein/min) 
10.76±1.68 1.30±0.36 4.62±0.76 4.50±0.83 
 
4.45±0.04 8.52±0.81 8.03±1.78 13.07±2.61 
Vmax/Km (nl/mg 
protein/min) 
0.180±0.009 0.045±0.010** 0.055±0.011** 0.074±0.016** 
 
0.324±0.050 0.167±0.058 0.124±0.016 0.283±0.098 
Uptake of [
3
H]Gly-Sar were conducted in the presence of different concentrations of unlabeled Gly-Sar (0-250 µM) at 4C and 37C, 
respectively.  Each value represents mean ± SD (n=3). **P < 0.01 compared with apical uptake observed in MDCKII-wt cells. 
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Passage Dependence of Gly-Sar Transport Efficiency in MDCKII Cell Lines 
Since the expression of transfected efflux transporters varies with ascending passage 
number, transport efficiency of apical peptide transporters-mediated specific [
3
H]Gly-Sar 
uptake was investigated in various MDCKII cell lines with different passage number. 
Figure 16 A-C illustrate that in comparison to wild-type cells with the value of 0.180 ± 
0.009 nl/mg protein/min, transport efficiency of [
3
H]Gly-Sar uptake mediated by apical 
peptide transporters was reduced to different extents after transfection.  Lowest transport 
efficiency values were observed at lowest cell passage. With passage number increasing, 
an increment on the transport efficiency for Gly-Sar uptake was achieved for all 
transfected cell lines. Finally apical peptide transporters showed relatively invariable 
transport efficiency values at higher cell passage. At passage 25, these values were 
obtained to be around 0.10 nl/mg protein/min for MDCKII-MDR1 cells, 0.12 nl/mg 
protein/min for MDCKII-MRP2 cells, and 0.15 nl/mg protein/min for MDCKII-BCRP 
cells, respectively.  
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Figure 16. Estimation of transport efficiency (Vmax/Km) for specific [
3
H]Gly-Sar uptake 
by apical peptide transporters in various transfected MDCKII cell lines with different 
passage number.  
Uptake of [
3
H]Gly-Sar were conducted in the presence of different concentrations of 
unlabeled Gly-Sar (0-250 µM) at 4C and 37C, respectively. A, MDCKII-MDR1 cells; 
B, MDCKII-MRP2 cells; C, MDCKII-BCRP cells. Each bar represents mean ± SD (n=3). 
* P < 0.05 and ** P < 0.01 compared with control. 
 
Effects of Peptide Transporter Inhibitors on Apical Gly-Sar Uptake in MDCKII 
Cell Lines 
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cefadroxil (20 mM) exhibited more remarkable inhibitory effects than PepT1 inhibitor 
Gly-Pro (20 mM) in all four MDCKII cell lines. Moreover, transfected cell lines with low 
cell passage (lower than passage number 6) exhibited less Gly-Sar uptake than high cell 
passage (higher than passage number 25). In comparison with MDCKII-wt cells, all 
transfected MDCKII cell lines showed reduced apical cellular accumulation of Gly-Sar, 
no matter of the cell passages. 
 
pH Dependent Transcellular Permeability of Gly-Sar in MDCKII Cell Lines  
Transporter-mediated specific Gly-Sar transport across both parental and transfected 
cell monolayers of MDCKII cell lines was estimated by subtracting nonspecific transport 
(passive diffusion) of [
14
C]Mannitol from [
3
H]Gly-Sar transport. Results for both AP-BL 
and BL-AP permeability values are summarized in Table 4. Gly-Sar transport mediated 
by peptide transporters on AP to BL direction showed significantly higher permeability in 
MDCKII-wt cells than transfected cells at all pHs examined. Additionally, AP-BL Gly-
Sar transport on all MDCKII cells exhibited gradual enhancement when apical pH 
increased from 4.0 to 7.4, and reached maximal at pH 7.4. However, apparent 
permeability values of BL-AP Gly-Sar transport across transfected cell monolayers were 
similar or greater than that on wild-type cells at all pHs observed. Furthermore, no 
obvious relationship between apical pH and BL-AP transcellular Gly-Sar permeability 
could be obtained on all MDCKII cells in this study.  
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Figure 17. Apical uptake of [
3
H]Gly-Sar (0.5 µCi/ml)  in the absence (control) or presence of peptide transporter inhibitors, fosinopril 
(100 µM), cefadroxil (20 mM) and glycyl-L-proline (Gly-Pro, 20 mM) at pH 7.4, 37C for 15 min in various MDCKII cell lines with 
different cell passages.  
Low Passage: passage number is less than 6; High Passage: passage number is more than 25. Each data point represents mean ± SD 
(n=3). * P < 0.05 and ** P < 0.01 compared with control. 
61 
 
Table 4. pH dependent transporter-mediated Gly-Sar transport on both AP-BL and BL-AP directions across various MDCKII cell 
monolayers.  
 
AP-BL Permeability ( 10-6 cm/s) 
 
BL-AP Permeability ( 10-6 cm/s) 
pH in AP 
chamber MDCKII-wt 
MDCKII-
MDR1 
MDCKII-
MRP2 
MDCKII-
BCRP  
MDCKII-wt 
MDCKII-
MDR1 
MDCKII-
MRP2 
MDCKII-
BCRP 
4.0 13.1±1.4 6.0±0.4 
a
 8.6±1.1
 a
 7.1±0.3
 a
 
 
9.4±0.4 10.1±1.3 8.5±0.6 10.9±0.7 
5.0 14.9±2.8 6.4±0.5
 a,b
 9.9±0.8
 a
 7.6±1.2
 a,c
 
 
6.6±0.6 7.6±0.8 6.3±0.4 6.5±0.7 
6.0 22.2±1.9 8.0±0.4
 a
 10.6±0.1
 a
 10.7±0.7
 a
 
 
6.0±01.0 8.2±0.5 7.5±0.5 7.2±0.9 
7.4 36.7±0.2 11.7±0.6
 a,b,d
 17.7±1.4
 a
 18.6±1.9
 a
 
 
8.0±0.9 12.9±1.3 15.7±0.6 15.6±0.1 
The pH of incubation media varied from 4.0 to 7.4 in apical (AP) chambers, and remained consistent in basolateral (BL) chambers to 
pH 7.4. Each value represents mean ± SD (n=4). Statistical analysis was performed to evaluate the difference of AP-BL permeability 
at each pH within MDCKII cell lines. 
a 
P < 0.01 compared with MDCKII-wt cells, 
b 
P < 0.01 and 
 c 
P < 0.05  compared with MDCKII-
MRP2 cells, and 
d 
P < 0.05 compared with MDCKII-BCRP cells, respectively. 
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Real-time PCR Assay  
Levels of mRNA for both endogenous peptide transporters (cPepT1 and cPepT2) and 
transfected human efflux transporters (hP-gp, hMRP2, and hBCRP) expressed on various 
MDCKII cell lines were determined using real-time PCR. The relative amount of mRNA 
expression at different passage number was illustrated in Figure 18. All three transfected 
MDCKII cell lines showed remarkably diminished efflux genes expression with 
ascending cell passage, and conversely enhanced peptide genes expression was observed 
on corresponding cell passages from low (passage number 4-8) to high (passage number 
30). The relative fold of hMDR1 (transfected) gene expression was reduced from 1.00 ± 
0.23 (passage number 5) to 0.03 ± 0.01 (passage number 30) in MDCKII-MDR1 cells. In 
contrast, endogenous influx cPepT1 and cPepT2 gene expression was enhanced from 
1.00 ± 0.22 fold and 1.00 ± 0.09 fold at passage 5 to 1.64 ± 0.47 fold and 3.27 ± 1.38 fold 
at passage 30, respectively (Figure 18A). Similar trend was also obtained in hMRP2- and 
hBCRP- transfected cell lines. Corresponding data in MDCKII-MRP2 cells at passage 30 
was found to be 0.37 ± 0.19, 1.88 ± 0.13, and 4.66 ± 1.44, for hMRP2, cPepT1, and 
cPepT2, respectively (Figure 18B), and in MDCKII-BCRP cells (passage 30) was 0.29 ± 
0.07, 1.77 ± 0.56, and 6.15 ± 1.95 for hBCRP, cPepT1, and cPepT2, respectively (Figure 
18C). 
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Figure 18. Determination of mRNA levels of endogenous influx transporters, canine 
PepT1 (cPepT1) and canine PepT2 (cPepT2), and exogenous efflux transporters, human 
P-gp (hMDR1), human MRP2 (hMRP2) and human BCRP (hBCRP) in various 
transfected MDCKII cell lines with different passage number using real-time PCR.  
A, MDCKII-MDR1 cells; B, MDCKII-MRP2 cells; C, MDCKII-BCRP cells. Each bar 
represents mean ± SD (n=3). * P < 0.05 and ** P < 0.01 compared with the lowest cell 
passage. 
 
Expression of endogenous PepT1 and PepT2 in MDCKII cells  
In order to evaluate protein levels of endogenous PepT1 and PepT2 in MDCKII cells 
after transfection with different human efflux genes, Western blot analysis was performed 
using polyclonal primary antibodies specific to PepT1 (78 kDa) and PepT2 (81 kDa) in 
the present study.  Results in Figure 19 showed that expression of endogenous (canine) 
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PepT2 in MDCKII-wt cells is much higher than PepT1.  Moreover, Figure 20 illustrates 
that MDCKII-MDR1, MDCKII-MRP2, and MDCKII-BCRP cells expressed significantly 
less amounts of cPepT2 protein (lane 3-8) as compared to the MDCKII-wt cells (lane 1-
2). Furthermore, PepT2 expression was observed to be enhanced at higher cell-passages 
for all transfected MDCKII cells (Figure 20B). However, this passage-dependent 
phenomenon can not be observed for cPepT1 expression (Figure 21). 
 
 
Figure 19. Determination of protein levels of endogenous canine PepT2 (A) and canine 
PepT1 (B) in wild-type MDCKII cell line by western blot assay.  
Lane 1, MDCKII-wt (Pg-14); lane 2, MDCKII-wt (Pg-30); 
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Figure 20. Determination of protein levels of endogenous (canine) PepT2 in wild-type 
and transfected MDCKII cell lines by western blot assay (A) and comparative canine 
PepT2 levels in MDCK cells after human MDR genes transfection (B).  
Lane 1, MDCKII-wt (Pg-14); lane 2, MDCKII-wt (Pg-30); lane 3, MDR1-L (Pg-5); lane 
4, MDR1-H (Pg-30); lane 5, MRP2-L (Pg-8); lane 6, MRP2-H (Pg-30); lane 7, BCRP-L 
(Pg-4); lane 8, BCRP-H (Pg-30). 
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Figure 21. Determination of protein levels of endogenous (canine) PepT1 in wild-type 
and transfected MDCKII cell lines by western blot assay (A) and comparative canine 
PepT1 levels in MDCK cells after human MDR genes transfection (B).  
Lane 1, MDCKII-wt (Pg-14); lane 2, MDCKII-wt (Pg-30); lane 3, MDR1-L (Pg-5); lane 
4, MDR1-H (Pg-30); lane 5, MRP2-L (Pg-8); lane 6, MRP2-H (Pg-30); lane 7, BCRP-L 
(Pg-4); lane 8, BCRP-H (Pg-30). 
 
Discussion  
MDCK cells have been wildly used as an alternative in vitro model to Caco-2 cells 
which exhibit good correlation with human intestinal mucosa (Irvine et al., 1999; Volpe, 
2008). In comparison with Caco-2 cells, MDCK cells have shown common epithelial 
characteristics and much shorter culture time (5 days for MDCK vs. 21 days for Caco-2). 
Therefore it has been accepted as an attractive tool for predicting absorption of new drug 
candidates in drug discovery stage. Especially MDCK strain II cells transfected with 
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different human efflux genes, have been utilized to screen efflux-mediated drug transport 
(Tang et al., 2002b; Tang et al., 2002a; Wang et al., 2005). However, some functions and 
biological characteristics of cells might change due to transfection. Our studies 
demonstrate that [
14
C]Mannitol transport, an indicator of paracellular permeability, was 
greatly reduced in MDR1, MRP2, and BCRP-transfected MDCKII cells on apical to 
basolateral direction in comparison with wild-type cells (Figure 11), suggesting an 
enhanced barrier function after transfection. Enhanced tight junctions in transfected 
MDCKII cells indicate that the function of endogenous active transporters may also be 
altered. Thus a potential imperfect permeability result may be obtained in transcellular 
transport of substrates determined on transfected cells when compared with wild-type 
cells. 
MDCK cells express endogenous canine peptide transporters on both apical and 
basolateral membranes, whereas all the transfected exogenous efflux genes are expressed 
apically (Tang et al., 2002b; Tang et al., 2002a; An and Morris, 2010). Figure 12 
displayed apical uptake of [
3
H]Gly-Sar, a typical substrate for peptide transporters, in 
various MDCKII cell lines at different days of culture. A remarkably different Gly-Sar 
cellular accumulation was obtained between wild-type and transfected cells. Total uptake 
of [
3
H]Gly-Sar at 37C, via the routes of both passive diffusion and peptide transporter-
mediated influx, was much lower in human P-gp, MRP2, and BCRP-overexpressed 
MDCKII cell lines. These results have been further confirmed by temperature 
dependence study (Figure 13). It has been reported that passive uptake of dipeptides 
(non-peptide transporter mediated) can be estimated by measuring uptake at cold 
temperature, and “transporter-mediated” component can be calculated by subtracting 
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passive uptake component observed at 4C from the total uptake measured at 37C (Scow 
et al., 2011). Significant temperature dependent peptide uptake was observed in all four 
MDCKII cell lines. Uptake of [
3
H]Gly-Sar was much higher at 37C than that at 4C, 
suggesting that the active transporter-mediated transport was involved in cellular uptake 
of Gly-Sar. Additionally, apical Gly-Sar influx via specific transporters in MDCKII-wt 
cells was 5- to 7- fold higher than that in MDCKII-MDR1, MDCKII-MRP2, and 
MDCKII-BCRP cells, indicating a reduced function of apical endogenous peptide 
transporters after transfection with exogenous efflux genes. This observation suggests 
that transfection of foreign gene(s) may affect the function of endogenous gene. 
H
+
/peptide co-transporters (PepT1 and PepT2) are generally believed to be 
functionally expressed at apical membranes of MDCK wild-type cells (Sawada et al., 
2001). It suggests that uptake of small peptides from apical side of MDCK cells can be 
stimulated by an inwardly directed H
+
 gradient. However, it has also been reported that 
the binding affinity for charged peptides to peptide transporters can change when 
extracellular pH altered (Daniel and Kottra, 2004). The neutral substrates like Gly-Sar at 
brush border or urinary pH (6.0 to 6.5) were observed to be preferred substrates for 
PepT1 and PepT2 (Terada et al., 2000; Pan et al., 2001). Specific peptide transporter-
mediated Gly-Sar uptake was found to be a “bell-shape” and reached greatest at pH 6.0–
6.5 when Terada et al tested apical [
14
C]Gly-Sar uptake in MDCK cells with changing 
environmental pH from 5.0 to 7.5 (Terada et al., 2000). In the present study, apical 
transporter-mediated specific [
3
H]Gly-Sar uptake in MDCKII-wt cells was also observed 
to be maximal at extracellular pH 6.0 (Figure 14). The pH profiles of uptake in human 
efflux genes-transfected cell lines appeared to be similar as MDCKII-wt cells, but the 
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uptake in these transfected cells was much lower. The most probable explanation is that 
characteristic of peptide transporters in the transfected cell lines possibly remains 
unchanged, but its expression level was possibly too low to facilitate a significant pH-
dependent difference in Gly-Sar uptake.  
In order to recognize its functional properties, concentration dependence of apical 
and basolateral peptide transporters-mediated specific Gly-Sar uptake was evaluated in 
various MDCKII cell lines. It was observed that mean values of apparent Km from apical 
side of both wild-type and transfected MDCKII cells varied in the range of 30 – 85 μM. 
According to the classification of substrates/inhibitors suggested by previous research 
(Luckner and Brandsch, 2005; Biegel et al., 2006), this result clearly demonstrates that 
apical peptide transporters exhibit the significant PepT2 characters of high-affinity (Km < 
0.1 mM) for Gly-Sar uptake. The corresponding Vmax values were tremendously 
diminished to about 12%, 43% and 42% of that in wild-type cells after transfection with 
hMDR1, hMRP2, and hBCRP efflux genes, respectively. It indicates that the capacity of 
apical peptide transporters markedly declined. However, Vmax values obtained from 
different laboratories are usually diverse, since its determination can be affected by 
different methodology and calculations applied by different investigators. In our current 
investigation, Vmax values obtained after subtraction of passive diffusion values.  Thus 
determination of transport efficiency (the ratio of Vmax to Km)  provides a more reliable 
way to investigate transporter function (Jedlitschky et al., 1996; Zhou et al., 2010). 
Transport efficiency values for apical peptide transporters summarized in Table 3 exhibit 
a significant decrease to around 25% (MDCKII-MDR1), 30% (MDCKII-MRP2), and 41% 
(MDCKII-BCRP) of that in wild-type cells. In contrast, basolateral peptide transporters 
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in transfected cell lines showed an increased rate for Gly-Sar translocation with higher 
Vmax values. These results again confirm our hypothesis that alien gene(s) in apical 
membrane can influence the function of endogenous transporters. 
To further investigate the properties of peptide transporter system expressed on 
apical membrane of MDCKII cell lines after transfection, inhibitory uptake of [
3
H]Gly-
Sar was carried out in the presence of various peptide transporter inhibitors. Gly-Pro 
showed markedly competitive inhibition for Gly-Sar uptake and was reported as a 
selected PepT1 inhibitor (Giacomini et al., 2010; Omkvist et al., 2010). Angiotensin-
converting enzyme (ACE) inhibitor fosinopril and aminocephalosporin antibiotic agent 
cefadroxil have been considered as powerful PepT2 inhibitors due to their high affinity 
for binding to PepT2 (Giacomini et al.; Ocheltree et al., 2004; Knutter et al., 2008). In the 
current study, 20 mM Gly-Pro exhibited a less reduction in [
3
H]Gly-Sar  uptake than 20 
mM cefadroxil and 100 µM fosinopril in MDCKII-wt cells indicating less PepT1 than 
PepT2 expressions on the apical membrane of MDCK cells and similar substrate 
specificity was observed in transfected cell lines (Figure 17). These findings provide 
further evidence that the type of apical peptide transporter system remained unaltered 
after transfection with exogenous efflux genes, but reduced capacity of influx transporter  
due to less expression resulting in decreased Gly-Sar uptake compared to wild-type cells. 
Functional activities of peptide transporters in MDCK cell lines influences 
significantly on transepithelial transport of [
3
H]Gly-Sar across cell monolayers. Previous 
studies have reported that apical peptide transporter present in MDCKII cells, primarily 
H
+
/peptide co-transporter system, is responsible to the luminal uptake into the cells, 
whereas the basolateral peptide transporter system, a novel peptide transporter which 
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does not appear pH-dependent, is involved in the cellular re-absorption of small peptides 
from peritubular capillaries (Terada et al., 2000; Sawada et al., 2001). Therefore 
transcellular transport of Gly-Sar from donor chamber to receiver chamber should be 
contributed by influx activities mediated by both apical and basolateral peptide 
transporters. As demonstrated by the present transport data in Table 4, MDCKII-wt cells 
displayed a significantly higher AP-BL permeability and a similar or slightly lower BL-
AP permeability of [
3
H]Gly-Sar over that in transfected cell lines at all pHs. These 
findings further confirm the reduced transport efficiencies, particularly the apical 
endogenous peptide transporters that we reported previously (Agarwal et al., 2007a). 
Moreover, such inefficiency in apical peptide transporters might be more significant than 
that in basolateral peptide transporters, as the difference of Gly-Sar transport between 
wild-type versus transfected cell lines on AP-BL direction seems to be much more than 
that on BL-AP direction. All human efflux transporter genes are transfected on apical 
membrane of MDCK cells, thus function of apical peptide transporters has attracted more 
attention in the present study. We assumed that the transfection of human MDR1, MRP2, 
and BCRP genes localized in the apical membrane of cells may affect the function of 
peptide transporters. Overexpression of efflux transporters at the apical cell membrane 
and their overriding activities may cause differential functional activities and inefficiency 
of endogenous peptide transporters in transfected MDCKII cell lines.  
Expression levels of transfected genes are cell-passage-dependent, since transfected 
cells may lose the cDNA with ascending passage number. Previous research has reported 
that higher passaged MDCK-MDR1 cells showed lower levels of transfected human 
MDR1 gene expression than lower passaged cells (Tang et al., 2002b). Thus cell-passage-
73 
 
dependent effects on the determination of transport efficiency of apical peptide 
transporters were investigated in various MDR genes-transfected MDCKII cell lines. All 
transfected cell lines demonstrated markedly reduced translocation efficiency for Gly-Sar 
apical uptake (Figure 16). Interestingly, this functional inefficiency was found to be 
clearly passage-dependent, since disparity in transport efficiency between intact and 
transfected cells attenuated with increasing cell passage. Lower Gly-Sar transport 
efficiency in transfected cell lines is possibly associated with a corresponding lower 
expression level of peptide transporters, which might be the results of down-regulation by 
highly-expressed robust efflux genes. When expression of these robust transporters 
diminishes, the down-regulatory effect also ceases. This assumption is well substantiated 
by the results of mRNA determination using real-time RT-PCR assay and subsequent 
protein expression by Western blot analysis.  
Expression of transfected human genes decreases quickly as cell passage increases 
(Figure 18). P-gp- overexpressed cells exhibited a faster diminishing than MRP2 and 
BCRP expression levels. This is possibly due to differential transfection stability with 
different genes. Conversely, expression of both peptide transporters PepT1 and PepT2 
present on apical membrane of various transfected MDCK II cell lines has been raised 
progressively with apical Gly-Sar gradually enhanced uptake along with increasing cell 
passage in various transfected cells (Figure 16). Additionally, a more significant 
enhancement in cPepT2 gene expression over cPepT1 was obtained in all three 
transfected cell lines. Such inverse correlation between endogenous influx genes and 
transfected efflux genes suggests that highly active exogenous efflux transporters may 
influence the expression and function of endogenous peptide transporters. This 
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assumption has been further confirmed by the results of Western blot analysis (Figure 20). 
Whether this inverse relationship between alien gene and endogenous gene is an 
adaptation to maintain cellular concord or domination of MDR gene to protect the cells 
from toxicity is yet to be completely established.  
Our study clearly demonstrates that transfected efflux robust genes dominate over 
endogenous influx transporters. The molecular mechanism of such interaction between 
transporters is yet to be elucidated. One explanation is that transfected exogenous genes 
may compete with the endogenous genes for binding sites on transcription factors or 
transcriptional coactivator and corepressor complexes. Recent studies have shown that 
transcription factors, Sp1 binding sites play a decisive role in the basal expression of 
MDR1 (human), MRP2 (rat), BCRP (human) and PepT1 (human) (Cornwell and Smith, 
1993; Kauffmann et al., 2001; Shimakura et al., 2006; Takakura et al., 2010; Zhang et al., 
2012). Competition with highly-expressed exogenous genes might trigger the down-
regulation of endogenous gene expression in these cells. Transfection of hMDR1 in 
MDCKII cells can cause negative feedback and trigger down-regulation of endogenous 
Mdr1 (Kuteykin-Teplyakov et al., 2010). This down-regulation of endogenous mRNA as 
well as protein expressions by exogenous gene transfection such as hMDR1 vs. Mdr1 has 
also been reported by the previous studies, which indicated a feedback-regulatory 
mechanism from endogenous gene/transcription factor to maintain cellular milieu (Lloyd 
et al., 1992). The fundamental difference of our work is that we have demonstrated the 
interplay between two unrelated genes i.e. hMDR1/ hMRP2/ hBCRP vs. PepT (canine) 
controlling efflux of xenobiotics and nutrients respectively which was unknown before. 
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The understanding of transporters crosstalk between divergent proteins is critical for 
developing new peptidomimetics. 
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CHAPTER 4 
SYNTHESIS OF STEREOISOMERIC AMINO ACID AND DIPEPTIDE PRODRUGS 
OF SAQUINAVIR 
Rationale 
Saquinavir (SQV) is the first HIV-protease inhibitor marketed for the treatment of 
AIDS in the United States. Although SQV has been reported for its potent activity against 
HIV, its therapeutic efficacy is limited in clinical application due to some undesirable 
properties like poor aqueous solubility as well as high affinity for efflux transporters and 
metabolic enzymes (Kim et al., 1998a; Plosker and Scott, 2003). In order to overcome 
these pharmaceutical and physicochemical barriers and improve absorption following 
oral administration, “transporter-targeted prodrugs” have been developed as an attractive 
strategy. In comparison with classical prodrugs, which represent a nonspecific chemical 
promoiety attached to the active parent drug by a covalent linker, targeted prodrugs 
approach is designed to target specific endogenous transporters to facilitate epithelial 
transport of these compounds (Han and Amidon, 2000; Yang et al., 2001; Rautio et al., 
2008). Following the translocation across cellular membrane, the prodrug could be 
cleaved by hydrolytic enzymes specifically to regenerate the active parent drug. 
Recent advances in transporter-targeted drug delivery indicated that peptide 
transporters, primarily expressed in the small intestine and kidney, are attractive targets 
for prodrug design because they have broad substrate specificity and high capacity, 
especially for smaller peptides i.e. di and tripeptides (Ganapathy and Leibach, 1996; 
Leibach and Ganapathy, 1996; Steffansen et al., 2004). On the basis of these findings, 
“peptidomimetic” prodrugs are designed by conjugating parent drug to small peptides. 
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Such prodrugs could be recognized easily by the peptide transporter-mediated influx 
system and ferried across the epithelial membrane (Ganapathy et al., 1995). Additionally, 
structure modification reduces the interaction of the parent drug with efflux transporters 
such as P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP). 
Therefore enhanced cellular permeation could be achieved by the cumulative effects of 
reducing secretion by efflux transporters and increasing absorption by influx transporters.  
Several peptide prodrugs of PIs have been synthesized successfully. Valine-valine 
and glycine-valine prodrugs derived from SQV have also exhibited 4.6- and 1.8- fold 
enhanced absorption relative to parent drug in rat jejunum, respectively (Jain et al., 2007). 
Also it has been reported previously that different stereoisomers of chiral drug molecules 
possess different biological properties (Siccardi et al., 2003; Wang et al., 2010). These 
encouraging findings prompted us to extend the study of valine-valine-SQV with its 
stereoisomeric configuration.  
In this chapter, four stereoisomeric dipeptide prodrugs derived from SQV including 
L-valine-L-valine-SQV (LLS), L-valine-D-valine-SQV (LDS), D-valine-L-valine-SQV 
(DLS) and D-valine-D-valine-SQV (DDS) and two amino acid prodrugs L-valine-SQV 
(LS) and D-valine-SQV (DS) were synthesized and purified, and their structures were 
identified using mass spectrography and 
1
H NMR. Furthermore, the quantitative 
dermination methods including HPLC and LC-MS/MS were developed in this chapter. 
 
Materials and Methods 
Materials 
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SQV mesylate salt was kindly donated by Hoffmann-La Roche. All chemicals and 
solvents were purchased from Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific 
Co. (Pittsburgh, PA), and all chemicals were products of special reagent grade and used 
as such. 
 
Synthesis of SQV Prodrugs 
Stereoisomeric dipeptide prodrugs (valine-valine-SQV) were prepared from amino 
acid prodrugs (valine-SQV) following the published procedure with slightly 
modifications (Jain et al., 2005). The synthetic procedure of valine-valine-SQV is shown 
in Figure 22 and 23. All the reactions were performed under anhydrous condition and 
protected by nitrogen. All chemicals were dessicated before reaction and anhydrous 
solvents were used.  
 
Synthesis of Amino Acid Prodrugs of SQV 
Stereoisomeric valine-SQV was synthesized in two steps: Conjugating SQV with N-
Boc-(L)-valine or N-Boc-(D)-valine, and then deprotection of amino protecting group N-
Boc. 280 mg N-Boc-(L)-valine or N-Boc-(D)-valine (1.30 mmol) and 390 mg 
dicyclohexylcarbodiimide (DCC, 1.95 mmol) were dissolved into 5 ml of 
dichloromethane (DCM) and stirred for 1 h on ice-bath (mixture A). In another round 
bottom flask, several drops of dry triethylamine (TEA) was added to 500 mg SQV (0.65 
mmol), then a proper amount of DCM with 240 mg dimethylamino pyridine (DMAP, 
1.95 mmol) were added until all SQV dissolved after 10-minute stirring (mixture B). 
Mixture A was removed from ice bath, and mixture B was added dropwise into mixture 
79 
 
A at room temperature while continually stirring the mixture for 24 h. Reactions were 
monitored with Mass Spectra to ensure complete conversion of the starting compounds to 
intermediates SQV-(L)-val-Boc or SQV-(D)-val-Boc. The intermediates were purified 
using silica column chromatography (Silica gel 60 Geduran
®
, 40-63 µm) with hexane and 
ethyl acetate (3:7) as eluent. The deprotection of the N-Boc protecting group was 
achieved using 10 ml of DCM and trifluoroacetic acid (TFA) (1:1) at 0 ºC for 2.5 h to get 
final L-val-SQV or D-val-SQV (mono-TFA salt). Crude products were purified by 
recrystallization using cold diethyl ether and dried in Speed Vac (SPD101B, Savant 
Instruments INC, Holbrook, NY) until the weight was constant. Synthesis process of DS 
is shown in Figure 22. 
 
 
Figure 22. Synthesis process of D-valine-saquinavir (DS). 
Reagents and conditions: (i) Boc-D-valine-OH, DCC, DCM, N2, 0

C, 1 hour; (ii) TEA, 
DMAP, DCM, N2, RT, 24 hours; (iii) TFA/ DCM (1:1), 0

C 2.5 hours. 
 
Synthesis of Dipeptide Prodrugs 
Dipeptide prodrugs were synthesized using the similar procedure described above. 
The starting material was 570 mg stereoisomeric valine-SQV conjugate (0.65 mmol), 
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which was treated with 2 ml of TEA instead of DMAP, and the reaction was conducted at 
room temperature for 24 h. Intermediates N-Boc-valine-valine-SQV were purified using 
silica gel 60 column with MeOH/DCM (3:97) as eluent. Synthesis process of LDS is 
shown in Figure 23.  
 
 
Figure 23. Synthesis process of L-valine-D-valine-saquinavir (LDS). 
Reagents and conditions: (i) Boc-L-valine-OH, DCC, DCM, N2, 0

C, 1 hour; (ii) , TEA, 
DCM, N2, RT, 24 hours; (iii) TFA/ DCM (1:1), 2.5 hours. 
 
Identification of Prodrugs  
Structure and purity of reaction intermediates and final compounds were confirmed 
by Mass Spectrography and 
1
H NMR. 
1
H NMR was carried out using a Varian-400MHz 
NMR spectrometer.  
 
Quantitative Analysis 
HPLC 
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All samples, SQV and prodrugs, for in vitro studies were analyzed by HPLC 
chromatography with a reversed Luna C-8 column (250mm×4.6mm, 5 µm; Phenomenex, 
Torrance, CA). The HPLC system included HP 1050 pump, Waters dual wavelength 
absorbance UV detector, and an Alcott HPLC autosampler 718AL. Mobile phase was 
composed of acetonitrile/water/triethylamine (60:39:1, v/v/v), and pH in aqueous phase 
was adjusted to 6.50 with o- phosphoric acid. Detection wavelength was set to 240 nm, 
and flow rate of mobile phase was 1.0 ml/min.  
 
LC-MS/MS 
QTrap
® 
LC-MS/MS mass spectrometer (Applied Biosystems, Foster City, CA) 
equipped with Agilent 1100 Series quaternary pump (Agilent G1311A), vacuum degasser 
(Agilent G1379A) and autosampler (Agilent G1367A, Agilent Technology Inc., Palo 
Alto, CA) was utilized to analyze SQV and prodrug samples. The detection was operated 
in multiple-reaction monitoring (MRM) mode. The precursor and the product ion 
generated for SQV, valine-SQV, and valine-valine-SQV are 671.4/570.3, 770.5/367.2, 
and 869.5/367.2, respectively. Samples were prepared using liquid-liquid extraction 
technique with ice-cold tert-butyl methyl ether. Verapamil (200 nM) was employed as an 
internal standard. Relative extraction efficiency for SQV and its prodrugs were around 
70%. Samples reconstituted in distilled deionized water with 0.05% cremophor EL were 
loaded onto a Luna C-18 column (100×2.0 mm, 3 µm; Phenomenex Torrance, CA) and 
eluted with acetonitrile/water (40:60) in presence of 0.1% formic acid at a flow rate of 
0.2 ml/min.  
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Results 
Synthesis of SQV Stereoisomeric Prodrugs 
The final amino acid and dipeptide prodrugs were obtained as white powder with a 
yield of 85% and 80%, respectively (calculated from SQV). Three-dimensional structures 
of obtained dipeptide and amino acid prodrugs are showed in Figure 24. 
 
Identification of Prodrugs  
Structure and purity of reaction intermediates and final compounds were confirmed 
by Mass Spectrography (DS in Figure 25 and DLS in Figure 26) and 
1
H NMR.  
 
 
Figure 24. Structures of saquinavir stereoisomeric prodrugs 
A. L-valine-saquinavir (LS) 
B. D-valine-saquinavir (DS) 
C. L-valine-L-valine-saquinavir (LLS) 
D. L-valine-D-valine-saquinavir (LDS) 
E. D-valine-L-valine-saquinavir (DLS) 
F. D-valine-D-valine-saquinavir (DDS) 
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Figure 25. Mass spectrometry of D-valine-SQV (DS) 
 
 
Figure 26. Mass spectrometry of D-valine- L-valine-SQV (DLS) 
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D-val-SQV: LC/MS(M/z): 770.1; 
1
HNMR (DMSO-d6): δ 0.99 – 1.04 (m, 6H), 1.30 
(s, 9H), 1.35- 1.36 (m, 1H), 1.52 – 1.57 (m, 2H), 1.64 – 1.67 (m, 4H), 1.71-1.97 (m, 4H), 
2.24 – 2.29 (m, 2H), 2.56 – 2.73 (m, 3H), 2.84 – 2.89 (m, 2H),3.13 – 3.15 (m, 3H), 3.24 – 
3.51 (m, 1H), 3.97(brs, 1H), 4.47 – 4.49 (m, 1H), 4.74 – 4.80 (m, 1H), 5.35 – 5.59 (brs, 
1H), 6.96 – 7.01 (m, 1H), 7.08 – 7.10 (m, 3H), 7.24 – 7.25 (m, 2H), 7.58 (brs, 1H), 7.73 – 
7.77 (m, 1H), 7.87 – 7.91 (m, 1H), 8.11 – 8.23 (m, 4H), 8.43 (brs, 3H), 8.60 – 8.62 (d, J = 
8Hz 1H), 8.83 – 8.85 (d, J = 8Hz, 1H). 
L-val-SQV: LC/MS(M/z): 770.4; 
1
HNMR (DMSO-d6): δ 8.89 (d, 1H), 8.52 (m, 1H), 
8.42 (bd, 4H), 8.21 (d, 2H), 8.08 (m, 1H), 7.86 (m, 1H), 7.74 (m, 1H), 7.63 (bd, 2H), 
7.01–7.20 (m, 5H), 5.52 (m, 1H), 4.83 (m, 1H), 4.58 (m, 1H), 3.85 (m, 1H), 3.26 (m, 1H), 
2.3–2.74 (m, 7H), 1.59–1.99 (m, 13H), 1.36 (s, 9H), 1.06 (dd, 6H). 
L-val-D-val-SQV: LC/MS(M/z): 870.5; 
1
HNMR (DMSO-d6): δ 0.92 – 1.09 (m, 
12H), 1.13 - 1.35 (m, 14H), 1.52 - 1.96 (m, 9H), 2.08 – 2.23 (m, 2H), 2.50 – 2.67 (m, 2H), 
2.93 – 3.53 (m, 5H), 3.77 – 3.86 (m, 1H), 4.33 – 4.53 (m, 1H), 4.76 – 4.81 (m, 1H), 5.25 
– 5.29 (brs, 1H), 5.59 – 5.61(brs, 1H), 6.96 – 7.08 (m, 4H),  7.16 (brs, 2H), 7.51 (brs, 1H), 
7.73 – 7.77 (m, 1H), 7.87 – 7.92 (m, 1H), 8.11 – 8.19 (m, 7H), 8.61 -  8.64 (m, 2H), 8.88 
(brs, 1H). 
D-val-L-val-SQV: LC/MS(M/z): 870.2; 
1
HNMR (DMSO-d6): δ 0.87 – 0.99 (m, 
12H), 1.15 - 1.33 (m, 14H), 1.38 - 1.99 (m, 8H), 2.15 – 2.23 (m, 2H), 2.64 – 2.71 (m, 3H), 
3.23 – 3.41 (m, 3H), 3.84 – 4.05 (m, 2H), 4.36 – 4.38 (m, 1H), 4.49 – 4.53 (m, 2H), 4.74 
– 4.78 (m, 1H), 5.46 – 5.49 (brs, 1H), 7.02  – 7.22 (m, 6H),  7.54 (brs, 1H), 7.73 – 7.77 
(m, 1H), 7.88 – 7.91 (m, 1H), 8.02 – 8.18 (m, 7H), 8.60 – 8.69 (m, 2H), 8.80 – 8.82 (brs, 
1H). 
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D-val-D-val-SQV: LC/MS(M/z): 870.3; 
1
HNMR (DMSO-d6): δ 0.89 – 0.99 (m, 
12H), 1.19 - 1.30 (m, 14H), 1.50 - 1.73 (m, 9H), 2.08 – 2.24 (m, 2H), 2.62 – 2.65 (m, 2H), 
3.30 – 3.45 (m, 5H), 3.79 – 3.87 (m, 1H), 4.33 – 4.41 (m, 1H), 4.75 – 4.80 (m, 1H), 5.28 
– 5.34 (brs, 1H), 5.51 – 5.61(brs, 1H), 6.96 – 7.08 (m, 4H),  7.21 (brs, 2H), 7.45 (brs, 1H), 
7.73 – 7.77 (m, 1H), 7.87 – 7.91 (m, 1H), 8.10 – 8.19 (m, 7H), 8.58 - 8.62 (m, 2H), 8.82 
(brs, 1H). 
L-val-L-val-SQV: LC/MS (M/z)870.4; 
1
HNMR (DMSO-d6): δ 8.78 (d, 1H), 8.62 
(m, 1H), 8.19 (d, 2H), 8.10 (bd, 6H), 7.87 (m, 1H), 7.74 (m, 1H), 7.39 (bd, 2H), 6.95–
7.05 (m, 5H), 5.24 (m, 1H), 4.83 (m, 1H), 3.77 (m, 5H), 1.81–3.01 (m, 21H), 1.28 (s, 9H), 
0.94 (m, 12H). 
 
Quantitative Analysis 
HPLC 
Retention time and quantitative limit for each prodrugs using HPLC analysis method 
are summarized in Table 5. Four stereoisomeric SQV dipeptide prodrugs showed varied 
retention times (8.09 min - 9.21 min) after injection into HPLC system. Similarly, two 
amino acid SQV prodrugs, LS and DS, also exhibited differential retention time, which is 
7.62 min and 7.23 min, respectively. These results indicate that the observed prodrugs 
with same molecular formula and molecular weight have different spatial structure. 
 
LC-MS/MS 
The precursor and product ion generated for SQV, valine-SQV (VS), and valine-
valine-SQV (VVS), and quantitative limit for each prodrugs using LC-MS/MS method 
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are summarized in Table 6. Results in the present study indicate that sensitivity of LC-
MS/MS is much higher than HPLC. 
 
Table 5. Parameters of HPLC analysis method for the dermination of SQV stereoisomeric 
prodrugs. 
 
Retention time (min) 
Lower limit of 
quantification (µM) 
SQV 5.32 0.2 
Dipeptide prodrugs 
  
  LLS 8.71 
0.5 
  LDS 8.40 
  DLS 9.21 
  DDS 8.09 
Amino acid prodrugs 
  
  LS 7.62 
0.5 
  DS 7.23 
 
Table 6. Parameters for LC-MS/MS analysis method. 
 
SQV VS VVS 
Q1/Q3  671.4/570.3 770.6/367.3 869.7/266.3 
Lower limit of quantification 
(nM)  1 5 20 
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Discussion 
In the present chapter, various SQV prodrugs conjugated with stereoisomeric amino 
acid valine or dipeptide valine-valine were synthesized successfully. Moreover, HPLC 
and LC-MS/MS analysis methods were developed for quantitative determination of the 
observed prodrugs. 
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CHAPTER 5 
PHYSICOCHEMICAL PROPERTIES AND IN VITRO EVALUATION 
Rationale 
Recent advances in transporter-targeted drug delivery indicated that “peptidomimetic” 
prodrugs could be recognized easily by the peptide transporter-mediated influx system 
and ferried across the epithelial membrane (Ganapathy et al., 1995). Moreover, structure 
modification reduces the interaction of the parent drug with efflux transporters. Therefore 
enhanced cellular permeation could be achieved by the cumulative effects of reducing 
secretion by efflux transporters and increasing absorption by influx transporters.  
It has been reported that different stereoisomers of chiral drug molecules possess 
different biological properties (Siccardi et al., 2003; Wang et al., 2010). Stereoisomers 
are molecules that are identical in atomic constitution and bonding, but differ in the three-
dimensional arrangement of the atoms. Conjugates attached with different stereoisomeric 
promoieties could be featured with various physicochemical and biological properties. 
Most amino acids currently applied in prodrug strategy are L-isomers. Major advantages 
to L-configurations include their natural occurrence in the body, as well as their rapid and 
specific recognition by peptide transporters (Pochopin et al., 1994; Sawada et al., 1999). 
In vitro permeability studies on L-valyl, L-leucyl, and L-phenylalanyl ester conjugates of 
indinavir and saquinavir demonstrated an increased translocation across Caco-2 cell 
monolayers (Fountoulakis and Suter, 2002). However, most L-isomeric derivatives have 
limited chemical or enzymatic stability (Pochopin et al., 1994; Talluri et al., 2008). In 
contrast, D-amino acid prodrugs of dapsone exhibited much better resistance to 
enzymatic hydrolysis and showed a longer residence time in vivo (Pochopin et al., 1994). 
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These findings give us strong support for studying stereoisomeric peptide prodrugs of 
SQV. 
In this chapter, we provided a comparison of physicochemical and biological 
properties of SQV prodrugs synthesiszed in last chapter, including aqueous solubility, in 
vitro cytotoxicity, as well as chemical and enzymatic stability with respect to hydrolysis 
under physiological conditions. Affinities for specific proteins like efflux pumps (P-gp 
and MRP2) and influx peptide transporters, and permeability studies across in vitro cell 
monolayers have also been investigated here. Moreover, stereoselectivity in protein 
binding was evaluated in rat plasma in this study. The purpose of this screening is to 
select the most promising stereoisomeric dipeptide prodrug that could improve cellular 
permeation of parent drug SQV across intestinal barriers. 
 
Materials and Methods 
Materials 
SQV mesylate was kindly donated by Hoffmann-La Roche. [
14
C]Erythromycin (80 
Ci/mmol) was obtained from American Radiolabeled Chemicals Inc. (St. Louis, MO). 
[
3
H]glycylsarcosine ([
3
H]Gly-Sar, 4Ci/mmol) was purchased from Moravek 
Biochemicals (Brea, CA). Madin-Darby canine kidney cells transfectant overexpressing 
hP-gp/MDR1 (MDCK-MDR1), hMRP2 (MDCK-MRP2), and wild type MDCK cells 
(MDCK-wt) were generously provided by Dr. P. Borst and Dr. A. Schinkel (The 
Netherlands Cancer Institute, Amsterdam, Netherland), respectively. Caco-2 and U937 
cells were obtained from ATCC (Manassas, VA). TrypLE
TM
 Express Stable Trypsin 
Replacement and Dulbecco’s modified Eagle’s Medium (DMEM) and RPMI-1640 were 
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obtained from Invitrogen (Carlsbed, CA). Fetal bovine serum (FBS) was purchased from 
Atlanta Biologicals (Lawenceville, GA). Sprague–Dawley rat plasma was purchased 
from Valley Biomedical Inc. (Winchester, VA). GF120918 was generously provided by 
GlaxoSmithKline Ltd. MK-571 was purchased from Biomol (Plymouth Meeting, PA). 
Triton X-100, HEPES, d-glucose and all other chemicals were purchased from Sigma 
Chemical Co (St. Louis, MO). Scintillation cocktail reagent was obtained from Fisher 
Scientific (Fair Lawn, NJ). BioRad protein estimation kit was obtained from BioRad 
(Hercules, CA). Transwell
®
 inserts and 12-well tissue culture plates were purchased from 
Corning Costar Corp (Cambridge, MA). All chemicals were products of special reagent 
grade and used as such. 
 
Aqueous Solubility Study 
Generally 5 mg of compound was added to 2 ml of distilled deionized water in a 10 
ml screw-capped glass tube. These tubes were shaken mechanically at 25ºC for 24 hrs. At 
the end of 24 hrs, the mixture was centrifuged at 12,500 rpm, 25ºC for 10 min. The 
supernatant was collected and filtered through 0.45 µm membrane (Nalgene syringe 
filter). The filtrate was appropriately diluted with water and drug concentration was 
measured with LC-MS/MS. 
 
Chemical Hydrolysis  
Chemical hydrolysis study of SQV prodrugs was determined in buffer over a pH 
range of 1.4 to 10.4. Buffers containing 50 mM of hydrochloric acid/ potassium chloride 
(pH 1.4), phthalate (pH 3.4 and 5.4) and phosphate (pH 7.4 and 10.4) were prepared for 
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this study and ionic strength was adjusted to 0.1 M. The pH was adjusted to within ±0.02 
units of the target using hydrochloric acid or sodium hydroxide. Two hundred microliter 
of prodrug solution (230 µM) was incubated with 1.8 ml of buffers at 37ºC under various 
pH conditions for 48 hrs. Aliquot (100 µl) of samples was collected at predetermined 
time intervals and stored in −80ºC until future analysis by HPLC. 
 
Enzymatic Hydrolysis in Cell Homogenates 
Caco-2 cells were maintained in 75 cm
2
 cell culture flasks for 21 days under same 
conditions as MDCK-MDR1 cells. Cells were isolated using a mechanical scraper after 3 
times washing with DPBS (pH 7.4), and then were suspended in proper volumes of 
chilled water and homogenized using Multipro Variable Speed Homogenizer (DREMEL, 
Racine, WI) for 5 min on ice bath. Cell homogenates were centrifuged at 12,500 rpm, 4ºC 
for 10 min to remove debris, and supernatant was diluted properly to achieve a final 
protein concentration of 0.3 mg/ml. Protein content was determined according to the 
method of Bradford using BioRad protein estimation kit. Cell homogenates were warmed 
up at 37ºC for 15 min before stability studies. 1.8 ml of cell homogenate with 200 µl of 
prodrug solution (final concentration 23 µM) was incubated at 37˚C in a shaking water 
bath (60 rpm) for 3 hrs. Samples (100 µl) were collected at predetermined time intervals 
and an equal volume of ice-cold acetonitrile: methanol (5:4) mixture was added to stop 
the enzymatic hydrolysis. Samples were stored at −80˚C until further analysis by HPLC.  
 
Cell Culture 
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MDCK-wt cells, MDCK-MDR1 cells (passages 5-12) and MDCK-MRP2 cells 
(passages 5-25) were maintained following the method in Chapter 3. Human leukemic 
monocyte lymphoma cell line U937 were maintained in suspension culture in RPMI-
1640 supplemented with 10% (v/v) heat-inactivated FBS, 2 mM l-glutamine and 10 mM 
HEPES, at 37°C in a humidified atmosphere of 5% CO2. 
 
Cytotoxicity Assay 
Cellular toxicity study was performed using LDH Cytotoxicity Detection Kit (Takara 
Bio Co. St Louis, MO) on MDCK-wt cells. Cell suspension (200 µl/well) was added in 
the 96-well tissue culture plate at the density of 10,000 cells/well, and then incubated at 
37ºC, 5% CO2 and 90% humidity. The medium was aspirated after 12 hours-postseeding, 
and 200 µl of assay medium (serum-free DMEM) with different concentrations (0−150 
µM) of SQV or prodrugs was added to each well. Positive control (1% Triton X-100 in 
assay medium), negative control (only assay medium) and background control (assay 
medium in the wells without cells) were also evaluated at the same time. After 24 hours-
incubation, 100 µl/well of supernatant was carefully transferred into corresponding wells 
of an optically clear 96-well flat bottom microtiter plate (MTP). Then 100 µl of dye 
mixture solution from LDH Cytotoxicity Detection Kit was added into each well and 
incubated for 20 min. Absorbance of the solutions was measured at 450 nm using DTX 
880 Multimode Detector (Beckman Coulter, Brea, CA) and the LDH release was 
calculated in each of the drug treated wells and was compared with the control. 
 
Uptake Studies 
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Cellular accumulation of SQV and prodrugs in MDCK-MDR1 and MDCK-MRP2 
cells were conducted following the procedures in Chapter 3. U937 cells grown in RPMI 
1640 with 10% (v/v) FBS were added into 1.5 ml centrifuge tube at the cell density of 
4106 cells/ml. Cells were then washed twice with DPBS (pH7.4) at 37C. Uptake was 
initiated by addition of 10 µM of SQV and its prodrugs in above DPBS. After 30 min 
incubation at 37C, drug uptake was terminated by rinsing the cells three times with ice-
cold stop solution (200 mM KCl and 2 mM HEPES) followed by cell disruption with 
water at -80C for 30 min. Cellular drug uptake was determined by LC-MS/MS and then 
was normalized by amount of protein measured using BioRad protein estimation kit in 
each tube. 
 
Transport Studies 
Drug transport across MDCK-MDR1 and MDCK-MRP2 cell monolayers were 
conducted following the procedures in Chapter 3.  
 
Determination of Protein Binding in Rat Plasma 
The protein binding of SQV and its stereoisomeric prodrugs in rat plasma were 
determined using ultra-filtration technique reported previously (Boffito et al., 2002). 
Briefly, stock solutions (100 µl) of SQV or prodrugs in isotonic phosphate-buffered 
saline (IPBS), pH 7.4, containing 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, and 0.24 
g/L KH2PO4, were added into 900 µl blank rat plasma to yield final concentrations of 0.5 
µM. Equal volume of fresh IPBS (pH7.4) replaced drug solutions to be used as control to 
evaluate non-specific adsorption and plasma binding. During the 30 min-equilibration at 
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37C, spiked plasma samples were agitated gentlely every 10 min. Then 500 µl samples 
were transferred to Amicon ultra-0.5ml centrifugal filters (10 k NMWL, Millipore 
Corporation, Bedford, MA) and centrifuged at 10,000 g, 37C, for 1 h. Around 250 µl 
of ultra-filtrate containing the unbound drug was obtained in basolateral chamber. After 
centrifugation, aliquots of filtered (200 µl) and unfiltered (20 µl, diluted with IPBS to 200 
µl) samples were taken and analyzed using LC-MS/MS immediately to calculate protein 
binding of drugs in rat plasma. Unbound fraction (fu) was calculated by the ratio of drug 
in the filtered samples to the sum of filtered and unfiltered samples. 
 
Sample Preparation and Analysis  
SQV and its prodrugs were analyzed by HPLC and LC-MS/MS which are described 
in Chapter 4. Samples for LC-MS/MS were prepared using liquid-liquid extraction 
technique. Briefly, 200 µl samples were added to 10 µl of internal standard (4 µM 
verapamil) and 400 µl of ice-cold tert-butyl methyl ether. All samples were vortexed for 
2 min to extract the drug from the aqueous to organic phase. Then 300 µl of tert-butyl 
methyl ether was decanted and dried in vacuo (DD-4X GeneVac, Gardiner, NY). The 
residue was reconstituted in 70 µl of deionized distilled water containing 0.05% (v/v) 
cremophor EL. Subsequently 40 µl of reconstituted extract was injected onto a LC-
MS/MS system for analysis. Relative extraction efficiency for SQV and its prodrugs was 
around 70%.  
 
Data and Statistical Analysis 
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Apparent permeability coefficients Papp (cm/s) were calculated by linear regression 
analysis on the time course plot of amount of drugs transported across cell monolayers.  
      Where TRcum/dt is the flux rate of (pro)drug obtained from the slope of transport 
profile. A is the surface area of cell monolayers. C0 is initial concentration of (pro)drug in 
the donor chambers. 
All experiments were conducted at least in triplicate and repeated independently 
three or four times. The results were expressed as mean ± SD. Statistical significance was 
detected using Student’s t-test. Difference between mean values was considered 
statistically significant at p < 0.05 and very statistically significant at p < 0.01. 
 
Results 
Apparent Aqueous Solubility  
Results of the solubility study presented in Table 7 demonstrate that all 
stereoisomeric dipeptide prodrugs improved aqueous solubility over parent drug SQV 
(mesylate salt) to a certain extent. Solubilities of LLS, LDS, DLS and DDS were 
dramatically greater than that of SQV mesylate by around 2.8, 2.7, 2.6 and 2.5-fold, 
respectively. Amino acid prodrugs also displayed significant increase in aqueous 
solubility relative to SQV.  
 
 
 
 
𝑃app =
TRcum 𝑑𝑡 
𝐶0 × 𝐴
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Table 7. Apparent aqueous solubility of SQV and its stereoisomeric prodrugs 
 Apparent aqueous solubility (mg/ml) 
SQV (mesylate salt) 1.34 ± 0.22 
Dipeptide prodrugs  
LLS 3.73 ± 0.20
**
 
LDS 3.65 ± 0.47
**
 
DLS 3.52 ± 0.27
**
 
DDS 3.34 ± 0.45
**
 
Amino acid prodrugs  
LS 2.81 ± 0.12
**
 
DS 2.70 ± 0.10
**
 
Data represented are mean ± SD (n=4). ** P < 0.01 compared with SQV (mesylate salt). 
 
Chemical Hydrolysis in Buffer 
Effect of pH on hydrolysis of the SQV prodrugs was evaluated within the pH range 
of 1.4 to 10.4. The half lives (t1/2) of each prodrug were estimated by plotting the natural 
logarithm of prodrug concentrations versus time (Table 8). All prodrugs showed a 
gradient increase in susceptibility to hydrolysis as pH was raised from acidic (pH 1-5) 
towards basic conditions (pH 7-10). The hydrolysis data indicate that SQV dipeptide 
conjugates were chemically more stable in comparison to amino acid prodrugs at all the 
pH levels. Besides, DDS appears to be most stable compared to other dipeptide 
conjugates. 
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Table 8. Degradation half lives (h) for various SQV prodrugs at different pH conditions. 
 pH1.4 pH3.4 pH5.4 pH7.4 pH10.4 
LLS 336.4 ± 23.7 203.2 ± 11.3 49.3 ± 0.9 10.4 ± 0.6 7.2 ± 0.2 
LDS 357.2 ± 18.9 228.7 ± 23.5 55.0 ± 2.1 12.9 ± 1.4 8.0 ± 0.4 
DLS 364.7 ± 21.2 242.3 ± 14.6 55.1 ± 4.3 16.0 ± 1.8 9.3 ± 0.2 
DDS 412.5 ± 14.4 249.3 ± 16.3 63.1 ± 1.8 19.9 ± 1.1 11.8 ± 0.4 
LS 30.2 ± 1.7 15.1 ± 1.1 5.0 ± 0.6 2.5 ± 0.3 1.9 ± 0.2 
DS 43.3 ± 3.3 38.3 ± 3.6 6.9 ± 0.8 3.2 ± 0.2 2.3 ± 0.1 
Data represented are mean ± SD (n=4). 
 
Enzymatic Hydrolysis in Cell Homogenates 
The concentration profile for SQV prodrugs in Caco-2 cell homogenates at pH 7.4 
for a period of 3 h is depicted in Figure 27. Regeneration of valine-SQV and SQV 
demonstrates the role of esterase and peptidase enzymes in the metabolism process. 
Dipeptide prodrugs are more stable than amino acid prodrugs in Caco-2 cell homogenates. 
LLS appears the least enzymatically stable compared to the other three dipeptide 
prodrugs. The percentage of LLS remaining in 0.25 mg/ml cell homogenates after 3-hour 
incubation was around 35%, while more than 70% of DLS, DDS, and LDS were detected 
in the samples. Table 9 displays the estimated degradation rate constants and half-lives 
obtained from linear regression of pseudo-first-order plots of prodrug concentration 
versus time in cell homogenate. DDS exhibited the highest enzymatic stability with a half 
life of 12.6 h. LLS showed 7-fold less stability compared to DDS. LDS and DLS showed 
similar moderate stability in response to enzymatic hydrolysis in Caco-2 cell 
homogenates.  
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Figure 27. Degradation rate of SQV stereoisomeric dipeptide prodrugs (VVS, 23 µM) in 
0.25 mg protein/ml Caco-2 cell homogenates and regeneration of relative amino acid 
prodrug (VS) and parent drug (SQV).  
(a), LLS; (b), LDS; (c), DLS; and (d), DDS; (e), LS; and (f), DS. Each point represents 
mean ± SD (n=3). 
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Table 9. Degradation rate constants (Kd) and half lives (t1/2) for various SQV prodrugs in 
0.25 mg protein/ml Caco-2 cell homogenates. 
 Kd (h
-1
) t1/2 (h) 
LLS 0.4145 ± 0.0488 1.7 ± 0.2 
LDS 0.0948 ± 0.0052 7.3 ± 0.4 
DLS 0.0930 ± 0.0062 7.5 ± 0.5 
DDS 0.0548 ± 0.0039 12.6 ± 0.9 
LS 0.3060 ± 0.0322 2.3 ± 0.4 
DS 0.2418 ± 0.0274 2.9 ± 0.3 
Data represented are mean ± SD (n=3). 
 
Cytotoxicity Studies 
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme present in most cells. 
It is released into cell culture medium upon damage of the cell membrane and could be 
detected to represent damage in cells. Results obtained after 24 hours-exposure of 
different amounts of SQV (pro)drugs (5 µM to 150 µM) to MDCK-wt cells are depicted 
in Figure 28. SQV and its prodrugs increased cellular toxicity in a concentration-
dependant manner. In comparison to SQV, significantly less cellular toxicity was induced 
from prodrugs especially at higher concentrations. Two D-valine conjugate DDS 
displayed the least toxic on MDCK-wt cells at all concentration levels in this study. 
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Figure 28. Cytotoxicity of SQV and stereoisomeric prodrugs after 24-hrs incubation on 
MDCK-wt cells.  
Each point represents mean ± SD (n=4). *P < 0.05, and **P < 0.01 compared with SQV 
at same concentration. 
 
Affinity for Efflux Pumps 
   Accumulation of [
14
C]erythromycin (0.25 µCi/ml), a model substrate for both P-gp 
and MRP2, was determined in the presence of SQV or its peptide derivatives in MDCK 
cells to evaluate the affinity of prodrugs for P-gp or MRP2 efflux proteins. Results 
depicted in Figure 29 show that uptake of [
14
C]erythromycin in MDCK-MDR1 cells in 
the presence of 75 µM of drugs were 286.7 ± 15.7% (SQV), 209.7 ± 10.0% (LLS), 214.9 
± 5.8% (LDS), 182.0 ± 17.5% (DLS), and 219.4 ± 8.7% (DDS), respectively. Similar 
results were also found in MDCK-MRP2 cells. Accumulation of [
14
C]erythromycin was 
reduced significantly from 3-fold with SQV to less than 2-fold with various SQV 
stereoisomeric dipeptide prodrugs in both MDR1 and MRP2 cells.  
101 
 
 
 
Figure 29. Uptake of [
14C]erythromycin (0.25 μCi/ml) in the absence (Control) or 
presence of 75 µM of SQV and its prodrugs in MDCK-MDR1 and MDCK-MRP2 cells. 
Each point represents mean ± SD (n=4). **P<0.01 compared with uptake of 
[
14
C]erythromycin in the presence of SQV. 
 
Recognition by Peptide Transporters 
   Gly-Sar is a good substrate for peptide transporters. Figure 30 shows that 
accumulation of [
3
H]Gly-Sar was inhibited in the presence of 1 mM unlabeled Gly-Sar or 
75 µM dipeptide (L-val-L-val) in both transfected MDCK cells. Dipeptide conjugates 
LLS, LDS, and DLS (75 µM) displayed significant inhibition to [
3
H]Gly-Sar uptakes to 
the range of 65%-75% relative to control in MDCK-MDR1 cells, whereas SQV and DDS 
did not show any significant inhibition on [
3
H]Gly-Sar uptake. Results in MDCK-MRP2 
cells also exhibit similar inhibition effects on accumulation of [
3
H]Gly-Sar. Percentage of 
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[
3
H]Gly-Sar uptake observed for LLS, LDS, DLS, and DDS compared to the control was 
73.4%, 72.3%, 73.9% and 94.5%, respectively. 
 
 
Figure 30. Uptake of [
3
H] Gly-Sar (0.5 μCi/ml) in the absence (Control) or presence of 
unlabeled Gly-Sar (1 mM), L-val-L-val (75 µM), SQV (75 µM) or SQV prodrugs (75 µM) 
in MDCK-MDR1 and MDCK-MRP2 cells. 
Each point represents mean ± SD (n=4). ** P<0.01 compared with control. 
 
Recognition by Human Leukemic Monocytes   
Human leukemic monocyte lymphoma cell line U937 was used in this study to 
compare cellular cumulation of SQV with its prodrug derivatives (10 µM) by lymphatic 
cells. Results in Figure 31 indicate that cellular uptake of amino acids prodrugs in U937 
cells was about 90% of SQV. Dipeptide prodrugs showed slightly less monocytes uptake 
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than SQV. After 30 min incubation in U937 cells, cellular uptake of LLS, LDS, DLS, and 
DDS was observed to be 90.5±17.8%, 87.5±9.0%, 86.6±12.3%, and 78.6±11.2% of SQV, 
respectively. 
 
 
Figure 31. Uptake of SQV and prodrugs (10 µM) in human leukemic monocytes U937 
cells. Each point represents mean ± SD (n=4). 
 
Transepithelial Permeability Determination  
To determine whether stereoisomeric prodrug modifications could actually improve 
absorption across intestinal epithelium, both apical-to-basolateral (A-B) and basolateral-
to-apical (B-A) permeabilities for SQV and its prodrugs were measured across MDCK-
MDR1 and MDCK-MRP2 cell monolayers. The transport studies were performed at pH 
5.4 to reduce chemical hydrolysis since all dipeptide prodrugs of SQV showed higher 
stability in comparison to those at pH 7.4 (Table 8). Also, peptide transporters are more 
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active at acidic pH than at basic pH (Agarwal et al., 2007a). Figure 32 compares the 
bidirectional transport profiles of SQV in the presence or absence of P-gp inhibitor 
GF120918 (5 µM) and MRP inhibitor MK571 (50µM). The A-B flux of SQV was less 
than B-A flux across both MDR1 and MRP2 cells. The presence of GF120918 and 
MK571 reduced the efflux ratio between B-A and A-B directions significantly to around 
1.0 (Table 10). Furthermore, comparison of transepithelial transport between SQV and 
stereoisomeric prodrugs was evaluated by determining the apparent permeability 
coefficients (Papp) in both transport directions. Results in Table 10 indicate that A-B 
permeability of SQV was significantly enhanced by stereoisomeric prodrug modification, 
and B-A permeability was decreased on both MDR1 and MRP2 cell monolayers. Efflux 
ratios for prodrugs are in the range of 1.3 to 1.9 on MDCK-MDR1 cells and 1.1 to 1.4 on 
MDCK-MRP2 cells, respectively, which are much lower than that of SQV (4.50 on 
MDCK-MDR1 and 3.04 on MDCK-MRP2), but comparable to the values in the presence 
of P-gp inhibitor (1.14) and MRP inhibitor (1.00).  
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Figure 32. Bidirectional transepithelial transport of SQV (10 µM) across MDCK-MDR1 
cell monolayers (a), or MDCK-MRP2 cell monolayers (b).   
Each point represents mean ± SD (n=3).  
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Table 10. Apparent permeabilities (Papp) of SQV and stereoisomeric prodrugs on apical-
to-basolateral direction (A-B) and basolateral-to-apical direction (B-A) across MDCK-
MDR1 and MDCK-MRP2 cell monolayers. 
 
MDCK-MDR1 cells MDCK-MRP2 cells 
Papp(A-B) 
(cm/s, ×10
-6
) 
Papp(B-A) 
(cm/s, ×10
-6
) 
Efflux 
ratio 
Papp(A-B) 
(cm/s, ×10
-6
) 
Papp(B-A) 
(cm/s, ×10
-6
) 
Efflux 
ratio 
SQV 0.90±0.16 4.06±0.48 4.50 2.47±0.30 7.51±0.24 3.04 
SQV+MK571
(50µM) 
ND ND ND 5.95±1.60 5.97±0.81 1.00 
SQV+GF120
918(5µM) 
2.66±0.21 3.03±0.33 1.14 ND ND ND 
LLS 1.66±0.09 2.27±0.24 1.37 4.98±0.45 5.72±1.18 1.15 
LDS 1.52±0.31 2.13±0.57 1.40 4.60±1.35 6.08±1.10 1.32 
DLS 2.08±0.43 2.69±0.43 1.29 5.10±0.98 5.90±1.15 1.16 
DDS 1.35±0.14 2.52±0.12 1.87 4.66±0.57 6.61±0.23 1.42 
Data represented are mean ± SD (n=3). ND: not determined. 
 
Plasma Protein Binding  
Unbound fraction of SQV and various prodrugs in rat plasma were shown in Table 
11. The fu value of SQV is 0.036 ± 0.005 at a concentration of 0.5 µM. L-valine 
conjugates LS and LLS showed significantly enhanced mean fu values to 0.086 and 0.060, 
respectively. Unbound drug proportion of DS and DDS, i.e. the prodrugs conjugated with 
D-valines, were observed to be reduced to 0.016 and 0.024 in plasma, respectively.  
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Table 11. Unbound fraction (fu) of SQV and stereoisomeric prodrugs (0.5 µM) in rat plasma. 
 
SQV LS DS LLS LDS DLS DDS 
fu 0.036±0.005 0.086±0.015** 0.016±0.003** 0.060±0.012* 0.050±0.001* 0.031±0.011 0.024±0.010 
Data represented are mean ± SD (n = 3). *P < 0.05 and ** P < 0.01 for statistical difference between SQV and prodrug values. 
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Discussion 
   Apparent aqueous solubilities of all stereoisomeric val-val-SQV increased to more 
than 2-fold over SQV mesylate salt, and 1000-fold over SQV which is predicted as 2.47 
µg/ml at 25C (DrugBank database: DB01232). This increased solubility can be 
explained by three dimensional structure modification of SQV by amino acids. Generally 
the formation of hydrogen bonds between compounds and water molecules is considered 
to have strong influence on physical properties like aqueous solubility. The high 
hydrogen-bonding potential and the presence of charged amino groups in the promoiety 
val-val may dramatically contribute to the hydrophilicity of the conjugates. Similar 
results are obtained by MSX-4, a valine ester prodrug of the adenosine A2A receptor 
antagonist MSX-2, with an enhanced solubility to more than 73 times over its parent drug 
(Vollmann et al., 2008).  
A good prodrug candidate after oral administration should be stable enough in 
gastrointestinal (GI) tract, and then be absorbed across intestinal mucosa and converted to 
intact parent drug following its transport. Degradation of peptide prodrug in GI tract can 
proceed either by enzyme-catalyzed hydrolysis or via a base-catalyzed hydrolysis 
yielding amino acid prodrug or parent drug directly. Therefore chemical and enzymatic 
stability studies will help in screening the ideal prodrug candidate for the further research. 
Results in Table 8 indicate that all stereoisomeric valine-SQV conjugates underwent 
acid/base hydrolysis in the pH range of 1.4 to 10.4. Chemical stability enhanced with the 
increased number of isomers in promoieties, suggesting that dipeptide conjugates are 
chemically more stable than amino acid conjugates. These results are consistent with 
previous observations (Anand et al., 2003; Patel et al., 2005). In comparison to L-valine 
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conjugates, the attachment of D-valine with SQV exhibited higher chemical stability 
under various pH conditions. The t1/2 values of DS at different pH are either higher or 
comparable to that of LS, and two D-valine prodrug DDS displayed the longest 
degradation half lives at all pH conditions and is considered to be the most stable 
compound among all isomeric dipeptide prodrugs. Desiderio et al. also reported this 
stereoselective chemical stability. Approximately 42% of D,L-adenosylmethionine and 
26% of L,L-adenosylmethionine were left after 14 days- incubation in sodium phosphate 
buffer (pH 2.5), respectively, indicating L,L-diastereoisomer showed a stronger chemical 
hydrolysis than the D,L-form (Desiderio et al., 2005). Since the physical pH of major 
portion of drug absorption in GI tract is ranged from 5 to 8, dipeptide conjugates of SQV 
with longer residence time in intestine could be better candidates for oral drug delivery in 
comparison to amino acid prodrugs. 
Human colon adenocarcinoma cell line Caco-2 cells was used in metabolic 
hydrolysis study because it has been reported to be particularly abundant in many 
esterases like carboxylesterases and peptidases including aminopeptidases, dipeptidyl 
peptidases, endopeptidase, and membrane dipeptidase (Howell et al., 1992; Jumarie and 
Malo, 1994; Imai et al., 2005). These hydrolytic enzymes play an important role in the 
degradation of dipeptide prodrug to parent drug when it is absorbed across the intestinal 
mucosa. Time-course of various species formation in Caco-2 cell homogenates in Figure 
27 illustrates that the hydrolysis pattern of SQV dipeptide prodrugs is compliant to the 
mechanism of metabolic degradation as demonstrated by the previous study (Anand et al., 
2003). Dipeptide prodrug VVS was degraded to amino acid prodrug VS by peptidases 
and further to parent drug SQV by esterases. Formation of SQV directly from dipeptides 
110 
 
is also possible but the amount is very limited. Results in Table 9 indicate that LLS 
showed the least enzymatic stability in cell homogenates among all four stereoisomer 
prodrugs. Incorporation of D-isomer enhances the enzymatic stability of conjugation 
significantly. The half-lives of DLS and LDS are 4.4-fold and 4.3-fold longer than that of 
LLS, respectively. Two D-isomers conjugation DDS exhibits the most stability in cell 
homogenate, with a 7.4-fold longer half-life over LLS. This observation agrees well with 
the previously reported results (Pochopin et al., 1994; Fang et al., 2000; Talluri et al., 
2008; Tsume et al., 2008). Different metabolic stability of dipeptides may due to their 
different affinities to hydrolytic enzymes. These stereoisomers could interact with 
hydrolases with different kinetic parameters since they have different three-dimensional 
structures. Results in this study indicate that LLS is an excellent substrate for hydrolases. 
The incorporation of D-valine might reduce the recognition by hydrolases, thus it 
decreases the interaction between conjugates and active site of the enzymes. 
Correspondingly, DDS displayed significantly enhanced stability in cell homogenates.   
Cytotoxicity of SQV prodrugs was evaluated on MDCK-wt cells using LDH assay 
method. All prodrugs displayed similar or much lower toxicity in comparison to parent 
drug SQV. Additionally, the toxicity induced by prodrugs was stereoselective on MDCK-
wt cells. D-isomer conjugations, especially DDS, showed relatively lower cytotoxicity 
than other stereoisomeric prodrugs. Our previous work measuring metabolic hydrolysis 
in cell homogenates might explain this sereoselecitive toxicity. DDS showed the least 
affinity to hydrolases compared to other dipeptide prodrugs. It would lead to less cellular 
accumulation of SQV from DDS degradation and consequently contribute to less 
cytotoxicity because SQV is more toxic than prodrugs. In contrast, LLS could be 
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degraded into SQV to a greater extent since it is a better substrate for hydrolytic enzymes, 
and thereby LLS displayed a higher toxicity on MDCK-wt cells.  
Drug efflux proteins P-gp and MRP2, which are highly expressed in the intestinal 
mucosa, could be responsible for the low oral bioavailability of SQV (Washington et al., 
1998; Huisman et al., 2002). Peptide prodrug modifications, including valine-valine drug 
derivatives, have been reported by our laboratory for their partial avoidance of efflux 
pump mediated transport (David et al., 2005; Agarwal et al., 2008; Jain et al., 2008). 
However, modification of the three-dimensional structure may affect the interaction of 
the substrate with the enzyme significantly. In this regard, comparison of the affinity of 
SQV and stereoisomeric valine-valine prodrugs towards efflux transporters was 
examined employing human MDR1 and MRP2 gene-transfected MDCK cell lines. These 
two cell lines are widely employed as in vitro models of intestinal epithelium for 
screening drug permeability (Irvine et al., 1999; Tang et al., 2002b; Tang et al., 2002a). 
Cellular uptake of [
14
C]erythromycin was enhanced to 2.9-fold over the control with the 
administration of 75 µM SQV on MDCK-MDR1 cells, suggesting that the binding sites 
on P-gp were competitively occupied by SQV, thereby the cellular accumulation of 
another P-gp substrate erythromycin increased. However, equimolar amount of prodrugs 
exhibited significant reduction of [
14
C]erythromycin uptake compared to SQV. Similar 
extent of inhibition was also observed on MDCK-MRP2 cells. These differential 
inhibitory activities indicate that all four stereoisomeric peptide modifications possess 
lower affinity for both P-gp and MRP2 relative to SQV, and consequently result in 
reduced cellular accumulation of [
14
C]erythromycin. 
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Conversely, recognition of prodrugs by peptide transporters was the primary 
objective of our study. The presence of peptide transporters has been reported on MDCK 
cells (Brandsch et al., 1995; Agarwal et al., 2007a; Wang et al., 2013). Therefore 
accumulation of dipeptide Gly-Sar was determined on both MDCK-MDR1 and MDCK-
MRP2 cells to evaluate the affinity of SQV prodrugs for peptide transporters in this study. 
Uptake of [
3
H]Gly-Sar was inhibited by unlabeled Gly-Sar and val-val, suggesting the 
expression of peptide transporters on both MDCK-MDR1 and MDCK-MRP2 cell lines. 
Interaction between SQV prodrugs and peptide transporters is observed to be 
stereoselective. It is evident by the diminished cellular uptake of [
3
H]Gly-Sar in the 
presence of LLS, LDS, and DLS, except two D-isomer conjugate DDS. These results are 
consistent with the previous studies that peptides containing L-amino acids showed 
higher interactions with peptide transporters than those containing D-amino acids (Tamai 
et al., 1988; Lister et al., 1995; Mitsuoka et al., 2007). Our findings in uptake studies 
clearly demonstrate that stereoisomeric prodrugs LLS, LDS, and DLS could be 
translocated into cells by peptide transporter mediated influx as well as bypass efflux 
transporters (P-gp and MRP2), whereas DDS may only evade efflux pumps and did not 
show reasonable affinity for the peptide transporters. 
It has been reported that both tissue macrophages and blood monocytes can be 
infected with HIV-1 (Kedzierska and Crowe, 2002). Therefore cellular uptake of SQV 
and prodrug derivatives in lymphoma cells was also evaluated using U937 cells in this 
study. Results in Figure 31 demonstrate that all stereoisomeric prodrugs exhibit similar 
cellular uptake as parent drug SQV, suggesting that SQV uptake by lymphoma cells may 
not be influenced by valine-based prodrug modification proposed in this study.  
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Comparison of transepithelial flux of SQV on absorptive (apical-to-basolateral, A-B) 
and secretive (basolateral-to-apical, B-A) directions demonstrates the influence of efflux 
transporters which are located on the apical cell membrane. Results in Figure 32 and 
Table 10 exhibited a much lower absorptive transport of SQV compared to excretive 
transport. This asymmetric permeation is due to the involvement of efflux transporters 
present on apical cell membrane. Similar bidirectional transepithelial flux of SQV was 
obtained in the presence of GF120918 or MK571, inhibitors for P-gp and MRP2 
respectively. It confirms that efflux activities of P-gp and MRP2 proteins are one of the 
major obstacles which limit intestinal absorption of SQV (Siccardi et al., 2003; Taub et 
al., 2005). Both MDCK-MDR1 and MDCK-MRP2 cell lines are originated from same 
wild type MDCK cells. However, the apparent permeabilities of peptide prodrugs across 
MDCK-MDR1 are different from MDCK-MRP2 monolayers (Table 10). It suggests a 
different capacity of peptide translocation in these two cell lines. Previous studies in our 
laboratory have reported that transfection of human efflux genes like MDR1 influences 
the functional activities and biological expression of endogenous transporters such as 
peptide transporters (Agarwal et al., 2007a; Wang et al., 2013). According to Papp values 
summarized in Table 10, the bidirectional translocation of all prodrugs displayed 
insignificant asymmetry across both transfected MDCK cell lines. This increment may be 
due to combined effects of higher solubility and stability, less affinity for the efflux 
transporters and better recognition by peptide transporters. Among all stereoisomeric 
peptide prodrugs, the efflux ratio of DDS exhibited the least difference from SQV, 
suggesting its translocation across both MDCK cells is not as efficient as other isomeric 
conjugates. Even though DDS showed excellent chemical and enzymatic stability which 
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keeps more intact peptide prodrugs remaining in the 3 hours-transport study, the failure to 
be recognized by peptide transporters might attribute to its relatively low transepithelial 
permeation. 
 
Figure 33. Comparison of unbound fraction (fu) of SQV prodrugs with SQV in rat plasma. 
 
Protein binding in plasma is one of the determinant characteristics for the evaluation 
of drug disposition in human because only unbound fraction is available for absorption 
and to elicit its pharmacological action to achieve therapeutic effects. HIV PIs exhibit 
moderate to high plasma proteins binding, especially to α1-acid glycoprotein (AAG), an 
acute phase plasma α-globulin glycoprotein (Acosta et al., 2000). In the present study, 
unbound fraction of SQV was determined in vitro using Sprague–Dawley rat plasma. The 
fu value of SQV was observed to be 0.036 ± 0.005, suggesting that only 3.6% of total 
amount of SQV in rat plasma remained free for antiretroviral activity. This result is 
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consistent with the previous findings that SQV is 98% bound to plasma proteins in 
human (Flexner, 1998). Significant stereoselectivity was observed in protein binding 
studies. Position of different isomers in promoieties plays a key role in protein binding of 
SQV dipeptide prodrugs. Comparison of unbound fractions of various prodrugs has been 
summarized in Figure 33. Generally, a reduced plasma protein binding is noted when L-
valine is conjugated to SQV, conversely D-valine conjugated to parent drug SQV may 
contribute to increased protein binding. Moreover, type of terminal isomers in the 
promoieties can influence this stereoselective protein binding. Typically D-isomer on 
terminal position may reduce the unbound fraction, whereas L-isomer produces reverse 
effect. Because of the absence of any plasma proteins in in vitro studies, this differential 
plasma protein binding must be taken into consideration when interpreting in vitro data to 
estimate the in vivo pharmacokinetic or pharmacodynamic parameters. 
The study in this chapter suggests that stereoisomeric peptide might be an attractive 
pro-moiety employed in transporter-targeted prodrug design. All valine-valine-SQV 
stereoisomeric modifications exhibit similar enhanced aqueous solubility as well as 
reduced affinity for efflux transporters, but significant stereoselectivity in cellular toxicity, 
plasma protein binding, chemical and enzyme-catalyzed hydrolysis, as well as 
recognizition by peptide transporters. Conjugation of L-valine to SQV illustrates higher 
affinity towards peptide transporters, lower protein binding but poor stability and higher 
toxicity, whereas incorporation of D-valine displays good stability and lower toxicity but 
weak binding with peptide transporters and less unbound fraction in plasma. Results in 
this chapter indicate that D-valine-L-valine-SQV and L-valine-D-valine-SQV might be 
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potential targeted prodrug candidates which improve intestinal absorption of SQV and 
enhance oral bioavailability. 
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CHAPTER 6 
IN VITRO HYDROLYSIS AND ENZYMATIC METABOLISM STUDIES 
Rationale 
Poor pharmacokinetics of orally administered SQV are often attributed to rapid and 
extensive first-pass metabolism in small intestine and liver (Eagling et al., 2002; Usansky 
et al., 2008). Cytochrome P450 3A (CYP3A) has been identified as the predominant 
subfamily of hepatic and intestinal CYP enzymes. It is responsible for oxidative 
biotransformation of more than 50% of drugs in humans and rats. SQV is metabolized 
primarily by CYP3A4 to mono- and di- hydroxylated metabolites with negligible 
antiviral activity in humans (Noble and Faulds, 1996; Decker et al., 1998; Parker and 
Houston, 2008). Mean Cmax and AUC values were significantly elevated when SQV hard 
gel formulation was co-administered with other CYP3A4 inhibitors i.e. ritonavir or 
indinavir (Kumar et al., 1996; Figgitt and Plosker, 2000). In addition, activity of efflux 
pump P-gp also plays a critical role in reducing SQV oral bioavailability (Kim et al., 
1998a; Pal and Mitra, 2006). In comparison with other major secretary transporters like 
MRP2 located in rat jejunum, P-gp displays a dominating role on intestinal SQV 
absorption (Usansky et al., 2008). Transepithelial permeation of SQV across gut wall into 
systemic circulation is mainly restricted by P-gp, and consequently a larger fraction is 
available for pre-systemic biotransformation in GI tract. Optimizing oral administration 
of drugs with narrow therapeutic index is critically important, especially for chronically 
ill patients requiring long-term treatment. Many such agents are substrates for both CYP 
enzymes and efflux transport proteins. Absorption, distribution, and disposition of SQV 
have been reported to be significantly influenced by the dual effect of P-gp-mediated 
118 
 
efflux and CYP enzymes-mediated metabolism. Also, continuous use of SQV results in 
induction of P-gp at the target cells (Konig et al., 2010).  
The study in this chapter was to describe the application of stereoisomeric peptide 
prodrug modification as a strategy to overcome these problems and provide an extensive 
understanding of the stereoselective resistance to hydrolytic and oxidative enzymes. In 
this chapter, the first purpose of this study is to investigate affinity of SQV and 
stereoisomeric peptide conjugates towards P-gp expressed on Caco-2 cell membrane. The 
second aim is to determine enzyme kinetic parameters for the oxidative metabolism 
mediated by CYP3A in rat liver microsomes. Bioconversion from prodrugs to the parent 
drug was also studied in rat plasma and intestinal homogenates since hydrolytic enzymes 
located in these tissues play an important role in cleaving ester and peptide bonds. 
 
Materials and Methods 
Materials  
SQV mesylate was kindly donated by Hoffmann-La Roche. SQV stereoisomaric 
dipeptide prodrugs (LLS, LDS, DLS, and DDS) and amino acid prodrugs (LS and DS) 
were synthesized in our laboratory. Caco-2 cells were obtained from ATCC (Manassas, 
VA). [
3
H]saquinavir (1.0 Ci/mmol) was purchased from Moravek Biochemicals (Brea, 
CA). Sprague–Dawley rat plasma was purchased from Valley Biomedical Inc. 
(Winchester, VA). IGS Sprague–Dawley rat liver microsomes were obtained from 
XenoTech LLC (Lenexa, Kansas). Bestatin was purchased from USB Corporation 
(Cleveland, Ohio). Eserine and 4-(hydroxymercuri)benzoic acid sodium salt (PHMB) 
were obtained from Sigma Chemical Co. (St. Louis, MO). Pefabloc
®
 SC was purchased 
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from Fluka Chemical Corp. (Milwaukee, WI). TrypLE
TM
 Express Stable Trypsin 
Replacement and Dulbecco’s modified Eagle’s Medium (DMEM) were obtained from 
Invitrogen (Carlsbed, CA). Fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Lawenceville, GA). LY335979 (zosuquidar) was generously provided by 
Kanisa Pharmaceuticals, Inc. (San Diego, CA). Ketoconazole was obtained from Sigma 
Chemical Co. (St. Louis, MO). BioRad protein estimation kit was purchased from 
BioRad (Hercules, CA). Scintillation cocktail reagent was obtained from Fisher Scientific 
(Fair Lawn, NJ). Triton X-100, HEPES, D-glucose and all other chemicals and solvents 
were purchased from Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific Co. 
(Pittsburgh, PA). 
 
Animals  
Male Sprague–Dawley rats weighing 200–250 grams were obtained from Charles 
River Laboratories (Wilmington, MA). Animals were used in accordance with the 
protocol approved by University of Missouri-Kansas City Institutional Animal Care and 
Use Committee (IACUC) and housed in Laboratory Animal Research Core (LARC) 
facilities at University of Missouri-Kansas City. Before experiments, all rates were fasted 
overnight with free access to water. 
 
Cell Culture  
Caco-2 cells were seeded at a density of 40,000 cells/cm
2
 in 75 cm
2
 cell culture 
flasks and incubated at 37C, in a humidified atmosphere of 5% CO2, 90% relative 
humidity. Cells were maintained in DMEM containing 10% heat-inactivated FBS, 20 
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mM HEPES, 29 mM sodium bicarbonate, 100 units/ml penicillin, and 100 μg/ml 
streptomycin. Medium was changed every alternate day. After 7-days postseeding, cells 
were harvested and passaged using TrypLE
TM
 Express Stable Trypsin Replacement, and 
plated at the density of 2 × 10
4
 cells /cm
2
 on 12-well tissue culture plates for uptake 
studies, or and 7.5 × 10
4
 cells /cm
2
 on 12-well Transwell
®
 inserts (diameter 12 mm, pore 
size 0.4µm) for transport studies. Studies using Caco-2 cells were performed after 18-23 
days of growth. 
 
Uptake and Transport Studies  
Drug cellular accumulation and transport studies on Caco-2 cells were conducted 
following the methods described in Chapter 3.  
 
Metabolism Studies in Rat Liver Microsomes  
IGS Sprague–Dawley rat liver microsomes were employed to study affinity of the 
stereoisomeric prodrugs toward CYP3A relative to SQV. Incubations were conducted in 
Eppendorf tubes in a LabQuake

 Tube Shaker (Barnstead Thermolyne Corp., Dubuque, 
Iowa) at 37C. For inhibition study, depletion of SQV and prodrugs in the presence of 
specific CYP3A4 inhibitor ketoconazole (KTZ) was determined after 15 min-incubation 
in 1.0 mg protein/ml rat liver microsomes. Generally 135 µl of liver microsomes diluted 
in DPBS (pH7.4) with 10 mM magnesium chloride and 10 µM KTZ were pre-incubated 
at 37C for 10 min. After adding 150 µl drug solutions (2 µM) with 10 µM KTZ, the 
reaction was initiated by adding 15 µl of pre-warmed NADPH generating system 
containing 5mM glucose 6-phosphate, 1 U/ml glucose 6-phosphate dehydrogenase, and 
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1mM β-nicotinamide adenine dinucleotide phosphate (NADP). Final concentrations for 
drugs and KTZ were 1 µM and 10 µM, respectively. Aliquots (100 µl) of samples were 
taken at 0 min and 15 min, and then 100 µl of ice-cold acetonitrile was added 
immediately to terminate metabolic reaction. Subsequently samples were centrifuged at 
12,500 rpm, 4 C for 5 min and the supernatant was stored at −80C until further analysis 
by LC-MS/MS. Amounts of remained SQV and prodrugs in the absence of KTZ were 
also determined under same conditions.  
   For time dependent metabolism study, depletion of SQV and prodrugs was 
measured at the initial concentration of 1 µM for up to 2 hour-incubation in rat liver 
microsomes (0.2 mg protein/ml). Metabolic kinetic parameters including Km and Vmax 
were calculated by incubating SQV and its prodrugs with various concentrations over a 
range of 0.1-2.5 µM in 0.2 mg protein/ml rat liver microsomes for 5 min. The incubation 
followed the method mentioned in the inhibition study earlier. Samples (100 µl) were 
collected at predetermined time points. The metabolic reaction was terminated by adding 
equal volumes of ice-cold acetonitrile to the sample. Samples were stored at −80C until 
further analysis. All incubations were performed in quadruplicate. 
 
Preparation of Intestinal Homogenates  
Male Sprague-Dawley rats (200-250 g) were euthanized by a lethal injection of 
sodium pentobarbital through the tail vein (100 mg/kg). Small intestine was exposed and 
jejunum segment was externalized. Intestinal tissues were homogenized in 10 ml chilled 
isotonic phosphate buffered saline (IPBS, pH 7.4) using Multipro Variable Speed 
Homogenizer (DREMEL, Racine, WI) for 5 min on ice bath. Subsequently, homogenates 
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were centrifuged at 14,000 ×g, 4C for 25 min to remove cellular debris. The supernatant 
was diluted with IPBS properly to achieve a final protein concentration of 0.5 mg/ml. 
Protein content was determined according to the method of Bradford using BioRad 
protein estimation kit. 
 
In vitro Prodrug Hydrolysis in Rat Plasma and Intestinal Homogenates 
Hydrolysis of SQV peptide prodrugs was determined in triplicate in rat plasma and 
intestinal homogenate in the presence or absence of various hydrolytic enzyme inhibitors. 
Frozen Sprague–Dawley rat plasma was thawed quickly before experiment and diluted to 
90% (v/v) with IPBS (pH 7.4) to maintain the pH of solution. Prior to the initiation of 
hydrolysis study, plasma and intestinal homogenate were equilibrated at 37C for 15 min 
after adding enzyme inhibitors. The concentrations for enzyme inhibitors PHMB, eserine, 
bestatin, and Pefabloc
®
 AC were 1 mM, 1 mM, 0.5 mM, and 1 mM, respectively. 
Hydrolysis was initiated in a test tube by the addition of SQV prodrug solution to 1 ml 
plasma or intestinal homogenate in the presence or absence of enzyme inhibitor. Final 
prodrug concentration in the reaction mixture was 10 µM. Test tubes were incubated at 
37C in a shaking water bath (45 rpm) and aliquots (50 µl) were withdrawn at appropriate 
time intervals for up to 24 h. Samples were immediately diluted with 50 µl chilled 
acetonitrile to quench the reaction and centrifuged at 12,500 rpm for 15 min to precipitate 
protein. The supernatants were stored at−80C until further analysis by LC-MS/MS. 
 
Sample Preparation and Analysis  
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All SQV and prodrug samples were prepared using liquid-liquid extraction technique 
following the procedure in Chapter 5. Analysis procedures using LC-MS/MS system 
have been described in Chapter 4.  
 
Data and Statistical Analysis  
For oxidative metabolism studies, elimination rate constant (Ke) and half life (t1/2) of 
each drug in rat liver microsomes were calculated by plotting the natural logarithm of 
drug concentrations versus time. The data of metabolic rates (substrate turnover per 
minute per milligram microsomal protein) were fit to Michaelis-Menten equation by 
nonlinear regression to determine the kinetic parameters Km and Vmax. Data modeling was 
conducted using KaleidaGraph (Synergy Software). In vitro intrinsic clearance (CLint) 
was subsequently represented by dividing Vmax by Km as shown in the following equation. 
    Where V represents the total rate of uptake, Vmax is the maximum uptake rate for the 
carrier-mediated process, Km (Michaelis-Menten constant) is the concentration at half-
saturation, and [S] is the substrate concentration.  
For hydrolytic metabolism study in rat plasma and tissue homogenate, degradation 
rate constants (Kd) were calculated by plotting the natural logarithm of drug 
concentrations against time, and half lives (t1/2) were estimated by degradation rate 
constants. 
All experiments were conducted at least in triplicate and the results were expressed 
as mean ± S.E. Statistical significance was detected using Student’s t-test. Difference 
𝑉 =
𝑉𝑚𝑎𝑥 × [𝑆]
𝐾𝑚 + [𝑆]
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between mean values was considered statistically significant at p < 0.05 and very 
statistically significant at p < 0.01.   
 
Results 
Uptake and Transport in Caco-2 Cells  
Cellular accumulation of [
3
H]saquinavir (0.5 µCi/ml) was carried out in Caco-2 cells 
to determine whether stereoisomeric prodrug modifications could evade P-gp mediated 
efflux of SQV. Figure 34 shows that the accumulation of [
3
H]saquinavir markedly 
increased about 2.5-fold in the presence of LY335979, a potent P-gp inhibitor, suggesting 
P-gp mediated SQV efflux was competitively inhibited. Similarly, around 2.2-fold 
increase in [
3
H]saquinavir uptake with 50 µM of unlabelled SQV indicates that SQV is a 
good substrate for P-gp. However, the presence of equimolar SQV prodrugs showed only 
1.2- to 1.4-fold increase in cellular uptake of [
3
H]saquinavir, suggesting that the affinity 
to P-gp was significantly reduced by stereoisomeric prodrug modification (P < 0.01). No 
statistical difference was observed in the [
3
H]saquinavir uptake when various SQV 
prodrugs presented in this study.  
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Figure 34. Cellular uptake of [
3
H]saquinavir (0.5 µCi/ml) by Caco-2 cells in the absence 
(Control) and presence of P-gp inhibitor LY335979 (1 µM), SQV (50 µM) and various 
stereoisomeric prodrugs (50 µM).  
Statistically significant difference (**P < 0.01) was observed in uptake between prodrugs 
and equimolar concentrations of SQV. Values are mean ± S.E. (n = 4). 
 
Transepithelial transport of SQV and its stereoisomeric prodrugs were studied across 
Caco-2 cell monolayers. Cumulative amount of drug transported was plotted as a 
function of time. Since partial dipeptide prodrugs can be hydrolyzed to amino acid 
prodrugs and SQV by the enzymes present in cell cytoplasm during the transport process, 
amount of drugs transported into receiver chambers for prodrug transport studies was 
calculated as the sum of prodrugs and regenerated SQV. Bidirectional transport of SQV 
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across Caco-2 cells in Figure 35A demonstrates that absorptive flux (AB) of SQV was 
much lower than secretory direction (BA). The presence of specific P-gp inhibitor 
LY335979 (1 µM) can markedly increase absorptive permeability of SQV, and reduce its 
secretory permeability. Bidirectional transport of SQV prodrugs, amino acid prodrug DS 
and dipeptide prodrug DLS, across Caco-2 cell monolayers was illustrates in Figure 35B. 
All transport-time profiles of SQV prodrugs showed similar linear relationship over the 
time course of 3 hours (profiles of other prodrugs are not shown here). In comparison 
with SQV, a less asymmetric permeation was observed by all prodrugs. Values of 
apparent permeabilities (Papp) of SQV and stereoisomeric prodrugs across Caco-2 cell 
monolayers are summarized in Table 12. Efflux ratios, the ratio of Papp on BA direction 
to AB direction, were obtained to be 4.98 and 1.32 for SQV in the absence and presence 
of LY335979, respectively. The efflux ratios for prodrugs are in the range of 1.2 to 2.8, 
which are much lower than unmodified SQV, but comparable to the value observed in the 
presence LY335979. Prodrugs with L-valine as promoiety showed higher permeability 
relative to D- isomer conjugates. Efflux ratio for LS across Caco-2 monolayer is 1.22, 
about half of DS. The order of efflux ratio for dipeptide SQV prodrugs is LLS < DLS < 
LDS < DDS. 
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Figure 35. Bidirectional transepithelial transport of SQV (10 µM) in the presence and 
absence of P-gp inhibitor LY335979 (1 µM) (A), and SQV prodrugs DS and DLS (25 
µM) (B) across Caco-2 cell monolayers (mean ± S.E, n = 4). 
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Table 12. Bidirectional apparent permeabilities (Papp) of SQV and stereoisomeric 
prodrugs across Caco-2 cell monolayers (mean ± S.E, n = 4). 
 
Papp(AB) 
(10-6 cm/s) 
Papp(BA) 
(10-6 cm/s) 
Efflux ratio 
SQV  1.62 ± 0.28 8.06 ± 0.85 4.98 
SQV + LY335979 
(1µM) 
3.57 ± 0.28 4.73 ± 0.25 1.32 
Amino acid prodrugs  
  
LS 2.76 ± 0.21 3.38 ± 0.02 1.22 
DS 1.88 ± 0.18 4.83 ± 0.22 2.57 
Dipeptide prodrugs  
   
LLS 2.84 ± 0.14 3.32 ± 0.15 1.17 
LDS 2.47 ± 0.23 3.99 ± 0.10 1.62 
DLS 2.71 ± 0.02 3.85 ± 0.22 1.42 
DDS 2.09 ± 0.13 5.91 ± 0.14 2.83 
AB: on apical-to-basolateral direction; BA: basolateral-to-apical direction; Efflux ratio = 
Papp (BA)/Papp (AB).  
 
Inhibitory Hepatic Metabolism   
Depletion of SQV and prodrugs (1 µM) was determined in the presence or absence 
of specific CYP3A inhibitor KTZ (10 µM) after 15-min incubation in 1 mg protein/ml rat 
liver microsomes (Figure 36). The percentage SQV remaining was only 10.8% ± 0.8% at 
the end of experiment. However, it significantly increased by more than 8-fold to 86.4% 
± 8.7% when co-administered with KTZ. In comparison with SQV, all dipeptide and 
amino acid prodrugs exhibited improved stability against hepatic metabolism. Around 57% 
- 72% of valine-SQV prodrugs and 80% - 96% of stereoisomeric valine-valine conjugates 
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remained unchanged after 15-min of incubation in rat liver microsomes. In addition, all 
prodrugs appeared to be more stable in the presence of 10 µM KTZ. Less than 10% of 
biotransformation was noted.  
 
Figure 36. Amount of remained SQV and prodrugs in the absence or presence of CYP 3A 
inhibitor ketoconazole (10 µM) after 15 min incubation in 1.0 mg/ml rat liver 
microsomes (mean ± S.E, n = 4).  
Close bar: 1 µM of substrate; Open bar: 1 µM of substrate and 10 µM of ketoconazole. 
*P < 0.05, and **P < 0.01 compared with SQV. 
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instability towards hepatic metabolic enzymes. Almost 100% SQV underwent 
biotransformation to inactive metabolites after 1-h incubation. Dipeptide prodrugs 
exhibited longer residence time than amino acid prodrugs. DDS showed the longest 
resistance to hepatic enzymes with about 75% of the drug remaining unchanged after 2-h 
incubation. All depletion profiles displayed logarithm-linear relationship over the time 
course studied. Elimination rate constants (Ke) and half lives (t1/2) are summarized in 
Table 13. The shortest half life (7.3 ± 1.3 min) and the fastest biotransformation rate 
(0.0949 ± 0.0169 min
-1
) were observed for SQV in microsomal solutions. Dipeptide and 
amino acid prodrugs were less susceptible to hepatic enzymes, with significantly longer 
half lives by 12- to 40- fold and 6- to 7- fold relative to SQV, respectively. Additionally, 
D-isomer conjugates appear to be more enzymatically stable over L-isomer conjugates. 
The half life of DS (55.9±7.9 min) was longer than LS (46.5±7.8 min), and DDS 
exhibited the longest residence with the half life of 296.2±25.8 min, which is 3 times 
more than LLS. 
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Figure 37. Time dependent metabolism for SQV and various prodrugs in 0.2 mg 
protein/ml rat liver microsomes (mean ± S.E, n = 4).  
, SQV; ▲, LS; ■, DS; □, LLS; ○, LDS; ∆, DLS; ●, DDS. 
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Table 13. Elimination rate constants (Ke) and half lives (t1/2) for SQV and various 
stereoisomeric prodrugs in 0.2 mg protein/ml rat liver microsomes (mean ± S.E, n = 4). 
 
Ke  (min
-1
) t1/2 (min) 
SQV  0.0949 ± 0.0169 7.3 ± 1.3 
Amino acid prodrugs  
  
        LS  0.0149 ± 0.0025 46.5 ± 7.8 
        DS  0.0124 ± 0.0018 55.9 ± 7.9 
Dipeptide prodrugs  
  
       LLS  0.0078 ± 0.0012 88.9 ± 13.2 
       LDS  0.0039 ± 0.0003 177.7 ± 15.6 
       DLS  0.0031 ± 0.0003 223.6 ± 20.8 
       DDS  0.0023 ± 0.0002 296.2 ± 25.8 
 
Concentration Dependent Hepatic Metabolism 
Figure 38 depicts the relationship between metabolic rate and substrate concentration 
for SQV, LS and LLS. Oxidative biotransformation of SQV and stereoisomeric prodrugs 
follows Michaelis-Menten kinetics in rat liver microsomes. Kinetic parameters Km and 
Vmax were calculated and are listed in Table 14. Apparent Km for SQV (0.41 ± 0.06 µM) 
was increased by 2 to 5 times after prodrug modification, suggesting that this approach 
significantly reduced the affinity of SQV towards CYP-mediated phase I metabolism. 
Among the prodrugs studied, DDS was most stable towards metabolic enzymes, with a 
Km value of 1.98 ± 0.27 µM. Application of L- or D- isomers in conjugation also played 
an important role in enzyme recognition. The Km values for LS and DS were 0.64 µM 
and 0.98 µM, respectively, suggesting that the D- isomer conjugations display less 
affinity towards hepatic enzymes. This result is consistent with results from dipeptide 
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prodrugs. Apparent Km values for LLS and DDS determined in this study were 1.06 µM 
and 1.57 µM, respectively. Estimates of in vitro intrinsic clearance (CLint) summarized in 
Table 14 primarily represent the disparity in turnover of rat liver microsomes. The in 
vitro intrinsic clearance of SQV in microsomes was calculated as 1.85 ± 0.20 ml/min/mg 
microsomal protein. Significantly lower CLint estimates were observed for all prodrugs in 
comparison with SQV. DLS showed the most reduced turnover rate at 0.78 ± 0.13 
ml/min/mg protein, with 60% less metabolites generated relative to parent drug SQV. 
 
 
 
134 
 
 
 
Figure 38. Relationship between metabolic rate and substrate concentration for SQV (a), 
LS (b) and LLS (c) in 0.2 mg protein/ml rat liver microsomes (mean ± S.E, n = 4).  
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Table 14. Kinetic parameters Km, Vmax and in vitro intrinsic clearance (CLint) of 
saquinavir and stereoisomeric prodrugs in 0.2 mg protein/ml rat liver microsomes (mean 
± S.E., n = 4).  
 
Km 
(µM) 
Vmax 
(nmol/min/mg protein) 
CLint 
(ml/min/mg protein) 
SQV  0.41±0.06 0.749±0.030 1.85±0.20 
Amino acid prodrugs  
 
 
LS  0.64±0.23 0.856±0.073* 1.43±0.31* 
DS  0.98±0.13** 1.318±0.122** 1.35±0.04** 
Dipeptide prodrugs  
  
 
LLS 1.06±0.30** 1.369±0.292** 1.30±0.15** 
LDS 1.15±0.38** 1.304±0.406** 1.14±0.04** 
DLS 1.33±0.12** 1.031±0.125** 0.78±0.13** 
DDS 1.57±0.09** 1.467±0.127** 0.93±0.03** 
*P < 0.05, and **P < 0.01 compared with SQV.  
 
Hydrolytic Degradation in Rat Tissues  
Stability of various SQV stereoisomeric valine-valine prodrugs was evaluated in rat 
plasma and intestinal homogenates to identify the contribution of structural modification 
to enzymatic hydrolysis. Results in Figure 39 indicate that LLS may be the least 
enzymatically stable among all four dipeptide prodrugs. The estimated half lives (Table 
15) of LLS in rat intestinal homogenates (0.5 mg protein/ml) and plasma were 2.4 ± 0.1 h 
and 7.8 ± 0.1 h, respectively. DDS exhibited relatively higher enzymatic stability with 
half lives of 24.1 ± 0.5 h and 40.0 ± 5.0 h in rat intestinal homogenates and plasma, 
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which are around 10- fold and 5- fold higher over LLS, respectively. Our studies also 
indicate that all SQV dipeptide prodrugs displayed more susceptibility to hydrolytic 
enzymes in rat intestine as compared to plasma. 
 
 
Figure 39. Half-lives of SQV stereoisomeric peptide prodrugs in rat plasma and intestinal 
homogenates (mean ±S.E, n = 4). 
 
Hydrolytic Degradation in the Presence of Enzyme Inhibitors  
    Hydrolysis study of SQV stereoisomeric valine-valine prodrugs was performed in the 
presence of various classes of enzyme inhibitors to illustrate the enzyme class responsible 
for drug degradation in rat tissues. In rat intestinal homogenates (Table 15), addition of 
specific aminopeptidase inhibitor bestatin (0.5 mM) resulted in a complete inhibition for 
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the hydrolysis of LLS, LDS and DLS, but no effect was noted with DDS. Degradation of 
LLS was partially inhibited by irreversible serine hydrolase inhibitor pefabloc SC (1 mM), 
which did not prevent hydrolysis of the other three SQV dipeptide prodrugs. Half lives of 
LLS, LDS and DDS in rat intestinal homogenates were improved by different extents by 
both carboxylesterase inhibitor PHMB (1 mM) and cholinesterase reversible inhibitor 
eserine (1 mM), while stability of DLS remained unaffected with 1 mM PHMB.  
      Inhibition of SQV dipeptide prodrug hydrolysis in rat plasma has also been illustrated 
in Table 15. LLS hydrolysis was completely inhibited by both esterase inhibitors PHMB 
(1 mM) and eserine (1 mM), and peptidase inhibitors bestatin (0.5 mM) and pefabloc

 
SC (1 mM). However, half lives of LDS, DLS and DDS were significantly improved 
only when coadministered with 1 mM PHMB. Bestatin, pefabloc

SC and eserine showed 
no measurable inhibition to the hydrolysis of these three dipeptide prodrugs in rat plasma.
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Table 15. Half-lives (h) of SQV stereoisomeric dipeptide prodrugs in the presence of different enzyme inhibitors (mean ±S.E, n = 4).  
 
Rat intestinal homogenates 
 
Rat plasma 
 
LLS LDS DLS DDS 
 
LLS LDS DLS DDS 
Drug alone 2.4±0.1 14.5±0.5 19.7±5.3 24.1±0.5 
 
7.8±0.1 32.8±7.7 48.3±1.2 40.0±5.0 
Drug and various hydrolyse inhibitors 
PHMB (1mM) 9.3±3.9** 21.0±2.5* 16.9±3.0 45.5±8.7** 
 
17.7±1.2** 40.9±0.9* 61.7±11.8* 62.7±13.4** 
Eserine (1mM) 8.3±1.9** 19.3±0.3* 41.0±11.5** 31.5±7.6* 
 
19.5±3.4** 21.8±3.0 39.4±11.7 31.1±6.9 
Bestatin (0.5mM) 33.2±8.8** 28.0±3.7** 44.9±13.0** 24.3±0.7 
 
44.3±8.4** 27.4±5.3 42.6±6.4 31.8±4.2 
Pefabloc

 SC (1mM) 5.3±0.4* 12.9±0.3 14.3±1.6 14.8±3.5 
 
43.9±8.9** 37.9±0.9 42.5±4.4 38.1±0.3 
*P < 0.05, and **P < 0.01 compared with drug alone. 
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Discussion 
Previous work from our laboratory has reported that affinity of PI drugs towards P-
gp can be reduced by conjugating with different L-amino acids (Jain et al., 2005; Agarwal 
et al., 2008). Cellular uptake performed in this study provides the evidence that D-
isomeric SQV conjugates also partially circumvent P-gp. Colon carcinoma cell line Caco-
2 is an extensively used in vitro oral drug absorption model due to its similar epithelial 
cell characteristics and efflux proteins expression to human jejunum (Taipalensuu et al., 
2001). In our study, cellular [
3
H]saquinavir uptake in Caco-2 cells showed a 2.5-fold 
enhancement in the presence of LY335979, a potent P-gp inhibitor, confirming that SQV 
is a high-affinity substrate for P-gp. SQV prodrugs linked to various stereoisomeric 
amino acid promoieties demonstrated only 50-60% of [
3
H]saquinavir uptake relative to 
equimolar concentration of unlabeled SQV. This altered inhibition profile observed for 
SQV prodrugs indicates that the modification of three-dimensional structure can affect 
the interaction between the substrate and P-gp, regardless of L- or D- isomers in 
conjugates.  
Subsequent studies were carried out to determine the transepithelial flux of SQV and 
its prodrugs on both absorptive and secretory directions across Caco-2 cell monolayers. A 
similar bidirectional transepithelial SQV flux was obtained when P-gp, which is located 
on the apical surface of Caco-2 cells, was inhibited by LY335979. It provides additional 
evidence that efflux transport mediated by P-gp is one of the major obstacles to limit 
intestinal SQV absorption. Apparent Papp values summarized in Table 12 indicate that 
bidirectional translocation of all prodrugs displayed less asymmetry than SQV. This 
increment in absorptive permeation is probably due to lower affinity for the efflux pump 
140 
 
P-gp. Interestingly, efflux ratios between secretory and absorptive transport exhibited 
somewhat stereoselectivity. The rank order of efflux ratio is LLS < LS < DS < DDS. LLS 
showed the maximally reduced efflux ratio relative to SQV. Whereas the efflux ratio 
observed for DDS exhibited the closest value to SQV, suggesting that its transepithelial 
accumulation is not as efficient as other isomeric prodrugs. Such stereoselective 
permeation of SQV prodrugs may indicate variable structural affinity for peptide 
transporters. It has been reported that drugs linked to small peptides (so called as peptide 
prodrugs) can be recognized easily as substrates by the peptide transporter-mediated 
influx system and ferried across the epithelial membrane (Ganapathy and Leibach, 1996; 
Katragadda et al., 2006). However, peptides containing L-amino acids displayed higher 
affinity towards peptide transporters than those containing D-amino acids (Lister et al., 
1995; Mitsuoka et al., 2007). Previous uptake studies of stereoisomeric valine-valine-
SQV on MDCK cells also indicated that prodrugs conjugated with L-isomer can be 
recognized by peptide transporters, whereas double D-isomeric derivative, DDS did not 
show any comparable affinity for these influx transporters. Therefore incorporation of D-
valine in the peptide conjugate might lead to only partial recognition by peptide 
transporters, resulting in low transepithelial permeation across intestinal epithelium. 
Nevertheless, all prodrugs including DDS showed relatively higher transepithelial 
accumulation than the parent drug SQV. This result demonstrates a combined effect of 
the evasion of P-gp-mediated efflux and recognition by peptide transporters. Since the 
majority of SQV delivered by oral route is absorbed in the small intestine, overcoming 
the rate limiting barrier expressed by high-level of P-gp improves drug permeability 
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across intestinal epithelium and shut down repetitive exposure to metabolizing enzymes 
in intestinal lumen. 
SQV is known to be metabolized primarily by hepatic and intestinal CYP3A4 to 
mono- and di- hydroxylated metabolites in humans (Fitzsimmons and Collins, 1997; 
Eagling et al., 2002; Parker and Houston, 2008). Tremendous SQV biotransformation has 
also been reported in rat liver microsomes (Treijtel et al., 2009). Two major P450 
isoforms CYP3A2 and CYP3A1, oligomerically related to human CYP3A4, have been 
identified in rat liver (Nelson et al., 1996). Thus oxidative metabolism of SQV and its 
derivatives was also investigated in rat liver microsomes. KTZ is a potent CYP3A 
inhibitor at low concentrations in human (Michaud et al., 2010). Incubation of KTZ (10 
µM) with 1.0 mg/ml microsomes showed significant inhibitory effects on SQV 
biotransformation, confirming the previous findings that SQV is a substrate of rat hepatic 
CYP3A enzymes. In comparison to SQV, a remarkablely less biotransformation was 
observed by prodrug modification, ranging from 2-fold lower for LS to 20-fold lower for 
DLS and DDS. Time-course of biotransformation also illustrates that stability in 0.2 mg 
protein/ml microsomes follows the rank order of parent drug < amino acid derivatives < 
dipeptide derivatives. This result is possibly due to the modification of three-dimensional 
structure of SQV. Bonding interactions between the functionalities of substrates and 
complementary sites on enzyme surface have considerable steric constraints. Thus the “fit” 
between SQV and active site of CYP3A enzymes is reduced by conjugating chiral 
promoieties. Less affinity for enzyme was observed for molecules with larger spatial 
structure modification. Additionally, such weakened interaction exhibited significant 
stereospecificity due to different prolonged elimination t1/2 values in rat hepatic 
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microsomes. DDS is found to be the most stable in liver microsomes with the half life of 
3-fold longer than LLS and 42-fold longer than SQV. Correspondingly, SQV attached 
with one D-valine in dipeptide promoity, like DLS and LDS, showed moderate prolonged 
residence time as compared with LLS and DDS. This result suggests that introducing a 
D-isomer into SQV can reduce its susceptibility to oxidative biotransformation driven by 
rat hepatic CYP3A. 
To date, much less information is available on in vitro metabolic kinetics of SQV in 
rat liver microsomes. It has been reported that the Km and Vmax values for SQV in male 
Sprague-Dawley rat liver microsomes are 0.042 µM and 0.446 nmol/min/mg protein, 
respectively (Parker and Houston, 2008). These parameters differed from those estimated 
in our study (Table 14), probably due to the differences in methodology. Significantly 
higher Km for peptide prodrugs excluding LS was obtained as compared to SQV (0.41 
µM), indicating that its affinity towards metabolizing enzyme CYP3A can be reduced by 
prodrug modification. Previous conclusion about stereoselective interaction between 
SQV prodrugs and enzymes is further interpreted by Km determination. The Km values for 
DDS, DS and LS were 1.57 µM, 0.98 µM, and 0.64 µM, respectively, indicating the 
order of affinity for CYP3A enzymes is DDS < DS < LS. Therefore increasing the 
number of D-valine in SQV prodrugs might lead to an enhanced stability in rat liver 
microsomal samples. 
A true intrinsic clearance of free drug, defined as the volume of liver water cleared 
of drug in unit time in vivo, is influenced by many system dependent parameters such as 
protein binding, hepatocyte-medium partition and molecular diffusion (Treijtel et al., 
2009). The ratio of Vmax /Km, a measure of in vitro intrinsic clearance (CLint), generally 
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considered to be a simple and useful approach to extrapolate the activity of metabolizing 
enzymes in vivo (Miners et al., 2006; Treijtel et al., 2009). Thus CLint estimates based on 
rat liver microsomal kinetic data in this study were generated to predict the “true” hepatic 
clearance rates of SQV and prodrugs. Comparison of CLint in Table 14 indicates that 
SQV showed the most rapid turnover rate in rat liver microsomes. Biotransformation rate 
of SQV amino acid derivatives was found to be higher than dipeptide prodrugs in this 
study. SQV attached with chiral promoieties displayed a distinct stereochemical 
preference in that an “L” configuration in promoiety result in a relatively rapid clearance 
by CYP3A. Such disparity in in vitro elimination may contribute to the differential 
clearance catalyzed by hepatic or intestinal CYP3A in first-pass effect following oral 
administration.  
Aforementioned data provide evidence that, in comparison with amino acid prodrugs, 
SQV dipeptide conjugates exhibited higher potential to evade oxidative metabolism. 
Thus dipeptide prodrug modification might be a more promising strategy to overcome 
this dual CYP3A/P-gp-mediated oral bioavailability barrier. However, besides oxidative 
enzymes, the phase II conjugation enzymes are present ubiquitously in all biological 
fluids and tissues. Dipeptide prodrugs can be degraded to amino acid prodrugs or parent 
drug SQV by various hydrolases during the process of absorption and distribution. Hence 
it is critical to optimize bioconversion rates of orally administered prodrugs in gut, liver 
and plasma.  
Rat intestine and plasma were chosen as the most relevant media for hydrolysis 
studies because they are possible sites where bioconversion takes place. Similarly, 
stereoselective interaction was observed between prodrugs and hydrolytic enzymes. LLS 
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has been observed to be the least enzymatically stable in both rat intestinal homogenates 
and plasma among four dipeptide prodrugs. Stereoisomers interact with hydrolases 
resulting in different kinetic parameters due to their differential three-dimensional 
structures. It seems that spatial structure of D-configuration does not fit well to the active 
site of enzymes. Such reduced recognition by hydrolase may possibly contribute to the 
significantly enhanced stability of prodrugs attached with D-valine in tissues. This 
observation coincidences well with the previously reported results (Fang et al., 2000; 
Talluri et al., 2008; Tsume et al., 2008). Additionally, all prodrugs showed slower 
degradation rates and longer half lives in rat plasma than in rat intestinal homogenates. 
This result may attribute to the less enzyme capacity or concentration expressed in 
plasma.   
Valine-valine-SQV can be hydrolyzed at two positions, either at the ester bond or 
peptide bond. Therefore esterases and peptidases can play a key role in modulating the 
degradation rate of these dipeptide prodrugs. Among the peptidases located in intestinal 
brush border, aminopeptidase and serine hydrolase are proficient in cleaving peptide 
bonds in conjugated promoieties to generate amino acid prodrugs. Inhibitory data indicate 
that aminopeptidase appeared to be the principal peptidase in the bioconversion process 
of valine-valine-SQV. After co-administration with potent aminopeptidase inhibitor 
bestatin, half lives for LLS, LDS, and DLS in rat intestinal homogenates significantly 
increased by 13.8-, 1.9-, and 2.3-fold, respectively. However, serine hydrolase inhibitor 
Pefabloc
®
 SC only produced limited inhibition to hydrolysis of LLS in both rat plasma 
and intestinal homogenates. It is also important to note that chirality of the valine residue 
in SQV prodrugs dictates bioconversion rate mediated by peptidase. Enzyme specificity 
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towards the drug is mainly based on preferred residues adjacent to the scissile bond. 
Results from inhibitory studies indicate that peptidase favors L-configuration, since 
incorporation of L-valine leads to more susceptibility to peptidases. 
Generally, hydrolysis of all four SQV dipeptide prodrugs was inhibited by both 
cholinesterase inhibitor eserine and carboxylesterase inhibitor PHMB. Such inhibitory 
effect by PHMB was observed in both rat plasma and intestine, whereas eserine showed 
remarkable inhibitory effect only in rat intestinal samples. Usually esterases are 
expressed throughout the body, but the activity of these hydrolytic enzymes varies in 
different tissues. Serum carboxylesterase activity in Sprague-Dawley rat has been 
reported as 6158 nmol/ml serum/min, significantly higher than that of serum 
cholinesterase (Clement and Erhardt, 1990). Such differential activity clearly explains the 
results that hydrolysis of prodrugs was decelerated by both carboxylesterase and 
cholinesterase inhibitors in rat intestinal homogenates, but was only reduced by 
carboxylesterase inhibitor in rat plasma. Two L-valine derivative LLS still presented a 
remarkable enhancement in t1/2 when coadministered with esterase inhibitors. But no 
expectant stereoselective interaction with esterases was observed in this study because 
hydrolysis of DDS was also inhibited by esterase inhibitors.  
Enzymatic hydrolysis is considered a complicated process. Hydrolysis of drugs is 
often mediated by more than one enzyme at different sites. The bioconversion rate of 
SQV dipeptide prodrugs should be determined by the combined effects of esterases and 
peptidases. According to the results shown in Table 15, L-valine-L-valine-SQV showed 
extremely rapid bioconversion and poor stability in biological media. This result indicates 
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that LLS might be hydrolyzed rapidly into SQV in gut or plasma, thereby leading to low 
oral bioavailability caused by intestinal or hepatic first-pass metabolism. 
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CHAPTER 7 
EVALUATION OF IN VITRO/IN VIVO BIOAVAILABILITY 
Rationale 
In the previous chapters, we have reported that stereoisomeric dipeptide prodrugs 
exhibited enhanced cellular accumulation and transepithelial transport as compared with 
the parent drug SQV in in vitro cell models. This improvement may be achieved by the 
cumulative effects of evasion of efflux activities and CYP-mediated metabolisms as well 
as facilitated transport by peptide transport system. But no direct evidence shows that 
these prodrugs can overcome the absorption and metabolic barriers in vivo, and exhibit 
enhanced oral bioavailability over SQV.  
Drug pharmacokinetics including absorption, distribution, metabolism and 
elimination (ADME) are complicated processes in the body. Numerous transporters and 
enzymes are involved in these processes and contribute to drug disposition in systemic 
circulation. In vitro cell culture models provide a simple but extremely useful way to 
evaluate the molecular mechanisms of drug transport and metabolism, but the absence of 
tissue crosstalks occurring in vivo limits application of these single cell lines in drug 
screening. Recently physiologically based in vitro co-culture cell systems of enterocytes 
and hepatocytes have been developed to provide cell culture environment close to in vivo 
ADME processes (Ouattara et al., 2011; Rossi et al., 2012). These in vitro cell co-cultures 
offer a new testing platform to simulate more reliable in vivo drug disposition processes. 
Bioavailability of a drug is defined as the fraction of the dose that appears intact in the 
systemic circulation. Major factors influencing drug oral bioavailability include drug 
permeation across intestinal mucosa, enzymatic degradation and biotransformation 
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occurring in gut wall and liver. Therefore a static cell system MDCK cells overexpressed 
human MDR1 gene and CYP3A4 enzyme (MMC) co-cultivated with human hepatoma 
cell line HepG2 was developed in this study to estimate kinetic parameters related to in 
vivo ADME such as bioavailability. MMC has been characterized as a reliable in vitro 
model for assessing drug intestinal absorption and enteric CYP3A4–mediated 
metabolism (Kwatra et al., 2012), and HepG2 has been widely applied as a useful cell 
model in drug metabolism and toxicity studies (Roe et al., 1993; Donato et al., 2008). In 
this study MMC is employed to study transepithelial transport and metabolism of SQV 
and its prodrugs in the intestinal lumen. After crossing intestinal barrier such as MMC 
growing in Transwell filter, their hepatic metabolism in blood circulation can be 
evaluated by HepG2 cells growing in receiving chamber. 
In this chapter the in vitro bioavailability of SQV and its dipeptide prodrugs was 
estimated using this MMC/HepG2 co-culture system. Subsequently oral absorption 
studies were performed via oral gavage to male Sprague-Dawley rats to investigate the 
pharmacokinetics of dipeptide prodrugs in vivo. Plasma concentration of parent drug 
SQV regenerated from these prodrugs was also compared to the SQV administered orally 
to rats.  
 
Materials and Methods 
Chemicals 
Madin-Darby canine kidney cells transfectant overexpressing human P-gp/MDR1 
(MDCK-MDR1) was generously provided by Dr. Peter Borst, Netherlands Cancer 
Institute (Amsterdam, Netherland). Stable transfection of MDCK-MDR1 cell with human 
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CYP3A4 enzyme (MMC) was conducted in our laboratory (Kwatra et al., 2012). HepG2 
cells were obtained from American Type Culture Collection (Manassas, VA). TrypLE
TM
 
Express Stable Trypsin Replacement, modified Eagle’s Medium (MEM) with Earle’s B 
salt solution and Dulbecco’s modified Eagle’s Medium (DMEM) were obtained from 
Invitrogen (Carlsbed, CA). Fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Lawenceville, GA). Ketoconazole, quinidine, hydroxyl ethyl piperazine 
ethane sulfonic acid (HEPES), D-glucose, propylene glycol, triton X-100, cremophor EL 
and all other chemicals and solvents were purchased from Sigma-Aldrich Co. (St. Louis, 
MO) or Fisher Scientific Ltd.,Co. (Pittsburgh, PA). 
 
Animals  
Male Sprague–Dawley rats with jugular vein cannulated catheters, weighing 200–
250 grams, were obtained from Charles River Laboratories International, Inc. 
(Wilmington, MA). Animals were used in accordance with the protocol approved by 
University of Missouri-Kansas City Institutional Animal Care and Use Committee 
(IACUC) and housed in Laboratory Animal Research Core (LARC) facilities at 
University of Missouri-Kansas City. Before experiments, all rates were fasted overnight 
with free access to water. 
 
Cell Culture 
MMC and HepG2 cells were seeded in 75 cm
2
 cell culture flasks and incubated at 
37C, in a humidified atmosphere of 5% CO2, 90% relative humidity. MMC cells were 
maintained in DMEM containing 10% heat-inactivated FBS, 20 mM HEPES, 29 mM 
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sodium bicarbonate, 100 units/ml penicillin, and 100 μg/ml streptomycin. HepG2 cells 
were maintained in MEM with Earle’s B salt solution supplemented with 10% FBS, 2 
mM L-glutamine, 0.1 mM MEM non-essential amino acids, 1 mM sodium pyruvate, 1.5 
g/L sodium bicarbonate, 100 units/ml penicillin, and 100 μg/ml streptomycin. Medium 
was changed every alternate day. After 7-days postseeding, cells were harvested and 
passaged using TrypLE
TM
 Express Stable Trypsin Replacement, and seeded on 12-well 
Transwell
®
 inserts (diameter 12 mm, pore size 0.4µm, Corning, Lowell, MA) at the 
density of 7.5 × 10
4
 cells /cm
2
 for MMC cells, and 12-well tissue culture plates at the 
density of 2 × 10
4
 cells /cm
2
 for HepG2 cells, respectively.    
 
Construction of in vitro MMC/HepG2 Co-culture Model 
MMC cells and HepG2 cells were grown separately for 5-7 days before the 
experiment. The monolayer integrity of MMC was monitored by measuring 
transepithelial electrical resistance (TEER) values using volt–ohm meter (EVOM-G, 
World Precision Instruments, Sarasota, FL). Only the monolayers with TEER values of 
around 600 Ω•cm2 were used as permeability barriers. Before the experiments, both cell 
lines were washed twice with IPBS (pH7.4). Then 12-well Transwell inserts on which 
MMC cells have been cultured were installed to 12-well tissue culture plates growing 
HepG2 heptocytes to form co-culture system (Figure 40).  
 
Assessment of in vitro Bioavailability 
The in vitro bioavailability of SQV and its prodrugs was evaluated and compared 
using MMC/HepG2 co-culture system constructed in this study. Working volumes of the 
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apical (AP) and basolateral (BL) compartments were 0.5 and 1.5 ml, respectively. IPBS 
(pH 7.4) in the absence (as control) or presence of P-gp inhibitor (75 µM quinidine) 
and/or CYP3A4 inhibitor (10 µM ketoconazole) were added in both AP and BL 
chambers. After 15 min-preincubation, various SQV (10 µM) and prodrug (25 µM) 
solutions with or without the above inhibitors were used to replace IPBS in AP chambers 
to initiate transport process. Selection of donor concentrations is dependent on the 
detection of SQV and prodrugs in receiver chambers. Aliquots (200 µl) were withdrawn 
from BL chambers at predetermined time intervals over a period of 3 h and replaced with 
same volume of fresh transport medium (fresh IPBS, pH 7.4, or different inhibitor 
solutions in IPBS, pH7.4) to maintain sink conditions. Samples were stored at −80ºC 
until further analysis using LC-MS/MS. 
 
 
 
Figure 40. Construction of in vitro co-culture cell model MMC/HepG2. 
 
Oral Absorption Studies  
Oral absorption studies of SQV and prodrugs LDS and DLS were carried out at an 
equivalent dose of 30 mg/kg for didpeptide prodrugs corresponding to 25mg/kg SQV. 
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Solvent system employed to prepare drug solutions was 50:50 (v/v) propylene glycol and 
water. Rats were divided into 3 groups. According to statistical results of Power Analysis 
for two-group independent sample t-test (G*Power 3.1.7 version, University of Kiel, 
Germany), sample size was designed to be 3 animals for each group in this study. 
Maximum dose volume 0.8 ml was administered by oral gavage. Blood samples (200 μl) 
were collected from the jugular vein cannula at pre-determined time intervals over a 
period of 8 h post dosing. Heparinized saline (100 μl, 10 IU/ml) was injected through the 
vein to prevent clots in the catheter and maintain a fairly constant fluid volume. At the 
end of experiment animals were euthanized by administering an excess dose of sodium 
pentobarbital (100 mg/kg). Blood samples were collected in heparin-coated micro-
centrifuge tubes and centrifuged at 5000 g, 4C for 10 min to separate plasma. The 
plasma samples were immediately diluted with 50 µl ice-cold acetonitrile and centrifuged 
at 5000 g, 4C for 15 min to precipitate protein. The supernatants were decanted and 
dried in vacuo (DD-4X GeneVac, Gardiner, NY) and the residue was stored at −80C 
until further analysis by LC-MS/MS. 
 
Sample Preparation and Analysis  
All SQV and prodrug samples were prepared using liquid-liquid extraction technique 
following the procedure in Chapter 5. Analysis procedures using LC-MS/MS system 
have been described in Chapter 4.  
 
Data Analysis  
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Apparent permeability coefficients Papp (cm/s) were calculated by linear regression 
analysis on the time course plot of amount of drugs transported across MMC cell 
monolayers.  
 
where TRcum/dt is the flux rate of SQV or prodrugs obtained from the slope of transport 
profile. A is the surface area of cell monolayers. C0 is initial concentration of (pro)drugs 
in apical chambers of MMC/HepG2 co-culture system. 
Pharmacokinetic parameters were calculated with noncompartmental analysis (NCA) 
of plasma drug concentration-time profiles upon oral administrations of SQV and 
prodrugs DLS and LDS using Phoenix WinNonlin professional v6.1 (Pharsight Corp., 
Mountain View, CA).  
All experiments were conducted at least in triplicate. Results from in vivo/in vivo 
experiments are expressed as mean ± standard error (SE). Statistical significance was 
detected using Student’s t test. Difference between mean values was considered 
significant at p < 0.05 and very significant at p < 0.01. 
 
Results 
In vitro Bioavailability Prediction using MMC/HepG2 system 
Co-culture cell system MMC/HepG2 was developed in this study to simulate the 
most relevant environment of drug’s disposition in vivo. In vitro bioavailability of SQV 
and its prodrugs was predicted by determination of absorptive apparent permeability (Papp) 
on apical to basolateral direction across this co-culture cell model. Results in Figure 41 
𝑃app =
TRcum 𝑑𝑡 
𝐶0 × 𝐴
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indicate that, in comparison with SQV with a Papp value of (0.62 ± 0.02)  10
-6
 cm/s, a 
significantly higher permeability was obtained by all prodrugs tested. LDS and DLS 
exhibited the most enhanced Papp across MMC/HepG2 co-culture, which were observed 
to be 4- fold (2.50  10-6 cm/s) and 3.5- fold (2.17  10-6 cm/s) higher than SQV, 
respectively. Two amino acid prodrugs LS and DS also displayed higher Papp values than 
SQV, but to a less extent as compared with dipeptide prodrugs, suggesting a relative 
lower in vitro bioavailability than dipeptide derivatives of SQV. 
 
 Figure 41. Apparent permeability of absorptive transport of SQV and its stereoisomeric 
prodrugs across in vitro cell co-culture cell model MCC/HepG2.  
Each data point represents mean ± SE (n=4). ** P < 0.01 for statistical difference 
between SQV and prodrug values. 
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Then permeability studies of SQV and prodrugs across co-culture MMC/HepG2 cell 
system were evaluated in the presence of efflux pump inhibitor quinidine (75 µM) and/or 
metabolizing enzyme inhibitor ketoconazole (10 µM).  Results are summarized in Table 
16. Co-administration of qunidine, ketoconazole and quinidine+ketoconazole contributed 
to a 3-, 3- and 3.5- times enhancement in absorptive permeability of SQV, respectively. 
All prodrugs also generated enhanced permeabilities, but to a lower extent relative to 
SQV. A 1.5-2.5 times higher permeability was observed in the presence of both qunidine 
and ketoconazole than drug alone. Among dipeptide prodrugs, LLS appears to be the 
most susceptive to metabolizing enzymes, with Papp of (3.49 ± 0.28)  10
-6
 cm/s when co-
administered with 10 µM ketoconazole, about 2.4- fold higher than it alone. 
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Table 16. Apparent permeabilities (Papp, 10
-6
 cm/s) of SQV and stereoisomeric prodrugs across in vitro co-culture cell model 
MMC/HepG2. 
 
SQV LS DS LLS LDS DLS DDS 
Drug alone 0.62±0.02 1.13±0.09** 1.21±0.11** 1.47±0.15** 2.50±0.15** 2.17±0.10** 1.71±0.05** 
+Quinidine (75 µM) 1.82±0.08 1.26±0.10 1.41±0.03 2.21±0.14 3.32±0.20 3.23±0.32 2.03±0.09 
+Ketoconazole (10 µM) 1.81±0.14 1.60±0.02 1.59±0.20 3.49±0.28 3.67±0.12 3.41±0.30 2.05±0.08 
+Quinidine (75 µM) & 
Ketoconazole (10 µM) 
2.15±0.05 1.88±0.05 1.84±0.10 3.69±0.04 4.28±0.18 4.30±0.12 2.36±0.38 
Data represented are mean ± SE (n = 4).  ** P < 0.01 for statistical difference between SQV and prodrug values. 
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Oral Administration in Rats  
Plasma concentration versus time profiles for SQV and equivalent dose of dipeptide 
prodrugs LDS and DLS after single oral administration have been illustrated in this study 
(Figure 42, 43). Pharmacokinetic parameters after oral dosing of SQV and prodrugs in 
rats are outlined in Table 17. Following oral aqueous gavage dosing with SQV, initial 
drug absorption was rapid with a tmax value of 0.22 h and Cmax value of 46.1 ± 6.1 nM, 
and followed by rapid drug elimination. Subsequently a second SQV absorption peak 
appeared at about 3 h followed again by rapid elimination (Figure 42). Whereas only one 
absorption peak was obtained after oral administration of LDS and DLS, and the tmax 
values were estimated to be about 2.0 h and 3.0 h, respectively (Figure 43). In 
comparison to parent drug, both prodrugs showed remarkably enhanced Cmax, about 8-
fold (366.3 ± 89.1 nM for LDS) and 1.5-fold (66.4 ± 7.3 nM for DLS) higher than SQV. 
As indicated in Table 17, AUC0-8h values of LDS (1846.14 ± 478.29 hnmol/l) and DLS 
(377.95 ± 90.50 hnmol/l) were 10-fold and 2-fold higher than that of SQV (178.58 ± 
16.08 hnmol/l), respectively. These results are consistent with what we found in in vitro 
studies. Therefore prodrug modifications showed higher absorptive permeability across 
intestinal barrier probably due to evasion of P-gp-mediated efflux as well as facilitated 
transport by peptide transporters. Prodrug LDS also exhibited lower clearance (10 times 
less) and longer mean residence time (MRT) (1.3-fold higher) than SQV (Table 17), 
probably due to lower rate of enzymatic metabolism. 
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Figure 42. Plasma concentration-time profile of SQV after oral administration (25 mg/kg) 
in rats. Each data point represents mean ± SE (n=3). 
 
 
Figure 43. Plasma concentration-time profiles of SQV stereoisomeric dipeptide prodrugs 
LDS and DLS after single oral administration (30 mg/kg) in rats. Each data point 
represents mean ± SE (n=3). 
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Table 17. Estimated pharmacokinetic parameters of SQV and equivalent dose of prodrugs 
after oral administration in rats. 
Parameter SQV LDS DLS 
Lambda_z (1/h) 0.2320±0.0910 0.1700±0.0490 0.2540± 0.0364 
Half-life (h) 3.9±1.1 5.2±2.1 2.8±0.4 
tmax (h) 3.0 2.0 3.0 
Cmax (nM) 46.1±6.1 366.3±89.1 66.4±7.3 
AUC(0-8h) (h · nmol/l) 178.58±16.08 1846.14±478.29 377.95±90.50 
Clearance (l/h/kg) 210.8±19.8 20.9±5.1 99.2±19.3 
MRT (h) 5.66±0.86 7.52±2.11 5.53±0.49 
Data are reported as means ± SE (n=3). 
 
Determination of SQV Regenerated from Prodrugs  
Plasma concentration versus time profile of SQV and regenerated SQV from 
equivalent dose of dipeptide prodrugs LDS and DLS after oral administration are 
illustrated in Figure 44. In comparison to DLS, much more SQV was released by LDS in 
blood during 8-hour time period. Unlike oral SQV, which showed rapid decrease in 
plasma concentration after 3 hours of dosing, regeneration of SQV from dipeptide 
prodrug LDS was observed to slowly rise during the 8-hour process. It suggests that 
prodrug LDS might provide a controlled release of the active parent drug SQV, and 
maintain relatively high and steady level. 
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Figure 44. Plasma concentration-time profiles of (regenerated) SQV after oral 
administration of SQV (25 mg/kg) or its stereoisomeric dipeptide prodrugs LDS and DLS 
(30 mg/kg) in rats. Each data point represents mean ± SE (n=3).  
 
Discussion  
According to the findings in the previous chapters, all stereoisomeric prodrugs of 
SQV displayed an enhanced transepithelial transport across Caco-2 cells and human 
MDR gene-transfected MDCK cells (Chapters 5 and 6). A significantly higher stability 
against CYP3A-mediated oxidative metabolism was also observed by these prodrug 
modifications in rat hepatic microsomes (Chapter 6). These improvements are believed to 
be achieved by the cumulative effects of enhanced absorption (targeting influx peptide 
transporters) and decreased elimination (circumventing efflux pumps and metabolic 
enzymes). But there was no direct evidence demonstrating that oral bioavailability can be 
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improved by this prodrug modification. Therefore in the present study, bioavailability of 
SQV and stereoisomeric prodrugs was first estimated by measuring apparent 
permeabilities employing a static in vitro ADME simulation co-culture cell model. 
The bioavailability prediction using in vitro co-culture cell models has been proved 
to be a valuable drug screening method and attracted a lot of interest in recent years 
(Castrillon et al., 2009; Ouattara et al., 2011). Limitations of MMC/HepG2 co-cultures 
include relatively lower metabolic activity in HepG2 cells, such as CYP enzymes levels, 
as compared with primary cultured hepatocytes, and the absence of bloodborne factors 
that participate in tissue crosstalks occurring in vivo (Westerink and Schoonen, 2007; Lin 
et al., 2012). Yet it is a simple and accessible testing interface to predict kinetic 
mechanisms of orally administered drugs. Apparent Papp values summarized in Table 16 
indicate that a significant enhancement in oral bioavailability was observed by prodrugs 
as compared with SQV. This incremental permeability of SQV prodrugs provides the 
evidence that intestinal SQV permeation and its metabolic stability against enteric and 
hepatic enzymes can be improved by prodrug modifications. This result was further 
confirmed by inhibitory transport studies with specific P-gp and CYP3A4 inhibitors. An 
enhancement in absorptive permeabilities of prodrugs on MMC/HepG2 was less than that 
of SQV in the presence of quinidine or ketoconazole, suggesting that affinity of SQV 
towards efflux pumps and enzymes has been partially overcome by prodrug modification. 
Moreover, this in vitro bioavailability prediction appears to be stereoselective. Among 
dipeptide prodrugs, DDS exhibited the highest stability against metabolizing enzymes 
and the least affinity for P-gp efflux (Table 16), but its bioavailability was estimated to be 
much less than LDS and DLS, about 70% for LDS and 80% for DLS (Figure 41). It is 
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probably due to poor recognition of D-valines in promoiety of the prodrug by peptide 
transporter. LDS and DLS appear to be the best prodrug candidates since these two 
compounds might exhibit the most enhanced bioavailabilities over parent drug SQV. 
Taking into account of protein unbound fraction (Table 11), the concentration of unbound 
LDS is 5.5-fold higher than unbound SQV in rat plasma, and unbound DLS is about 3 
times more than free SQV. 
Subsequently in vivo bioavailability of SQV and the best prodrug candidates LDS 
and DLS was determined in male Sprague–Dawley rats. Figure 42 illustrates that the 
double absorption peaks and relatively rapid absorption and elimination were observed in 
the plasma concentration versus time profile after oral dosing with SQV mesylate salt in 
rats. This result is probably due to the low drug solubility in gut fluid, rapid metabolism 
and reabsorption. Rats do not have gall bladder, but enterohepatic circulation (EHC) 
exists in rats since bile can be excreted into the duodenum by the cannulated bile duct 
(Kuipers et al., 1985; van Wijk et al., 2001). Thus, once hydrophobic SQV was absorbed 
in systemic circulation, it was eliminated rapidly and transported into bile, and SQV in 
bile may be reabsorbed back into intestine and form the second absorption peak. This 
result is confirmed by the previous reports (Buchanan et al., 2008). 
Higher Cmax and AUC values were observed by prodrugs relative to SQV, 
particularly LDS exhibited a dramatically higher AUC and Cmax, which are about 10- and 
8- fold higher than SQV, respectively. Moreover prodrug LDS exhibited longer MRT, 
lower terminal elimination rate (lambda_z) and slower clearance values, suggesting that it 
is much more stable in blood circulation than parent drug SQV. All of these data taken 
together provide evidence that oral bioavailability of prodrugs is greater than SQV. These 
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in vivo observations are consistent with what we found with in vitro MMC/HepG2 co-
culture system. Oral bioavailability followed the same rank order of LDS  DLS  SQV 
in both in vitro and in vivo studies. But LDS showed remarkably higher bioavailability in 
rats than in vitro cell-based model. Such differential results may be due to the variety of 
expression and activities of enzymes and transporters under physiological conditions and 
cell-based milieu. In comparison with fresh-isolated primary human hepatocytes, hepatic 
cell line HepG2 shows significantly lower levels of phase I drug-metabolizing enzymes 
and moderately lower levels of phase II enzymes (Lin et al., 2012). Besides, MDCK cell 
lines have been reported for the reduced activity of peptide transporters after transfecting 
with human MDR genes (Wang et al., 2013). Therefore such disparity in activities of 
enzymes and transporters may contribute to the differential absorption and 
biotransformation of SQV prodrugs, and subsequently display extremely different 
bioavailability. 
Although we observed that prodrugs show higher oral bioavailability than SQV, it is 
critical to determine the amount of SQV regenerated from prodrugs into the systemic 
circulation because the antiviral activity (such as IC50 for HIV-1) of SQV is always 
higher than its prodrugs (Farese-Di Giorgio et al., 2000; Gaucher et al., 2004). LDS and 
DLS have been considered to be the best prodrug candidates according to in vitro studies. 
However, plasma concentration of SQV regenerated from LDS was much higher than 
DLS in rats. It indicates that LDS is more susceptive towards hydrolytic enzymes present 
in rats compared to DLS, and ester bond between parent drug and pro-moiety L-valine-D-
valine- of LDS is easier to be cleaved to release more free and active SQV in the 
systemic circulation as compared to DLS. Results in Figure 44 also demonstrate a 
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controlled, prolonged release of SQV regenerated from LDS, suggesting that prodrug L-
valine-D-valine-SQV may be a good substitute for SQV in clinical application. LDS can 
provide a continuous and effective therapeutic plasma concentration, as well as prevent 
development of resistant viral strains. It is critically important for drugs with narrow 
therapeutic index like SQV, especially for patients with chronic disease such as HIV-1 
infection requiring long-term treatment. 
In conclusion, the study in this chapter is the first investigation to evaluate 
pharmacokinetics of stereoisomeric valine-based SQV prodrugs using both in vitro and in 
vivo models. Our studies indicate an overall good correlation between in vitro and in vivo 
results. Oral bioavailability of SQV can be enhanced significantly by dipeptide derivative 
L-valine-D-valine-SQV. This enhancement is attributed to the cumulative effects of 
higher intestinal permeation facilitated by peptide transporters and evasion of both P-gp-
mediated efflux and CYP-mediated biotransformation. These findings demonstrate that 
peptide transporter-targeted prodrug strategy has enormous promise for improving the 
intestinal absorption and oral bioavailability of poorly absorbed antiviral agent saquinavir 
via the oral route of administration.  
165 
 
CHAPTER 8 
SUMMARY AND RECOMMENDATIONS 
Summary 
Clinical application of SQV is remarkably limited by its low oral bioavailability. 
Low aqueous solubility, high affinity for efflux proteins, fast CYP-mediated metabolism 
and high plasma protein binding are considered to be the major obstacles contributing to 
poor bioavailability of SQV. The purpose of this dissertation project is to design new 
transporter-targeted prodrugs to circumvent these biological and physicochemical barriers, 
and consequently to improve oral bioavailability and therapeutic outcomes of SQV.  
SQV is a high-affinity substrate for both efflux pumps and metabolizing enzymes. 
Hence our first purpose of this project is to modify molecular structure by conjugating 
with specific dipeptide pro-moieties, thereby to reduce the interaction between SQV and 
these proteins/enzymes. Moreover, peptide transporters essential for the intake and 
transport of various “peptidomimetic” xenobiotics are expressed on the cellular 
membranes of various tissues including intestine. So SQV dipeptide prodrugs proposed in 
this project could be recognized easily by the peptide transporter-mediated influx system 
and ferried across the epithelial membrane. In addition, typically different stereoisomeric 
prodrugs exhibit varied stereoselectivity in biological and physicochemical properties 
such as aqueous solubility, plasma protein binding, and enzymatic hydrolysis. With this 
background, a series of stereoisomeric valine-SQV (L- and D-) and valine-valine-SQV 
(L-L-, L-D-, D-L-, and D-D-) were designed and identified in this project (Chapter 4), and 
their in vitro and in vivo evaluations are demonstrated in the following chapters. Overall 
assessment of these transporter-targeted prodrugs has been summarized in Table 18. 
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Table 18. Overall in vitro/in vivo evaluations of transporter-targeted dipeptide prodrugs 
synthesized in this project to overcome major obstacles of SQV in oral administration 
 Stereoisomeric dipeptide prodrugs 
 LLS LDS DLS DDS 
Major problems of SQV 
    
Low aqueous solubility      
High affinity for efflux pumps     
Fast CYP metabolism      
High plasma protein binding      
Properties of prodrugs     
Recognition by PepT Yes Yes Yes No 
Stability against hydrolytic enzymes 
LLS  LDS  DLS  DDS 
Bioavailability evaluation     
In vitro co-culture cell model SQV  LLS  DDS  DLS  LDS 
Single dose of oral administration to 
rats 
    
 
 
With regards to the four major unfavorable properties of SQV, all four dipeptide 
prodrugs showed improved aqueous solubility and reduced affinity for both efflux pumps 
(P-gp and MRP2) and CYP3A enzymes as compared with parent drug SQV (Table 18). 
Plasma protein binding was found to be stereoselective, because LLS and LDS showed 
less protein binding than SQV whereas DDS and DLS exhibited higher protein binding 
levels in rat plasma. These findings indicate that dipeptide prodrug modification provides 
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a good strategy to overcome biological obstacles contributing to low oral bioavailability 
of SQV. 
Interaction between proposed prodrugs and influx peptide transporters as well as 
their degradation catalyzed by hydrolytic enzymes were then investigated, and results are 
compared in Table 18. All prodrugs except DDS can be recognized by peptide 
transporters-mediated influx system expressed on cellular membrane surface of in vitro 
cell-based models. Hydrolysis studies performed in rat intestinal homogenates and 
plasma demonstrate that prodrugs with D-valine in pro-moieties exhibited significantly 
reduced biodegradation, and the rank order of stability against hydrolytic enzymes has 
been obtained to be LLS  LDS  DLS  DDS.  
Based on these in vitro observations, LDS and DLS could be the best prodrug 
candidates possessing both high affinity for influx transport system and proper resistance 
against hydrolytic enzymes. This result was confirmed by the prediction of in vitro 
bioavailability using a MMC/HepG2 co-culture cell system (Table 18). Enhanced 
apparent transepithelial permeabilities over SQV were achieved by all stereoisomeric 
prodrug modifications, and LDS exhibited the most enhanced bioavailability as compared 
with SQV. Finally in vivo absorption studies after single-dose oral administration in rats 
further proved that specific stereoisomeric dipeptide prodrugs like LDS could be applied 
to improve oral bioavailability of SQV.  
Additionally, since MDCK cell lines transfected with various human MDR genes 
have been widely used as in vitro cell-based permeability screening models, influence of 
human efflux transporters (P-gp, MRP2 and BCRP) on the functional activities, and gene 
and protein expression of endogenous influx peptide transporters in these cell lines was 
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also evaluated in this dissertation project (Chapter 4). Results demonstrate that 
overexpression of MDR genes can reduce PepT function probably due to the phenomenon 
of transporter-compensation resulting in down-regulation of endogenous genes. It may 
provide some mechanistic insight into possible reasons for underestimation in drug 
screening using these cell models.  
 
Recommendations 
Besides the poor oral bioavailability, low brain absorption is another major challenge 
in current SQV application for the treatment of HIV infection. Inability to attain 
sufficient SQV concentration in CNS results in persistent viral replication and a HIV 
sanctuary site in the brain parenchyma. Expression of peptide transporters (i.e. PepT2) in 
brain is relatively low, whereas amino acid transport systems such as large neutral amino 
acid transporter (LAT) exhibit high expression on the BBB. Consequently amino acid 
prodrugs, which are regenerated from dipeptide prodrugs, may be easily identified and 
ferried by these amino acid transporters and reach in brain. However, the proposed amino 
acid prodrug valine-SQV shows poor enzymatic stability regardless of L- or D- isomers, 
and very low levels of valine-SQV can be detected in rat plasma. Therefore 
stereoisomeric SQV prodrugs conjugating with other amino acid pro-moieties, such as 
leucine, histidine and glutamine, can be developed in future studies. Firstly, different 
amino acid pro-moieties may contribute to varied enzymatic hydrolysis of prodrugs, and 
more stable amino acid prodrugs could be obtained by these dipeptide prodrugs. 
Secondly, other dipeptide prodrugs like histidine-based dipeptide prodrug could be 
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recognized by other carrier-mediated influx systems expressed on the BBB, such as 
peptide/histidine transporter 1 (PHT1), and reach CNS at high levels.  
Other structural modifications may be also applied in the proposed transporter-
targeted stereoisomeric prodrug strategy, such as attaching a linker or spacer between 
parent drug and dipeptide ligand. This linker/spacer could be carbon chains with varying 
length. Properties of prodrugs such as solubility, enzymatic stability, anti-HIV activity, 
and transepithelial permeability may be significantly changed due to the conjugation of 
linker/spacer. Therefore, modification of molecular structure of pro-moieties will 
facilitate the development of SQV prodrugs with optimized pharmacokinetic and 
pharmacodynamic properties. 
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